
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>bpmc-20160331ex102971a3b.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--HTML document created with Merrill Bridge  6.1.177.0-->
<!--Created on: 5/10/2016 3:07:25 PM-->
<html>
	<head>
		<title>
			bpmc_Ex102
		</title>
	</head>
	<body><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt 0pt 0pt 24pt;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<a name="_GoBack"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Exhibit 10.2</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 16pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:16pt;">Execution Version</font>
		</p>
		<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<a name="_Toc160414648"></a><a name="_Toc161486317"></a><a name="_Toc161540192"></a><a name="_Toc166667788"></a><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 24pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:24pt;">Collaboration and License Agreement</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Agreement is entered into with effect as of the Effective Date (as defined below)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">by and between</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc160414649"></a><a name="_Toc161486318"></a><a name="_Toc161540193"></a><a name="_Toc166667789"></a><a name="_Toc167093685"></a><a name="_Toc174327373"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">F. Hoffmann-La Roche Ltd</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland ("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche Basel</font><font style="display:inline;font-family:Times New Roman,Times,serif;">")</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">and</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc160414650"></a><a name="_Toc161486319"></a><a name="_Toc161540194"></a><a name="_Toc166667790"></a><a name="_Toc167093686"></a><a name="_Toc174327374"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Hoffmann-La Roche Inc.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. ("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche US</font><font style="display:inline;font-family:Times New Roman,Times,serif;">"; Roche Basel and Roche US together referred to as "</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche</font><font style="display:inline;font-family:Times New Roman,Times,serif;">")</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">on the one hand</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">and</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Blueprint Medicines Corporation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">with an office and place of business </font><font style="display:inline;font-family:Times New Roman,Times,serif;">at 38 Sidney Street, Suite 200, Cambridge, Massachusetts 02139, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">U.S.A.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM</font><font style="display:inline;font-family:Times New Roman,Times,serif;">")</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">on the other hand.</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Table of Contents</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.34%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Definitions</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Affiliate</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Agreement</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Agreement Term</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Allocable Overhead</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Animal POC</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.6</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Applicable Law</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.7</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Backup Compound</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.8</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Group</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.9</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM IP</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.10</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Net Sales</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.11</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.12</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Sole IP</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.13</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Technology</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.14</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Territory</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.15</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Business Day</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.16</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Calendar Quarter</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.17</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Calendar Year</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.18</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">CCS Criteria</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.19</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Change of Control</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.20</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Change of Control Group</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.21</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Clinical Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.22</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">CLS Achieved</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.23</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">CLS Criteria</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.24</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Collaboration Compound</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.25</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Collaboration Compound IP</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.26</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Collaboration Target</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.27</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Combination Product</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.28</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.29</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Commercially Reasonable Efforts</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.30</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Companion Diagnostic</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.31</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Composition of Matter Claim</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.32</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Compound Criteria</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.33</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Compulsory Sublicense Compensation</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.34</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Confidential Information</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.35</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Continuation Election Notice</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.36</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Control</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.37</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Cover</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.38</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">CRO</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.39</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Development Costs</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.40</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Development Plan</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.41</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Effective Date</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.42</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">EU</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.43</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Excluded Field</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.44</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Excluded Targets</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.45</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Expert</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.46</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Exploit</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;"></table></div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.47</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">FBMC</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.48</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">FDA</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.49</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">FDCA</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.50</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Field</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.51</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Filing</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.52</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">First Commercial Sale</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.53</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">GAAP</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.54</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Generic Product</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.55</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Handle</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.56</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">IFRS</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.57</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">IND</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.58</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Indication</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.59</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Initiation</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.60</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Initiation of GLP Tox Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.61</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Insolvency Event</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.62</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Invention</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.63</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">JDC</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.64</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Joint IP</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.65</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Joint Know-How</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.66</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Joint Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.67</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">JOT</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.68</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">JRC</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.69</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Know-How</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.70</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Lead Nomination</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.71</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Lead Optimization</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.72</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Lead Series Identified Criteria</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.73</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Leftover Targets</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.74</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Library Compound</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.75</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Licensed Product</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.76</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Major Countries</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.77</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.78</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">MTD</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.79</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">NDA</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.80</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Net Sales</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.81</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Data Criteria</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.82</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Data Package</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.83</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Data Package Trigger</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.84</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Exercise Date</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.85</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Exercise Notice</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.86</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Period</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.87</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Right</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.88</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Other Compound</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.89</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Out of Pocket Costs</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.90</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.91</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Part 1</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.92</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Part 2</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.93</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.94</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Person</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.95</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Pharmacovigilance Agreement</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.96</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase I Development Costs</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.97</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase I Plan</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.98</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase I Program</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.99</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase I Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;"></table></div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.100</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase II Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.101</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase III Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.102</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Pivotal Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.103</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Post-Marketing Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.104</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Product</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.105</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.106</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Regulatory Approval</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.107</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Regulatory Authority</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.108</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Research Plan</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.109</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Research and Development Term</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.110</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Clinical Compounds</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.111</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Group</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.112</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Know-How</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.113</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Marketed Products</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.114</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.115</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Sole IP</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.116</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Territory</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.117</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">ROW</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.118</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Royalty Term</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.119</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Sales</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.120</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Screening</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.121</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Screening Hit</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.122</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Sublicensee</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.123</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Target</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.124</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Target Hypothesis</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.125</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Target Validation</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.126</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Terminated Target</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.127</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Territory</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.128</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Third Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.129</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">US</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.130</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">US$</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.131</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Valid Claim</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.132</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Additional Definitions</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Grant of License and Exclusivity</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Licenses</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Right of First Negotiation and [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Sublicenses</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Third Party Payments</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Exclusivity</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">3.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option of Roche</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">3.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Right</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">3.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Information Sharing for Option Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">4.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Research Collaboration</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">4.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Conduct of the Research</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">4.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Records; Reports</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">5.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Conduct of the Phase I Program</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">5.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase I Program</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">5.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Records; Reports</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">6.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Diligence</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Development</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Scope</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Management</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Development of Program 2 and Program 4</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;"></table></div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Governance</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Joint Research Committee</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">JDC</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Members</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Responsibilities of the JRC</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Responsibilities of the JDC</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.6</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Meetings</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.7</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Minutes</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.8</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Decisions</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.9</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Information Exchange</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.10</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Alliance Director</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.11</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Limitations of Authority</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.12</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Expenses</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.13</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Lifetime</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.14</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Other Committees</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">9.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Manufacture and Supply</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">9.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Manufacturing Right</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">9.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Technology Transfer</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">9.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Inspection Right</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">9.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Review of Draft CRO Agreements</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Regulatory</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Responsibility</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Reporting Adverse Events</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">11.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Commercialization</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">11.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Responsibility</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">11.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Updates</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">11.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Recalls, Market Withdrawals or Corrective Actions.</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Payment</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Initiation Payment</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Pre-Option Exercise Fees</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Costs for Work Conducted Under Research Plans</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Exercise Fee</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Phase I Development Cost Share</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.6</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Development Cost Share</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.7</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Development Event Payments</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.8</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Sales Based Event</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.9</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Royalty Payments</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.10</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Disclosure of Payments</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.11</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Only One Royalty</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Accounting and reporting</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Timing of Payments</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Late Payment</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Method of Payment</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Currency Conversion</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Reporting</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">14.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Taxes</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">15.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Auditing</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">15.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Right to Audit</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">15.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Audit Reports</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">15.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Over- or Underpayment</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Intellectual Property</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Ownership of Inventions</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Patent Rights Owned Jointly</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;"></table></div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">German Statute on Employee&#x2019;s Inventions</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Trademarks and Labeling</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Prosecution by BPM</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.6</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Prosecution of Other Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.7</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Patent Coordination Team</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.8</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Unified Patent Court (Europe)</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.9</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">CREATE Act</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.10</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Infringement</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.11</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Defense</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.12</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Common Interest Disclosures</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.13</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Hatch-Waxman</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.14</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Patent Term Extensions</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Representations and Warranties</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Third Party Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Ownership of Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Inventors</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Grants</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Authorization</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.6</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Validity of Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.7</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Ownership and Validity of Know-How</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.8</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">No Claims</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.9</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">No Conflict</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">17.10</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">No Other Representations</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">18.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Indemnification</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">18.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Indemnification by Roche</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">18.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Indemnification by BPM</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">18.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Procedure</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">19.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Liability</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">19.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Limitation of Liability</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">19.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Disclaimer</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Obligation Not to Disclose Confidential Information</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Non-Use and Non-Disclosure</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Permitted Disclosure</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Press Releases</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Publications</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Commercial Considerations</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Term and Termination</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Commencement and Term</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Termination</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Consequences of Termination</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Survival</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">22.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Bankruptcy</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:90.44%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Miscellaneous</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.1</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Governing Law</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.2</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Disputes</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.3</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Arbitration</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.4</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Assignment</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.5</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Debarment</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.6</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Independent Contractor</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.7</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Unenforceable Provisions and Severability</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.8</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Waiver</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.9</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Appendices</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.10</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Entire Understanding</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.11</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Amendments</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.12</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Invoices</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.13</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Notice</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.14</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Counterparts</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.15</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Performance by Affiliates</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.16</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Force Majeure</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.17</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Compliance with Export Regulations</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.18</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Interpretation</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.19</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Waiver of Rule of Construction</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.22%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.20</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:84.78%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Headings</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.34%;;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc148947682"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Collaboration and License Agreement</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, </font><font style="display:inline;font-family:Times New Roman,Times,serif;">BPM owns or controls a proprietary uniquely annotated small molecule library addressing the entire kinome, including well-characterized library sub-sets suited for screening purposes, and provides significant chemistry and preclinical development expertise and experience in bringing hits from this library through lead optimization and GLP Tox Studies to Phase I Study in an efficient manner; and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, BPM has proprietary bioinformatics expertise including algorithms for mining of genomic information which supports elucidation of new targets or provides differentiated insights on biology of known targets; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical products, and owns or controls </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, Roche is a leader in the field of cancer immunotherapy clinical development including combination trials; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, Roche and BPM wish to combine their respective expertise to develop products against three (3) selected targets (</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) as well as up to an additional two (2) targets selected from a collaboratively shared screening and target validation effort based on BPM Technology (defined below) and Roche&#x2019;s proprietary assays and know-how in cancer immunotherapy; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, BPM is willing to grant to Roche rights to opt-into each of these five (5) programs at a defined point in time and to use BPM&#x2019;s intellectual property rights to Exploit Collaboration Compounds, Products and Licensed Products in the Territory for use in the Field (as such terms are respectively defined below), as contemplated herein; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, Roche and BPM agree that BPM will perform certain activities to Exploit the Collaboration Compounds, Products and Licensed Products for use in the Field (as such terms are respectively defined below).</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc148947671"></a><a name="_Toc362302471"></a><a name="_Toc442238490"></a><a name="_Toc442266136"></a><a name="_Toc445389967"></a><a name="_Toc450305348"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.&nbsp;&nbsp;&nbsp;&nbsp;Definitions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc269738841"></a><a name="_Toc285806765"></a><a name="_Toc286399272"></a><a name="_Toc286399515"></a><a name="_Toc269738843"></a><a name="_Toc285806767"></a><a name="_Toc286399274"></a><a name="_Toc286399517"></a><a name="_Toc148947672"></a><a name="_Toc362302478"></a><a name="_Toc442238491"></a><a name="_Toc442266137"></a><a name="_Ref442257374"></a><a name="_Ref442257392"></a><a name="_Toc445389968"></a><a name="_Toc450305349"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.1&nbsp;&nbsp;&nbsp;&nbsp;Affiliate</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Affiliate&#x201D; shall mean, with respect to a Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with such Person. As used in this definition of &#x201C;Affiliate,&#x201D; the term &#x201C;control&#x201D; shall mean the direct or indirect ownership of more than fifty percent </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">1</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">(&gt;50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of such Person whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, neither </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and/or its subsidiaries (if any) nor </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and/or its subsidiaries (if any) shall be deemed as Affiliates of Roche unless Roche provides written notice to BPM of its desire to include </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and/or their respective subsidiaries (as applicable) as Affiliate(s) of Roche.</font><a name="_Toc148947673"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302479"></a><a name="_Toc442238492"></a><a name="_Toc442266138"></a><a name="_Toc445389969"></a><a name="_Toc450305350"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.2&nbsp;&nbsp;&nbsp;&nbsp;Agreement</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Agreement&#x201D; shall mean </font><font style="display:inline;font-family:Times New Roman,Times,serif;">this document including any and all appendices and amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302480"></a><a name="_Toc442238493"></a><a name="_Toc442266139"></a><a name="_Toc445389970"></a><a name="_Toc450305351"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.3&nbsp;&nbsp;&nbsp;&nbsp;Agreement Term</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Agreement Term&#x201D; shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided in Article 21, expiring on the date when no royalty or other payment obligations under this Agreement are or will become due.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389971"></a><a name="_Toc450305352"></a><a name="_Toc442238494"></a><a name="_Toc442266140"></a><a name="_Toc362302482"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.4&nbsp;&nbsp;&nbsp;&nbsp;Allocable Overhead</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Allocable Overhead&#x201D; shall mean costs incurred by a Party or for its account which are attributable to a Party&#x2019;s supervisory or support services / functions, occupancy costs, corporate bonus (to the extent not charged directly to department), and its payroll, information systems, human relations or purchasing functions and which are allocated to company departments based on space occupied or headcount or other activity-based method.&nbsp;&nbsp;Allocable Overhead shall not include any costs attributed to a Party&#x2019;s direct personnel costs or Out of Pocket Costs or to general corporate activities including, by way of example, executive management, investor relations, business development, legal affairs and finance.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389972"></a><a name="_Toc450305353"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.5&nbsp;&nbsp;&nbsp;&nbsp;Animal POC</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Animal POC&#x201D; shall mean the demonstration of efficacy of Collaboration Compounds in at least one animal model performed by or on behalf of Roche during Lead Optimization.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238495"></a><a name="_Toc442266141"></a><a name="_Toc445389973"></a><a name="_Toc450305354"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.6&nbsp;&nbsp;&nbsp;&nbsp;Applicable Law</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Applicable Law&#x201D; shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same is applicable to the Parties&#x2019; respective rights or the performance by the Parties of their respective obligations under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302489"></a><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389974"></a><a name="_Toc450305355"></a><a name="_Toc442238496"></a><a name="_Toc442266142"></a><a name="_Ref441948604"></a><a name="_Toc362302473"></a><a name="_Ref440436145"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.7&nbsp;&nbsp;&nbsp;&nbsp;Backup Compound</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Backup Compound&#x201D; shall mean, on a Collaboration Target-by-Collaboration Target basis, any Collaboration Compound made under the Research Plan for a given Collaboration Target that is intended to replace a more advanced Collaboration Compound in the event development of such more advanced Collaboration Compound is terminated, </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389975"></a><a name="_Toc450305356"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.8&nbsp;&nbsp;&nbsp;&nbsp;BPM Group</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;BPM Group&#x201D; shall mean collectively BPM, its Affiliates and its Sublicensees.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442060437"></a><a name="_Ref442060440"></a><a name="_Ref442127955"></a><a name="_Toc442238497"></a><a name="_Toc442266143"></a><a name="_Toc445389976"></a><a name="_Toc450305357"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.9&nbsp;&nbsp;&nbsp;&nbsp;BPM </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">IP</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;BPM IP&#x201D; shall mean (a) Know-How and Patent Rights that BPM and its Affiliates Control (i) as of the Effective Date, and/or (ii) during the Agreement Term to the extent used by BPM or its Affiliates to perform activities under this Agreement (but excluding Supplemental Studies</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">2</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">unless Roche opts-in pursuant to Section 7.2), (b) BPM&#x2019;s interest in any Joint IP, and (c) BPM Sole IP, and in each case ((a) through (c)) that are necessary or useful for the Exploitation of Collaboration Compounds, Products or Licensed Products, but excluding BPM Technology, Collaboration Compound IP and Other Compound IP. The foregoing Patent Rights in the BPM IP shall be listed in Appendix 1.9 of this Agreement and updated from time to time (but failure to list same will not exclude them as BPM IP).&nbsp;&nbsp;For clarity, after any Change of Control of BPM, no Know-How or Patent Rights of any BPM Affiliate that becomes a BPM Affiliate after the Change of Control of BPM shall become &#x201C;BPM IP&#x201D; hereunder unless such Know-How or Patent Rights are intentionally used by BPM in BPM&#x2019;s performance of research, development or commercialization activities under this Agreement.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238498"></a><a name="_Toc442266144"></a><a name="_Toc445389977"></a><a name="_Toc450305358"></a><a name="_Toc362302475"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.10&nbsp;&nbsp;&nbsp;BPM Net Sales</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;BPM Net Sales&#x201D; shall mean</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> the net sales on behalf of BPM and any of its Affiliates or Sublicensees for any Licensed Product sold to Third Parties (other than Sublicensees) in bona fide, arms-length transactions, as determined in accordance with GAAP, less the following deductions:&nbsp;&nbsp;(a) normal trade and cash discounts, (b) amounts repaid or credited by reasons of defects, rejections, recalls or returns, (c) rebates and chargebacks to customers and Third Parties (including Medicare, Medicaid, Managed Healthcare and similar types of rebates), (d) any amounts recorded in gross revenue associated with goods provided to customers for free, (e) amounts provided or credited to customers through coupons and other discount programs, (f) delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates, (g) fee for service payments to customers for any non-separable services (including compensation for maintaining agreed inventory levels and providing information), (h) a fixed deduction of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for direct expenses related to the sales of Licensed Product(s) for distribution and warehousing expenses and uncollectible amounts on previously sold Licensed Products, (i) taxes and any other governmental charges or levies imposed upon or measured by the Exploitation of a Licensed Product (excluding income or franchise taxes) as well as government mandated fees and taxes and other government charges, including any fees, taxes or other charges specifically attributable to a Licensed Product that become due in connection with any healthcare reform, change in government pricing or discounting schemes, or other action of a government or regulatory body, and (j) other reductions or specifically identifiable amounts deducted for reasons similar to those listed above in accordance with GAAP.&nbsp;&nbsp;For clarity, no deduction may be taken more than once in the calculation of BPM Net Sales.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;color:#000000;">In the case of any sale or other disposal of a Licensed Product between or among BPM and any of its Affiliates or Sublicensees, for resale, BPM Net Sales shall be calculated only on the value charged or invoiced on the first arm&#x2019;s-length sale thereafter to a Third Party (other than a Sublicensee).&nbsp;&nbsp;In the case of any sale that is not invoiced or is delivered before invoice, BPM Net Sales shall be calculated at the time all the revenue recognition criteria under GAAP are met.&nbsp;&nbsp;Notwithstanding the foregoing, the following will not be included in BPM Net Sales: (i) sales between or among BPM and its Affiliates or Sublicensees (but BPM Net Sales will include sales to the first Third Party (other than a Sublicensee) by BPM or its Affiliates or Sublicensees); (ii) samples of Licensed Product used to promote additional BPM Net Sales, in amounts consistent with normal business practices of BPM or its Affiliates or Sublicensees; and (iii) disposal or use of Licensed Products in Clinical Studies or under compassionate use, patient assistance, named patient use, or test marketing programs or non-registrational studies or other similar programs or studies where the Licensed Product is supplied without charge or at the actual manufacturing cost thereof (without allocation of indirect costs or any mark-up).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">3</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;color:#000000;">With respect to a Combination Product, BPM Net Sales of such Combination Product eligible for royalties shall be adjusted to subtract the Relative Commercial Value of any Other Component of such Combination Product in accordance with Section 12.9.4.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">To the extent that BPM or its Affiliates or Sublicensees receives consideration other than or in addition to cash upon the sale of a Licensed Product, or the performance of any services (including preliminary treatments or follow-up treatments) related to such Licensed Product, BPM Net Sales will include the fair market value of such additional consideration.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238499"></a><a name="_Toc442266145"></a><a name="_Toc445389978"></a><a name="_Toc450305359"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.11&nbsp;&nbsp;&nbsp;BPM Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;BPM Patent Rights&#x201D; shall mean all Patent Rights contained in the BPM IP.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238500"></a><a name="_Toc442266146"></a><a name="_Toc445389979"></a><a name="_Toc450305360"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.12&nbsp;&nbsp;&nbsp;BPM Sole IP</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;BPM Sole IP&#x201D; shall mean all Patent Rights and Know-How arising from a BPM Invention.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238501"></a><a name="_Toc442266147"></a><a name="_Toc445389980"></a><a name="_Toc450305361"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.13&nbsp;&nbsp;&nbsp;BPM Technology</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;BPM Technology&#x201D; shall mean BPM&#x2019;s proprietary library (in the form as of the Effective Date or during the Research and Development Term) and related Patent Rights and Know-How against the kinome and its annotation.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238502"></a><a name="_Toc442266148"></a><a name="_Toc445389981"></a><a name="_Toc450305362"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.14&nbsp;&nbsp;&nbsp;BPM Territory</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;BPM Territory&#x201D; shall mean, with respect to Program 2 and Program 4, the US.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238503"></a><a name="_Toc442266149"></a><a name="_Toc445389982"></a><a name="_Toc450305363"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.15&nbsp;&nbsp;&nbsp;Business Day</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Business Day&#x201D; shall mean 9:00am to 5:00pm local time on a day other than a Saturday, Sunday or bank or other public or federal holiday in Switzerland or Massachusetts, US.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302490"></a><a name="_Toc442238504"></a><a name="_Toc442266150"></a><a name="_Toc445389983"></a><a name="_Toc450305364"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.16&nbsp;&nbsp;&nbsp;Calendar Quarter</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Calendar Quarter&#x201D; shall mean each period of three (3) consecutive calendar months, ending March 31, June 30, September 30, and December 31.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302491"></a><a name="_Toc442238505"></a><a name="_Toc442266151"></a><a name="_Toc445389984"></a><a name="_Toc450305365"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.17&nbsp;&nbsp;&nbsp;Calendar Year</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Calendar Year&#x201D; shall mean the period of time beginning on January 1 and ending December 31, except for the first year which shall begin on the Effective Date and end on December 31.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref441048896"></a><a name="_Ref441054579"></a><a name="_Toc442238506"></a><a name="_Toc442266152"></a><a name="_Toc445389985"></a><a name="_Toc450305366"></a><a name="_Toc362302492"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.18&nbsp;&nbsp;&nbsp;CCS Criteria</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;CCS Criteria&#x201D; shall mean the criteria set forth in Appendix 1.18 of this Agreement that constitute clinical candidate selection, unless such criteria are modified by the JRC.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238507"></a><a name="_Toc442266153"></a><a name="_Toc445389986"></a><a name="_Toc450305367"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.19&nbsp;&nbsp;&nbsp;Change of Control</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Change of Control&#x201D; shall mean, with respect to a Party: (a)&nbsp;the acquisition (in a transaction or series of related transactions) by any Third Party, together with its Affiliates, of beneficial ownership of fifty percent (50%) or more of the then outstanding securities or combined voting power of such Party, other than acquisitions by employee benefit plans sponsored or maintained by such Party; (b)&nbsp;the consummation of a business combination (including a merger or consolidation) involving such Party with a Third Party, unless, following such business combination, the stockholders of such Party immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (&gt;50%) of the then outstanding securities or combined voting power of the surviving entity or the parent of the surviving entity immediately after such business combination; or (c)&nbsp;the sale or other transfer to a Third Party of </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">4</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">all or substantially all of such Party&#x2019;s and its Affiliates&#x2019; assets or business relating to the subject matter of the Agreement.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389987"></a><a name="_Toc450305368"></a><a name="_Toc362302496"></a><a name="_Toc442238508"></a><a name="_Toc442266154"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.20&nbsp;&nbsp;&nbsp;Change of Control Group</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Change of Control Group&#x201D; shall mean with respect to a Party, the person or entity, or group of persons or entities, that is the acquirer of, or a successor to, a Party in connection with a Change of Control, together with affiliates of such persons or entities that are not Affiliates of such Party immediately prior to the completion of such Change of Control of such Party.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389988"></a><a name="_Toc450305369"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.21&nbsp;&nbsp;&nbsp;Clinical Study</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Clinical Study&#x201D; shall mean any Phase I Study, Phase II Study, Phase III Study, Pivotal Study, Post-Marketing Study, Supplemental Study or other study in humans to obtain information regarding the product, including information relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product, as applicable.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440432052"></a><a name="_Toc442238509"></a><a name="_Toc442266155"></a><a name="_Toc445389989"></a><a name="_Toc450305370"></a><a name="_Toc362302497"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.22&nbsp;&nbsp;&nbsp;CLS Achieved</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;CLS Achieved&#x201D; shall mean that a Product contains a Collaboration Compound meeting the CLS Criteria, unless such criteria are modified by the JRC.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440977234"></a><a name="_Toc442238510"></a><a name="_Toc442266156"></a><a name="_Toc445389990"></a><a name="_Toc450305371"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.23&nbsp;&nbsp;&nbsp;CLS Criteria</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;CLS Criteria&#x201D; shall mean the criteria set forth in Appendix 1.23 of this Agreement that constitute clinical lead selection, unless such criteria are modified by the JRC.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238511"></a><a name="_Toc442266157"></a><a name="_Toc445389991"></a><a name="_Toc450305372"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.24&nbsp;&nbsp;&nbsp;Collaboration Compound</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Collaboration Compound&#x201D; shall mean any compound made under the Research Plan for a given Collaboration Target that satisfies the Compound Criteria. A Collaboration Compound includes all salts, polymorphs, metabolites, prodrugs, isomers, enantiomers and stereoisomers of such Collaboration Compound, in each case that satisfies the Compound Criteria.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238512"></a><a name="_Toc442266158"></a><a name="_Toc445389992"></a><a name="_Toc450305373"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.25&nbsp;&nbsp;&nbsp;Collaboration Compound IP</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Collaboration Compound IP&#x201D; shall mean all Patent Rights and Know-How Covering Collaboration Compounds and that is generated by either Party individually or both Parties jointly pursuant to a Research Plan or Phase I Plan.&nbsp; </font><a name="_Toc442238513"></a><a name="_Toc442266159"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389993"></a><a name="_Toc450305374"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.26&nbsp;&nbsp;&nbsp;Collaboration Target</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Collaboration Target&#x201D; shall mean (i) each of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (Uniprot </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;(</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;] </font><font style="display:inline;font-family:Times New Roman,Times,serif;">is Uniprot </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;] </font><font style="display:inline;font-family:Times New Roman,Times,serif;">and </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;] </font><font style="display:inline;font-family:Times New Roman,Times,serif;">is Uniprot </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (Uniprot </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and (ii) each of the Targets selected from the Pool to pursue in Part 2 or mutually selected by the Parties in Part 2 </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, for each of (i) and (ii) subject to exchange of such Target pursuant to Sections 4.1.5 or 4.1.6, as applicable.&nbsp;&nbsp;For clarity, the Collaboration Targets shall not include any Excluded Targets, Leftover Targets or Terminated Targets. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref441868512"></a><a name="_Ref441870311"></a><a name="_Ref441948433"></a><a name="_Toc442238514"></a><a name="_Toc442266160"></a><a name="_Toc445389994"></a><a name="_Toc450305375"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.27&nbsp;&nbsp;&nbsp;Combination Product</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Combination Product&#x201D; shall mean</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442259377"></a><font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;a single pharmaceutical formulation (whether co-formulated or administered together via the same administration route) containing as its active ingredients both a Collaboration Compound and one or more other therapeutically or prophylactically active ingredients (each an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Other Component</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), or</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">5</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;a combination therapy comprised of a Collaboration Compound and one or more Other Component(s), whether priced and sold in a single package containing such multiple products, packaged separately but sold together for a single price, or sold under separate price points but labeled for use together. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">in each case, including all dosage forms, formulations, presentations, and package configurations.&nbsp;&nbsp;Drug delivery vehicles, adjuvants and excipients will not be deemed to be &#x201C;active ingredients&#x201D;, except in the case where such delivery vehicle, adjuvant or excipient is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7).&nbsp;&nbsp;All references to Products or Licensed Products in this Agreement shall be deemed to include Combination Products.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc450305376"></a><a name="_Toc362302498"></a><a name="_Toc442238515"></a><a name="_Toc442266161"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.28&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;color:#000000;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445389996"></a><a name="_Toc450305377"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.29&nbsp;&nbsp;&nbsp;Commercially Reasonable Efforts</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Commercially Reasonable Efforts&#x201D; shall mean, with respect to the performance of an obligation under this Agreement, such level of efforts and resources consistent with the efforts Roche or BPM, as applicable, devotes to a similar obligation at the same stage of research, development or commercialization, as applicable, for its own internally developed pharmaceutical </font><font style="display:inline;font-family:Times New Roman,Times,serif;">products in a similar area with similar market potential, at a similar stage of their product life, taking into account the existence of other competitive products in the market place or under development, the proprietary position of the product, the regulatory structure involved, the anticipated profitability of the product and other relevant factors. It is understood that such level of efforts or resources may change from time to time based upon changing scientific, business and marketing and return on investment considerations; provided, however, that the payments required to be made by a Party to the other Party pursuant to this Agreement will not be taken into account.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">However, Roche (and its Affiliates) does not always seek to market its own products in every country or seek to obtain Regulatory Approval in every country or for every potential Indication. As a result, the exercise of diligence by Roche under this standard is to be determined by judging Roche&#x2019;s efforts in (i) the Major Countries, taken as a whole, and (ii) the Territory excluding the Major Countries, taken as a whole.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302499"></a><a name="_Toc442238516"></a><a name="_Toc442266162"></a><a name="_Toc445389997"></a><a name="_Toc450305378"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.30&nbsp;&nbsp;&nbsp;Companion Diagnostic</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Companion Diagnostic&#x201D; shall mean any product or service that:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;identifies a person having a disease or condition, or a molecular genotype or phenotype that predisposes a person to such disease or condition, for which a Product or Licensed Product could be used to treat and/or prevent such disease or condition;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;defines the prognosis or monitors the progress of a disease or condition in a person for which a Product or Licensed Product could be used to treat and/or prevent such disease or condition; </font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;is used to select a therapeutic or prophylactic regimen, wherein at least one&nbsp;(1) potential therapeutic or prophylactic regimen involves a Product or Licensed Product, and where the selected regimen is determined, based on the use of such product or service, to likely be effective and/or to be safe for a person; and/or</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;is used to confirm a Product or Licensed Product&#x2019;s biological activity and/or to optimize dosing or the scheduled administration of a Product or Licensed Product.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238517"></a><a name="_Toc442266163"></a><a name="_Toc445389998"></a><a name="_Toc450305379"></a><a name="_Toc362302501"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.31&nbsp;&nbsp;&nbsp;Composition of Matter Claim</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term "Composition of Matter Claim" shall mean, for a given Licensed Product in a given country of the Territory, a Valid Claim of the Collaboration Compound IP or BPM IP or any Patent Rights owned or in-licensed by Roche or its Affiliates (only in the case of sales of Licensed Product </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">6</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">in the BPM Territory for Program 2 and Program 4) that Covers the composition of matter of the Collaboration Compound that is included in such Licensed Product, in whole or as a component thereof.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445115040"></a><a name="_Toc445115041"></a><a name="_Toc445115042"></a><a name="_Ref440433236"></a><a name="_Ref441951096"></a><a name="_Toc442238519"></a><a name="_Toc442266165"></a><a name="_Toc445389999"></a><a name="_Toc450305380"></a><a name="_Ref359832732"></a><a name="_Toc362302503"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.32&nbsp;&nbsp;&nbsp;Compound Criteria</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Compound Criteria&#x201D; shall mean the criteria, on a Collaboration Target-by-Collaboration Target basis, that are (i) determined by the JRC, (ii) approved by the Parties, and (iii) documented as part of the applicable Research Plan. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238520"></a><a name="_Toc442266166"></a><a name="_Ref442259429"></a><a name="_Ref442262691"></a><a name="_Toc445390000"></a><a name="_Toc450305381"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.33&nbsp;&nbsp;&nbsp;Compulsory Sublicense</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> Compensation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Compulsory Sublicense Compensation&#x201D; shall mean, for a given country or region, the compensation paid to the Roche Group or the BPM Group (as applicable) by a Third Party (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Compulsory Sublicensee</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) under a license or sublicense of any applicable Patent Rights granted to the Compulsory Sublicensee (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Compulsory Sublicense</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) through the order, decree or grant of a governmental authority having competent jurisdiction in such country or region, authorizing such Third Party to manufacture, use, sell, offer for sale, import or export a Licensed Product in such country or region.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref359803096"></a><a name="_Toc362302504"></a><a name="_Toc442238521"></a><a name="_Toc442266167"></a><a name="_Toc445390001"></a><a name="_Toc450305382"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.34&nbsp;&nbsp;&nbsp;Confidential Information</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Confidential Information&#x201D; shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Disclosing Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to the other Party or its Affiliates (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Receiving Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). Confidential Information shall not include any information, data or know-how that:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;text-indent: -24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;was generally available to the public at the time of disclosure, or becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;text-indent: -24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;text-indent: -24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iii)&nbsp;&nbsp;&nbsp;is obtained by the Receiving Party at any time lawfully from a Third Party under circumstances permitting its use or disclosure,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;text-indent: -24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iv)&nbsp;&nbsp;&nbsp;is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential Information, or</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;text-indent: -24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(v)&nbsp;&nbsp;&nbsp;&nbsp;is approved in writing by the Disclosing Party for release by the Receiving Party.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;text-indent: -24pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The terms of this Agreement shall be considered Confidential Information of the Parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302505"></a><a name="_Toc442238522"></a><a name="_Toc442266168"></a><a name="_Toc445390002"></a><a name="_Toc450305383"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.35&nbsp;&nbsp;&nbsp;Continuation Election Notice</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Continuation Election Notice&#x201D; shall mean the notice BPM provides to Roche under Section&nbsp;21.3.1 describing (i)&nbsp;BPM&#x2019;s </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">bona fide</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> intention(s) to continue ongoing development and commercialization of Licensed Product(s) and (ii)&nbsp;BPM&#x2019;s request for Roche&#x2019;s continuation of activities during the termination period or transfer of the data, material and information relating to the Licensed Product(s) in accordance with Section&nbsp;21.3.1.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302506"></a><a name="_Toc442238523"></a><a name="_Toc442266169"></a><a name="_Toc445390003"></a><a name="_Toc450305384"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.36&nbsp;&nbsp;&nbsp;Control</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Control&#x201D; shall mean (as an adjective or as a verb including conjugations and variations such as &#x201C;Controls&#x201D; &#x201C;Controlled&#x201D; or &#x201C;Controlling&#x201D;)</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (a)&nbsp;with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b)&nbsp;with respect to proprietary materials, the possession by a Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party or </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">7</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">without being obligated to pay any royalties or other consideration therefor, except for that which BPM or its Affiliates in-licenses and under which Roche elects to take a sublicense and agrees to make the associated payments pursuant to Section 2.4 which shall be considered under the Control of BPM or its Affiliates.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302507"></a><a name="_Toc442238524"></a><a name="_Toc442266170"></a><a name="_Toc445390004"></a><a name="_Toc450305385"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.37&nbsp;&nbsp;&nbsp;Cover</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Cover&#x201D; shall mean (as an adjective or as a verb including conjugations and variations such as &#x201C;Covered,&#x201D; &#x201C;Coverage&#x201D; or &#x201C;Covering&#x201D;) that the Exploitation of a given compound, formulation or product would infringe a Valid Claim in the absence of a license under or ownership in the Patent Rights to which such Valid Claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular Valid Claim shall be made on a country-by-country basis.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440618271"></a><a name="_Toc442238525"></a><a name="_Toc442266171"></a><a name="_Toc445390005"></a><a name="_Toc450305386"></a><a name="_Toc362302509"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.38&nbsp;&nbsp;&nbsp;CRO</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;CRO&#x201D; shall mean a contract research organization or a contract manufacturing organization, a list of approved CROs is attached as Appendix 1.38, as such appendix may be amended or restated from time to time in accordance with the terms of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390006"></a><a name="_Toc450305387"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.39&nbsp;&nbsp;&nbsp;Development Costs</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Development Costs&#x201D; shall mean as to each Collaboration Target in the Field in the Territory, those (i) costs and expenses directly incurred (including personnel costs and Allocable Overhead associated with employees and contractors of a Party) with the performance of any clinical development activities (other than Phase I Studies) for Collaboration Compounds, Products or Licensed Products for such Collaboration Target, (ii) fees charged by Third Party service providers and other Out of Pocket Costs reasonably incurred in connection with the performance of any Clinical Study (other than Phase I Studies) with respect to Collaboration Compounds, Products, Licensed Products, or Companion Diagnostics for such Collaboration Target, and (iii) all costs associated with research or development of Companion Diagnostics, in each case, that are recorded as an expense in accordance with IFRS or GAAP as applicable and consistently applied. In addition, Development Costs shall include (A) the cost of additional studies on the toxicological, pharmacokinetic, metabolic or clinical aspects of such Product or Licensed Product conducted by individual investigators or consultants and (B) expenses for data management, statistical designs and studies, document preparation, and other expenses associated with the clinical testing program for additional studies. For clarity, Development Costs for each Product or Licensed Product shall include (a) manufacturing and supply costs and expenses associated with such Product or Licensed Product, and (b) costs related to preparing the initial regulatory dossier for such Product or Licensed Product.&nbsp;&nbsp;All manufacturing and supply costs and expenses for Roche Clinical Compounds and Roche Marketed Products shall be at Roche&#x2019;s sole expense. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For clarity, Development Costs shall exclude (A) capital expenditures, (B) Phase I Development Costs, and (C) for Program 2 and Program 4, any costs and expenses associated with Supplemental Studies (other than Supplemental Studies that a Party opts-in to pursuant to Section 7.2).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc440984794"></a><a name="_Toc362302510"></a><a name="_Toc442238527"></a><a name="_Toc442266173"></a><a name="_Toc445390007"></a><a name="_Toc450305388"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.40&nbsp;&nbsp;&nbsp;Development Plan</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Development Plan&#x201D; shall mean, for each Program, the plan for the clinical development of Licensed Products for such Program in the Field in the Territory, which plan shall include a budget for each of Program 2 and Program 4 and the planned Clinical Studies for the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Label Pursuits for each of Program 2 and Program 4.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">8</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302518"></a><a name="_Toc442238528"></a><a name="_Toc442266174"></a><a name="_Toc445390008"></a><a name="_Toc450305389"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.41&nbsp;&nbsp;&nbsp;Effective Date</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Effective Date&#x201D; shall mean </font><a name="_DV_C531"></a><font style="display:inline;font-family:Times New Roman,Times,serif;">March 14, 2016.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302521"></a><a name="_Toc442238529"></a><a name="_Toc442266175"></a><a name="_Toc445390009"></a><a name="_Toc450305390"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.42&nbsp;&nbsp;&nbsp;EU</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;EU&#x201D; shall mean the European Union and all its then-current member countries.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238530"></a><a name="_Toc442266176"></a><a name="_Toc445390010"></a><a name="_Toc450305391"></a><a name="_Toc167093708"></a><a name="_Toc362302522"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.43&nbsp;&nbsp;&nbsp;Excluded Field</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Excluded Field&#x201D; shall mean </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440433425"></a><a name="_Toc442238531"></a><a name="_Toc442266177"></a><a name="_Toc445390011"></a><a name="_Toc450305392"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.44&nbsp;&nbsp;&nbsp;Excluded Targets</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Excluded Targets&#x201D; shall mean the Targets listed in Appendix 1.44 of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238532"></a><a name="_Toc442266178"></a><a name="_Toc445390012"></a><a name="_Toc450305393"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.45&nbsp;&nbsp;&nbsp;Expert</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Expert&#x201D; shall mean a person with no less than ten&nbsp;(10) years of pharmaceutical industry experience and expertise having occupied at least one senior position within a large pharmaceutical company relating to drug discovery, product development (in the case of Section 2.5.2) or commercialization and/or licensing (in the case of Section 12.9.4) but excluding any current or former employee or consultant of either Party or its Affiliates. Such person shall be fluent in the English language.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238533"></a><a name="_Toc442266179"></a><a name="_Toc445390013"></a><a name="_Toc450305394"></a><a name="_Toc362302523"></a><a name="_Toc167093709"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.46&nbsp;&nbsp;&nbsp;Exploit</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Exploit&#x201D; shall mean (including conjugations and variations such as &#x201C;Exploiting&#x201D; or &#x201C;Exploitation&#x201D;) to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell, have sold and offer for sale and have offered for sale, including all research, development, manufacturing and commercialization activities.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390014"></a><a name="_Toc450305395"></a><a name="_Toc442238534"></a><a name="_Toc442266180"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.47&nbsp;&nbsp;&nbsp;FBMC</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;FBMC&#x201D; shall mean the sum of (a) the cost of goods produced, determined in accordance with IFRS or GAAP guidelines as consistently applied by Roche or BPM in the ordinary course of its business, including direct labor, material, payments to Third Parties for costs incurred and product testing costs of Collaboration Compounds, Products or Licensed Products, as well as Allocable Overhead, and (b) any other Out of Pocket Costs borne by Roche or BPM for the packaging, transport, customs clearance, and storage of Collaboration Compounds, Products or Licensed Products (e.g., containers, freight, duties, insurance and warehousing).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390015"></a><a name="_Toc450305396"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.48&nbsp;&nbsp;&nbsp;FDA</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;FDA&#x201D; shall mean the Food and Drug Administration of the United States of America.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302524"></a><a name="_Toc442238535"></a><a name="_Toc442266181"></a><a name="_Toc445390016"></a><a name="_Toc450305397"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.49&nbsp;&nbsp;&nbsp;FDCA</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;FDCA&#x201D; shall mean the Food, Drug and Cosmetics Act.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc167093710"></a><a name="_Toc362302525"></a><a name="_Toc442238536"></a><a name="_Toc442266182"></a><a name="_Toc445390017"></a><a name="_Toc450305398"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.50&nbsp;&nbsp;&nbsp;Field</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Field&#x201D; shall mean any use other than the Excluded Field.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc167093711"></a><a name="_Toc362302526"></a><a name="_Toc442238537"></a><a name="_Toc442266183"></a><a name="_Toc445390018"></a><a name="_Toc450305399"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.51&nbsp;&nbsp;&nbsp;Filing</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Filing&#x201D; shall mean the filing of an application by the FDA as defined in the FDCA and applicable regulations, or the equivalent application to the equivalent agency in any other country or group of countries, the official approval of which is required before any lawful commercial sale or marketing of Licensed Products.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">9</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc167093712"></a><a name="_Toc362302528"></a><a name="_Toc442238538"></a><a name="_Toc442266184"></a><a name="_Toc445390019"></a><a name="_Toc450305400"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.52&nbsp;&nbsp;&nbsp;First Commercial Sale</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;First Commercial Sale&#x201D; shall mean, on a country-by-country and Licensed Product-by-Licensed Product basis, the first commercial sale of a Licensed Product to a Third Party by the Roche Group or by the BPM Group, as applicable, in such country following the receipt of any Regulatory Approval required for the sale of such Licensed Product in such country, or if no such Regulatory Approval is required, the date of the first commercial sale of a Licensed Product in such country to a Third Party by (i) the Roche Group in such country or (ii) the BPM Group in the BPM Territory, as applicable</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238539"></a><a name="_Toc442266185"></a><a name="_Toc445390020"></a><a name="_Toc450305401"></a><a name="_Toc167093713"></a><a name="_Toc362302531"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.53&nbsp;&nbsp;&nbsp;GAAP</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;GAAP&#x201D; shall mean US Generally Acceptable Accounting Principles.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238540"></a><a name="_Toc442266186"></a><a name="_Toc445390021"></a><a name="_Toc450305402"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.54&nbsp;&nbsp;&nbsp;Generic Product</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Generic Product&#x201D; shall mean,</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">with respect to a particular Licensed Product and on a country-by-country basis, a generic pharmaceutical product that is marketed for sale by a Third Party (not licensed, supplied or otherwise permitted by the Roche Group or the BPM Group) and that: (i) (a) contains the same or substantially the same active ingredient as the Collaboration Compound in such Licensed Product; and (b) is approved for use in such country by a Regulatory Authority through an Abbreviated New Drug Application as defined in the FDCA, and the regulations promulgated thereunder, pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001, or any enabling legislation thereof, or pursuant to any similar abbreviated route of approval in such country; or (ii) (a) contains the same or substantially the same active ingredient as the Collaboration Compound in such Licensed Product; and (b) is approved for use in such country by a Regulatory Authority through a regulatory pathway referencing clinical data first submitted by the Roche Group or the BPM Group for obtaining Regulatory Approval for such Licensed Product.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc167093714"></a><a name="_Toc362302532"></a><a name="_Toc442238541"></a><a name="_Toc442266187"></a><a name="_Toc445390022"></a><a name="_Toc450305403"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.55&nbsp;&nbsp;&nbsp;Handle</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Handle&#x201D; shall mean preparing, filing, prosecuting (including interference and opposition proceedings) and maintaining (including interferences, reissue, re-examination, pre- and post-grant reviews, inter-parties reviews, derivation proceedings and opposition proceedings, patent term adjustment and extensions (including those arising from Regulatory Approvals), supplementary protection certificates and other similar proceedings), but not with respect to any infringement or other enforcement activities.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc443289272"></a><a name="_Toc443310210"></a><a name="_Toc443314872"></a><a name="_Toc443319398"></a><a name="_Toc443501262"></a><a name="_Toc443891136"></a><a name="_Toc443911719"></a><a name="_Toc443911987"></a><a name="_Toc443289273"></a><a name="_Toc443310211"></a><a name="_Toc443314873"></a><a name="_Toc443319399"></a><a name="_Toc443501263"></a><a name="_Toc443891137"></a><a name="_Toc443911720"></a><a name="_Toc443911988"></a><a name="_Toc443289274"></a><a name="_Toc443310212"></a><a name="_Toc443314874"></a><a name="_Toc443319400"></a><a name="_Toc443500490"></a><a name="_Toc443501264"></a><a name="_Toc443891138"></a><a name="_Toc443911721"></a><a name="_Toc443911989"></a><a name="_Toc362302535"></a><a name="_Toc442238543"></a><a name="_Toc442266189"></a><a name="_Toc445390023"></a><a name="_Toc450305404"></a><a name="_Toc167093716"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.56&nbsp;&nbsp;&nbsp;IFRS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;IFRS&#x201D; shall mean International Financial Reporting Standards.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302537"></a><a name="_Toc442238544"></a><a name="_Toc442266190"></a><a name="_Toc445390024"></a><a name="_Toc450305405"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.57&nbsp;&nbsp;&nbsp;IND</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;IND&#x201D; shall mean an application as defined in the FDCA and applicable regulations promulgated by the FDA, or the equivalent application to the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of the Products and/or Licensed Products in humans.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238545"></a><a name="_Toc442266191"></a><a name="_Toc445390025"></a><a name="_Toc450305406"></a><a name="_Toc362302538"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.58&nbsp;&nbsp;&nbsp;Indication</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Indication&#x201D; shall mean</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">a disease (i)&nbsp;for which the Licensed Product is indicated for treatment and (ii)&nbsp;that is described in the Licensed Product label as required by the Regulatory Approval granted by the applicable Regulatory Authority</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">10</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302539"></a><a name="_Toc442238546"></a><a name="_Toc442266192"></a><a name="_Toc445390026"></a><a name="_Toc450305407"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.59&nbsp;&nbsp;&nbsp;Initiation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Initiation&#x201D; shall mean</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">the date that a human is first dosed with the Product or Licensed Product, as applicable, in a Clinical Study approved by the respective Regulatory Authority.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238547"></a><a name="_Toc442266193"></a><a name="_Ref442264409"></a><a name="_Toc445390027"></a><a name="_Toc450305408"></a><a name="_Toc362302540"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.60&nbsp;&nbsp;&nbsp;Initiation of GLP Tox Study</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Initiation of GLP Tox Study&#x201D; shall mean</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">the date of the approval by the JRC of the final protocol for a study of the relationship between dose and its effects on the exposed animal, where (i)&nbsp;the study is to be conducted in accordance with Good Laboratory Practice standards and (ii)&nbsp;the study has been designed in expectation that the results may support establishment of a safe starting dose of the Product in human clinical studies (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">GLP Tox Study</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238548"></a><a name="_Toc442266194"></a><a name="_Toc445390028"></a><a name="_Toc450305409"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.61&nbsp;&nbsp;&nbsp;Insolvency Event</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Insolvency Event&#x201D; shall mean circumstances under which a Party (i)&nbsp;has a receiver or similar officer appointed over all or a material part of its assets or undertaking; (ii)&nbsp;passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (iii)&nbsp;enters into any composition or arrangement with its creditors (other than relating to a solvent restructuring); (iv)&nbsp;ceases to carry on business; or (v)&nbsp;is unable to pay its debts as they become due in the ordinary course of business.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc269738898"></a><a name="_Toc285806823"></a><a name="_Toc286399330"></a><a name="_Toc286399573"></a><a name="_Ref266956736"></a><a name="_Ref266956748"></a><a name="_Ref266956758"></a><a name="_Toc362302541"></a><a name="_Toc442238549"></a><a name="_Toc442266195"></a><a name="_Ref445463856"></a><a name="_Ref445463870"></a><a name="_Ref445463877"></a><a name="_Toc445390029"></a><a name="_Toc450305410"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.62&nbsp;&nbsp;&nbsp;Invention</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Invention&#x201D; shall mean an invention that is conceived in connection with any activity carried out pursuant to this Agreement. Under this definition, but subject to Section&nbsp;16.1, an Invention may be made by employees, consultants or contractors of</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> BPM </font><font style="display:inline;font-family:Times New Roman,Times,serif;">solely or jointly with a Third Party (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Invention</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), by employees, consultants or contractors of the Roche Group solely or jointly with a Third Party (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche Invention</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), or jointly by employees, consultants or contractors of</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> BPM </font><font style="display:inline;font-family:Times New Roman,Times,serif;">and employees, consultants or contractors of the Roche Group with or without a Third Party (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Joint Invention</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238550"></a><a name="_Toc442266196"></a><a name="_Toc445390030"></a><a name="_Toc450305411"></a><a name="_Toc362302542"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.63&nbsp;&nbsp;&nbsp;JDC</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;JDC&#x201D; shall mean the joint development committee that oversees all activities pursuant to the Phase I Plans and all clinical development of Licensed Products by the Parties after exercise of an Option Right, and is described in Section 8.2.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238551"></a><a name="_Toc442266197"></a><a name="_Toc445390031"></a><a name="_Toc450305412"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.64&nbsp;&nbsp;&nbsp;Joint IP</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Joint IP&#x201D; shall mean all Joint Patent Rights and Joint Know-How.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238552"></a><a name="_Toc442266198"></a><a name="_Toc445390032"></a><a name="_Toc450305413"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.65&nbsp;&nbsp;&nbsp;Joint Know-How</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Joint Know-How&#x201D; shall mean all Know-How that is conceived jointly by the Parties or their Affiliates or their Sublicensees in connection with any activity carried out pursuant to this Agreement.&nbsp;&nbsp;For clarity, Joint Know-How shall include all Know-How within the Biomarker IP.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302543"></a><a name="_Toc442238553"></a><a name="_Toc442266199"></a><a name="_Toc445390033"></a><a name="_Toc450305414"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.66&nbsp;&nbsp;&nbsp;Joint Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Joint Patent Rights&#x201D; shall mean all Patent Rights arising from a Joint Invention.&nbsp;&nbsp;For clarity, Joint Patent Rights shall include all Patent Rights within the Biomarker IP.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238554"></a><a name="_Toc442266200"></a><a name="_Toc445390034"></a><a name="_Toc450305415"></a><a name="_Toc362302544"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.67&nbsp;&nbsp;&nbsp;JOT</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;JOT&#x201D; shall mean a joint operating team if established by the JRC under Section 8.4 or the JDC under Section 8.5.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">11</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238555"></a><a name="_Toc442266201"></a><a name="_Toc445390035"></a><a name="_Toc450305416"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.68&nbsp;&nbsp;&nbsp;JRC</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;JRC&#x201D; shall mean the joint research committee that oversees all activities under the Research Plans, and is described in Section&nbsp;8.1.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302547"></a><a name="_Toc442238556"></a><a name="_Toc442266202"></a><a name="_Toc445390036"></a><a name="_Toc450305417"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.69&nbsp;&nbsp;&nbsp;Know-How</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Know-How&#x201D; shall mean data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or commercialization of Products and/or Licensed Products.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238557"></a><a name="_Toc442266203"></a><a name="_Toc445390037"></a><a name="_Toc450305418"></a><a name="_Toc362302551"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.70&nbsp;&nbsp;&nbsp;Lead Nomination</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Lead Nomination&#x201D; shall mean the preclinical development activities performed for each Collaboration Target at the beginning of Part 1 and for Collaboration Targets selected in Part 2 after Target Validation with the goal to identify Collaboration Compounds which satisfy the Lead Series Identified Criteria.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238558"></a><a name="_Toc442266204"></a><a name="_Toc445390038"></a><a name="_Toc450305419"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.71&nbsp;&nbsp;&nbsp;Lead Optimization</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Lead Optimization&#x201D; shall mean the preclinical development activities performed for each Collaboration Target following Lead Nomination, with the goal to identify Collaboration Compounds suitable for GLP Tox Studies and meeting CCS Criteria.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440437092"></a><a name="_Toc442238559"></a><a name="_Toc442266205"></a><a name="_Toc445390039"></a><a name="_Toc450305420"></a><a name="_Toc362302552"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.72&nbsp;&nbsp;&nbsp;Lead Series Identified</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> Criteria</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Lead Series Identified Criteria&#x201D; shall mean the lead series identified criteria set forth in Appendix 1.72 of this Agreement, unless such criteria are modified by the JRC.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238560"></a><a name="_Toc442266206"></a><a name="_Toc445390040"></a><a name="_Toc450305421"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.73&nbsp;&nbsp;&nbsp;Leftover Targets</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Leftover Targets&#x201D; shall mean those Collaboration Targets for which an Option Right has not been exercised by Roche, including those (i) in the Pool after the JRC&#x2019;s right to replace Collaboration Targets in the Pool has ended pursuant to Section 4.1.6, and/or (ii) that have been replaced with a new Collaboration Target, or for which further preclinical development activities are not pursued under Part 2.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390041"></a><a name="_Toc450305422"></a><a name="_Toc442238561"></a><a name="_Toc442266207"></a><a name="_Toc362302554"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.74&nbsp;&nbsp;&nbsp;Library Compound</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Library Compound&#x201D; shall mean any compound included in BPM Technology but excluding any Other Compound or Collaboration Compound.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390042"></a><a name="_Toc450305423"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.75&nbsp;&nbsp;&nbsp;Licensed Product</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Licensed Product&#x201D; shall mean a Product to which Roche has exercised its Option Right to the corresponding Collaboration Target.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">For clarity, a Reversion Product shall not be considered a Licensed Product.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238562"></a><a name="_Toc442266208"></a><a name="_Toc445390043"></a><a name="_Toc450305424"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.76&nbsp;&nbsp;&nbsp;Major Countries</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Major Countries&#x201D; shall mean </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc450305425"></a><a name="_Toc362302557"></a><a name="_Toc442238563"></a><a name="_Toc442266209"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.77&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;color:#000000;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445569806"></a><a name="_Toc445390045"></a><a name="_Toc450305426"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.78&nbsp;&nbsp;&nbsp;MTD</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;MTD&#x201D; shall mean, for each Collaboration Target, the dose and schedule that will be used for the Product </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in the expansion part of the first Phase I Study or in the first Phase II Study, if no expansion is planned for the first Phase I Study. The MTD may be the maximum </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">12</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">tolerated dose, as defined in the Phase I Study protocol for each Collaboration Target, or it may be a lower dose. The MTD for each Collaboration Target will be confirmed by the JDC.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390046"></a><a name="_Toc450305427"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.79&nbsp;&nbsp;&nbsp;NDA</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;NDA&#x201D; shall mean a new drug application, including all necessary documents, data, and other information concerning a Licensed Product, required for Regulatory Approval of the Licensed Product as a pharmaceutical product by the FDA or an equivalent application to the equivalent agency in any other country or group of countries (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> the marketing authorization application (MAA) in the EU).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref266955955"></a><a name="_Toc362302558"></a><a name="_Toc442238564"></a><a name="_Toc442266210"></a><a name="_Toc445390047"></a><a name="_Toc450305428"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.80&nbsp;&nbsp;&nbsp;Net Sales</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Net Sales&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean, for a Licensed Product in a particular period, the amount calculated by subtracting from the </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Sales</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of such Licensed Product for such period: (i)&nbsp;a lump sum deduction of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of Sales in lieu of those deductions that are not accounted for on a Licensed Product-by-Licensed Product basis (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, freight, postage charges, transportation insurance, packing materials for dispatch of goods, custom duties); (ii)&nbsp;uncollectible amounts accrued during such period based on a proportional allocation of the total bad debts accrued during such period and not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Licensed Product for such period; (iii)&nbsp;credit card charges (including processing fees) accrued during such period on such Sales and not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Licensed Product for such period; and (iv)&nbsp;government mandated fees and taxes and other government charges accrued during such period not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Licensed Product for such period, including, for example, any fees, taxes or other charges that become due in connection with any healthcare reform, change in government pricing or discounting schemes, or other action of a government or regulatory body. For clarity, no deductions taken in calculating Sales under Section&nbsp;1.119 may be taken a second time in calculating Net Sales.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman,Times,serif;text-justify:inter-ideograph;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;color:#000000;">With respect to a Combination Product, Net Sales of such Combination Product eligible for royalties shall be adjusted to subtract the Relative Commercial Value of any Other Component of such Combination Product in accordance with Section&nbsp;12.9.4.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman,Times,serif;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">To the extent that Roche or its Affiliates or Sublicensees receives consideration other than or in addition to cash upon the Sale of a Licensed Product, or the performance of any services (including preliminary treatments or follow-up treatments) related to such Licensed Product, Net Sales will include the fair market value of such additional consideration.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442367494"></a><a name="_Toc445390048"></a><a name="_Toc450305429"></a><a name="_Ref442290034"></a><a name="_Toc442238565"></a><a name="_Toc442266211"></a><a name="_Toc362302560"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.81&nbsp;&nbsp;&nbsp;Option Data Criteria</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Option Data Criteria&#x201D; shall mean, for each Collaboration Target, the categories of information (including the criteria within such categories) for a Product in accordance with the Phase I Plan with respect to such Collaboration Target, which categories are set forth in Appendix 1.81, and the criteria within such categories will be determined on a Collaboration Target-by-Collaboration Target basis and finalized by the JDC prior to the filing of the first IND for such Collaboration Target.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445306524"></a><a name="_Ref445307398"></a><a name="_Ref445307804"></a><a name="_Toc445390049"></a><a name="_Toc450305430"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.82&nbsp;&nbsp;&nbsp;Option Data Package</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Option Data Package&#x201D; shall mean, for each Collaboration Target, (i) a document setting forth the available data resulting from the Phase I Studies conducted by BPM for such Collaboration Target, including the applicable Option Data Criteria, (ii) the availability of the data </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">13</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">for such Phase I Studies in an organized and clean format in the Clinical Study database for such Collaboration Target through the Option Data Package Trigger for such Collaboration Target, and (iii) if applicable, the availability of the data of any Phase I Studies conducted by Roche in an organized and clean format for a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> through the Option Data Package Trigger for such </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;For clarity, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM&#x2019;s Portion</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; of the Option Data Package shall mean the items set forth in clauses (i) and (ii) of this Section 1.82.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390050"></a><a name="_Toc450305431"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.83&nbsp;&nbsp;&nbsp;Option Data Package Trigger</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Option Data Package Trigger&#x201D; shall mean, for each Collaboration Target, the earlier of (a) the date the JDC has determined that the Option Data Criteria have been met, or (b) the cut-off date determined by the JDC pursuant to Section 3.1.3.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390051"></a><a name="_Toc450305432"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.84&nbsp;&nbsp;&nbsp;Option Exercise Date</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Option Exercise Date&#x201D; shall mean, on a Collaboration Target-by-Collaboration Target basis, the date on which an Option Exercise Notice delivered by Roche to BPM for such Collaboration Target pursuant to Section 3.1.3 takes effect.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238566"></a><a name="_Toc442266212"></a><a name="_Toc445390052"></a><a name="_Toc450305433"></a><a name="_Ref442186836"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.85&nbsp;&nbsp;&nbsp;Option Exercise Notice</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Option Exercise Notice&#x201D; shall mean the written notice Roche delivers to BPM to exercise its Option Right with respect to a Collaboration Target.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238567"></a><a name="_Toc442266213"></a><a name="_Ref445491949"></a><a name="_Ref445569840"></a><a name="_Toc445390053"></a><a name="_Toc450305434"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.86&nbsp;&nbsp;&nbsp;Option Period</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Option Period&#x201D; shall mean, for each Collaboration Target, the period beginning the date the MTD for the first Product for such Collaboration Target is designated by the JDC and ending upon the earliest of (i) the date that such Collaboration Target becomes a Leftover Target, (ii) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after Roche&#x2019;s receipt of the Option Data Package for such Collaboration Target, (iii) the date such Collaboration Target becomes a Terminated Target, (iv) the date upon which a Product (including Backup Compounds) for such Collaboration Target is no longer in GLP Tox Studies, in Phase I Studies, or progressing from GLP Tox Studies to Phase I Studies, or (v) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after achievement of Lead Series Identified Criteria has been confirmed by the JRC for such Collaboration Target if Initiation of the GLP Tox Study has not been achieved for such Collaboration Target prior to such date.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302559"></a><a name="_Toc442238568"></a><a name="_Toc442266214"></a><a name="_Toc445390054"></a><a name="_Toc450305435"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.87&nbsp;&nbsp;&nbsp;Option Right</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Option Right&#x201D; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">shall mean, with respect to a Collaboration Target, Roche&#x2019;s right to obtain an exclusive (subject to BPM&#x2019;s retained rights if applicable) commercial license with respect to that Collaboration Target in accordance with Section&nbsp;3.1.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<a name="_Toc442238569"></a><a name="_Toc442266215"></a><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390055"></a><a name="_Toc450305436"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.88&nbsp;&nbsp;&nbsp;Other Compound</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Other Compound&#x201D; shall mean any compound made under the Research Plan for a given Collaboration Target that does </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">not</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> satisfy the Compound Criteria as determined by the JRC and is not a Library Compound as of the Effective Date.&nbsp;&nbsp;An Other Compound includes all salts, polymorphs, metabolites, prodrugs, isomers, enantiomers and stereoisomers of such compound, in each case that do </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">not</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> satisfy the Compound Criteria and are not a Library Compound as of the Effective Date.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390056"></a><a name="_Toc450305437"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.89&nbsp;&nbsp;&nbsp;Out of Pocket Costs</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Out of Pocket Costs&#x201D; shall mean, with respect to certain activities hereunder direct expenses paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for Collaboration Compounds, Products, Licensed Products or Companion Diagnostics, as applicable, including payments to contract </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">14</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">personnel (including contractors, consultants, CROs and subcontractors) in each case pursuant to the Phase I Plans or Development Plans.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238570"></a><a name="_Toc442266216"></a><a name="_Toc445390057"></a><a name="_Toc450305438"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.90&nbsp;&nbsp;&nbsp;Party</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Party&#x201D; shall mean BPM or Roche, as the case may be, and &#x201C;Parties&#x201D; shall mean BPM and Roche collectively.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238571"></a><a name="_Toc442266217"></a><a name="_Toc445390058"></a><a name="_Toc450305439"></a><a name="_Toc362302561"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.91&nbsp;&nbsp;&nbsp;Part 1</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Part 1&#x201D; shall mean the activities under the Research Plan and Phase I Plan for the Collaboration Targets </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238572"></a><a name="_Toc442266218"></a><a name="_Toc445390059"></a><a name="_Toc450305440"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.92&nbsp;&nbsp;&nbsp;Part 2</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Part 2&#x201D; shall mean the activities under Screening, Target Validation and the Research Plans and Phase I Plans for the Targets selected for activities in Part 2 that become Collaboration Targets.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238573"></a><a name="_Toc442266219"></a><a name="_Toc445390060"></a><a name="_Toc450305441"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.93&nbsp;&nbsp;&nbsp;Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Patent Rights&#x201D; shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or continuation-in-part of any of the foregoing.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238574"></a><a name="_Toc442266220"></a><a name="_Toc445390061"></a><a name="_Toc450305442"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.94&nbsp;&nbsp;&nbsp;Person</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Person&#x201D; shall mean</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> any natural person, corporation, unincorporated organization, partnership, association, sole proprietorship, joint stock company, joint venture, limited liability company, trust or government, or any other similar entity.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238575"></a><a name="_Toc442266221"></a><a name="_Ref442293601"></a><a name="_Toc445390062"></a><a name="_Toc450305443"></a><a name="_Toc362302562"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.95&nbsp;&nbsp;&nbsp;Pharmacovigilance Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Pharmacovigilance Agreement&#x201D; shall mean an agreement entered into by the Parties to set forth the protocols and procedures for reporting adverse events and complying with reporting requirements set forth by Regulatory Authorities.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390063"></a><a name="_Toc450305444"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.96&nbsp;&nbsp;&nbsp;Phase I Development Costs</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Phase I Development Costs&#x201D; shall mean, with respect to each Phase I Plan, and subject to the cap in Section 5.1.3, those (i) costs and expenses directly incurred (including personnel costs and Allocable Overhead associated with employees and contractors of a Party)&nbsp;&nbsp;with the performance of any Phase I Studies for Collaboration Compounds or Products for such Collaboration Target, (ii) costs associated with research or development of Companion Diagnostics, and (iii) fees charged by Third Party service providers and other Out-of-Pocket Costs reasonably incurred in connection with the performance of any Phase I Study with respect to Collaboration Compounds or Products for such Collaboration Target, in each case, in accordance with the applicable Phase I Plan and that are recorded as an expense in accordance with IFRS or GAAP as applicable consistently applied. Phase I Development Costs shall include (A) the cost of studies on the toxicological, pharmacokinetic, metabolic, pharmacodynamic or clinical aspects of such Product conducted by individual investigators or consultants in accordance with the applicable Phase I Plan and (B) expenses for data management, statistical designs and studies, document preparation, and other expenses associated with the clinical testing program for the applicable Phase I Plan.&nbsp;&nbsp;For clarity, Phase I Development Costs for each Product shall include (i) manufacturing and supply costs and expenses associated with the Phase I Plan for such Product, and (ii) costs related to preparing and filing Filings associated with the Phase I Plan for such Product (including associated filing fees, translation expenses, and legal and other</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">15</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">professional service fees).&nbsp;&nbsp;All manufacture and supply costs and expenses for Roche Clinical Compounds and Roche Marketed Products shall be at Roche&#x2019;s sole expense.&nbsp;&nbsp;For clarity, Phase I Development Costs shall exclude (a) capital expenditures, and (b) Development Costs.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238577"></a><a name="_Toc442266223"></a><a name="_Toc445390064"></a><a name="_Toc450305445"></a><a name="_Toc362302563"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.97&nbsp;&nbsp;&nbsp;Phase I Plan</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Phase I Plan&#x201D; shall mean, for each Collaboration Target, a plan and budget describing the one or more Phase I Studies to be conducted with respect to such Collaboration Target in the Field that will be established and approved by the JDC, with the goal to provide the Option Data Package for such Collaboration Target. </font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238578"></a><a name="_Toc442266224"></a><a name="_Toc445390065"></a><a name="_Toc450305446"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.98&nbsp;&nbsp;&nbsp;Phase I Program</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Phase I Program&#x201D; shall mean the activities undertaken by the Parties pursuant to the Phase I Plans for all Collaboration Targets.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238579"></a><a name="_Toc442266225"></a><a name="_Toc445390066"></a><a name="_Toc450305447"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.99&nbsp;&nbsp;&nbsp;Phase I Study</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Phase I Study&#x201D; shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. </font><font style="font-weight:bold;display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">&#xA7; &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302564"></a><a name="_Toc442238580"></a><a name="_Toc442266226"></a><a name="_Toc445390067"></a><a name="_Toc450305448"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.100&nbsp;&nbsp;Phase II Study</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Phase II Study&#x201D; shall mean </font><font style="font-weight:bold;display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. &#xA7; 312.21(b) (FDCA), as amended from time to time, </font><font style="display:inline;font-family:Times New Roman,Times,serif;">and the foreign equivalent thereof</font><font style="font-weight:bold;display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc184031390"></a><a name="_Toc184035974"></a><a name="_Toc362302567"></a><a name="_Toc442238581"></a><a name="_Toc442266227"></a><a name="_Toc445390068"></a><a name="_Toc450305449"></a><a name="_Toc148947674"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.101&nbsp;&nbsp;Phase III Study</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Phase III Study&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">shall mean</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="font-weight:bold;display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. &#xA7; 312.21(c) (FDCA), as amended from time to time, </font><font style="display:inline;font-family:Times New Roman,Times,serif;">and the foreign equivalent thereof</font><font style="font-weight:bold;display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390069"></a><a name="_Toc450305450"></a><a name="_Toc362302568"></a><a name="_Toc442238582"></a><a name="_Toc442266228"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.102&nbsp;&nbsp;Pivotal Study</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Pivotal Study&#x201D; shall mean, with respect to any Licensed Product, a Clinical Study that at the time of commencement (or any later expansion of patient enrollment, if applicable), is expected by the JDC to be the basis for Regulatory Approval of such Licensed Product.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390070"></a><a name="_Toc450305451"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.103&nbsp;&nbsp;Post-Marketing Study</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Post-Marketing Study&#x201D; shall mean a non-human or human clinical study of a Licensed Product initiated after receipt of Regulatory Approval for such Licensed Product in a country or territory, which is required by the Regulatory Authority in such country or territory to maintain the Regulatory Approval for such Licensed Product in such country or territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390071"></a><a name="_Toc450305452"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.104&nbsp;&nbsp;Product</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Product&#x201D; shall mean, on a Collaboration Target-by-Collaboration Target basis, any pharmaceutical product that, prior to Roche&#x2019;s exercise of its Option Right for such Collaboration Target</font><font style="display:inline;font-family:Times New Roman,Times,serif;">,</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> contains a Collaboration Compound with respect to such Collaboration Target generated under a Research Plan, </font><font style="display:inline;font-family:Times New Roman,Times,serif;">including without limitation any Combination Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">One Product can be distinguished from another Product by containing a different Collaboration Compound as its active pharmaceutical ingredient.&nbsp;&nbsp;For clarity, a Reversion Product will not be considered a Product.</font><a name="_Toc184031398"></a><a name="_Toc184035982"></a><a name="_Toc184031400"></a><a name="_Toc184035984"></a><a name="_Toc184031401"></a><a name="_Toc184035985"></a><a name="_Toc184031404"></a><a name="_Toc184035988"></a><a name="_Toc184031407"></a><a name="_Toc184035991"></a><a name="_Toc184031408"></a><a name="_Toc184035992"></a><a name="_Toc184031410"></a><a name="_Toc184035994"></a><a name="_Toc184031411"></a><a name="_Toc184035995"></a><a name="_Toc184031413"></a><a name="_Toc184035997"></a><a name="_Toc184031414"></a><a name="_Toc184035998"></a><a name="_Toc184031416"></a><a name="_Toc184036000"></a><a name="_Toc184031417"></a><a name="_Toc184036001"></a><a name="_Toc184031418"></a><a name="_Toc184036002"></a><a name="_Toc184031419"></a><a name="_Toc184036003"></a><a name="_Toc184031420"></a><a name="_Toc184036004"></a><a name="_Toc184031421"></a><a name="_Toc184036005"></a><a name="_Toc184031422"></a><a name="_Toc184036006"></a><a name="_Toc184031424"></a><a name="_Toc184036008"></a><a name="_Toc184031425"></a><a name="_Toc184036009"></a><a name="_Toc184031428"></a><a name="_Toc184036012"></a><a name="_Toc184031429"></a><a name="_Toc184036013"></a><a name="_Toc184031430"></a><a name="_Toc184036014"></a><a name="_Toc184031432"></a><a name="_Toc184036016"></a><a name="_Ref440621332"></a><a name="_Toc442238583"></a><a name="_Toc442266229"></a><a name="_Toc362302571"></a>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">16</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445463794"></a><a name="_Toc445390072"></a><a name="_Toc450305453"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.105&nbsp;&nbsp;Program</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Program&#x201D; shall mean the program to develop and commercialize Licensed Products directed to a specific Collaboration Target in the Field in the Territory.&nbsp;&nbsp;Subject to the program switch right in Section 3.1.4, a Program shall be numbered in accordance with the order in which Roche exercises its Option Right so that &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Program 1</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; is the Program to develop and commercialize Licensed Products directed to the first Collaboration Target for which Roche exercises its Option Right; &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Program 2</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; is the Program to develop and commercialize Licensed Products directed to the second Collaboration Target for which Roche exercises its Option Right; &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Program 3</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; is the Program to develop and commercialize Licensed Products directed to the third Collaboration Target for which Roche exercises its Option Right; &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Program 4</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; is the Program to develop and commercialize Licensed Products directed to the fourth Collaboration Target for which Roche exercises its Option Right; and &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Program 5</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; is the Program to develop and commercialize Licensed Products directed to the fifth Collaboration Target for which&nbsp;&nbsp;Roche exercises its Option Right.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238585"></a><a name="_Toc442266231"></a><a name="_Toc445390073"></a><a name="_Toc450305454"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.106&nbsp;&nbsp;Regulatory Approval</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Regulatory Approval&#x201D; shall mean</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">any approvals, licenses, registrations or authorizations by Regulatory Authority, necessary for the manufacture and sale of a Licensed Product in the Field in a regulatory jurisdiction in the Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302572"></a><a name="_Toc442238586"></a><a name="_Toc442266232"></a><a name="_Toc445390074"></a><a name="_Toc450305455"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.107&nbsp;&nbsp;Regulatory Authority</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Regulatory Authority&#x201D; shall mean </font><font style="display:inline;font-family:Times New Roman,Times,serif;">any national, supranational (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of Regulatory Approval for the Licensed Product.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref266256438"></a><a name="_Ref266437467"></a><a name="_Toc362302573"></a><a name="_Toc442238587"></a><a name="_Toc442266233"></a><a name="_Toc445390075"></a><a name="_Toc450305456"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.108&nbsp;&nbsp;Research Plan</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Research Plan&#x201D; shall mean, for each Collaboration Target, a plan describing the screening activities and preclinical development of Library Compounds, Other Compounds and Collaboration Compounds (including Backup Compounds) for such Collaboration Target in the Field up to and including GLP Tox Studies and that is approved by the JRC. Each Research Plan shall also comprise the properties and their related criteria to be measured at defined points of preclinical development. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc441059868"></a><a name="_Toc441060106"></a><a name="_Toc441059869"></a><a name="_Toc441060107"></a><a name="_Toc441059870"></a><a name="_Toc441060108"></a><a name="_Toc362302575"></a><a name="_Toc442238588"></a><a name="_Toc442266234"></a><a name="_Toc445390076"></a><a name="_Toc450305457"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.109&nbsp;&nbsp;Research and Development Term</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Research and Development Term&#x201D; shall </font><font style="display:inline;font-family:Times New Roman,Times,serif;">mean the period beginning upon the Effective Date and ending upon the earlier of (i) the exercise of the last Option Right available for exercise, or (ii) the expiration of the Option Period for the last Collaboration Target available for exercise.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238589"></a><a name="_Toc442266235"></a><a name="_Toc445390077"></a><a name="_Toc450305458"></a><a name="_Toc362302577"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.110&nbsp;&nbsp;Roche Clinical Compounds</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Roche Clinical Compounds&#x201D; shall mean clinical-stage compounds controlled by Roche or its Affiliates (but not Products or Licensed Products) and provided for combination Clinical Studies with Products or Licensed Products.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238590"></a><a name="_Toc442266236"></a><a name="_Toc445390078"></a><a name="_Toc450305459"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.111&nbsp;&nbsp;Roche Group</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Roche Group&#x201D; shall mean collectively Roche, its Affiliates and its Sublicensees.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">17</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302578"></a><a name="_Toc442238591"></a><a name="_Toc442266237"></a><a name="_Toc445390079"></a><a name="_Toc450305460"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.112&nbsp;&nbsp;Roche Know-How</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Roche Know-How&#x201D; shall mean (a) all Know-How that Roche and its Affiliates Controls as of the Effective Date or during the Agreement Term to the extent used by Roche or its Affiliates to perform activities under this Agreement (including Roche Sole IP and Roche&#x2019;s interest in Joint IP) </font><font style="display:inline;font-family:Times New Roman,Times,serif;">(but excluding Supplemental Studies unless BPM opts-in pursuant to Section 7.2)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and (b) with respect to Program 2 and Program 4, any Know-How that Roche or its Affiliates uses in Exploiting any Licensed Products for Program 2 and Program 4 (as applicable) </font><font style="display:inline;font-family:Times New Roman,Times,serif;">(but excluding Supplemental Studies unless Roche opts-in pursuant to Section 7.2)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and in each case (a) and (b) that is necessary or useful to perform activities under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238592"></a><a name="_Toc442266238"></a><a name="_Toc445390080"></a><a name="_Toc450305461"></a><a name="_Ref318985460"></a><a name="_Ref318985527"></a><a name="_Toc362302579"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.113&nbsp;&nbsp;Roche Marketed Products</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Roche Marketed Products&#x201D; shall mean marketed products controlled by Roche or its Affiliates (but not Products or Licensed Products) and provided for combination Clinical Studies with Products or Licensed Products.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440525750"></a><a name="_Ref440525792"></a><a name="_Toc442238593"></a><a name="_Toc442266239"></a><a name="_Toc445390081"></a><a name="_Toc450305462"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.114&nbsp;&nbsp;Roche Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Roche Patent Rights&#x201D; shall mean (a) </font><font style="display:inline;font-family:Times New Roman,Times,serif;">all Patent Rights that Roche and its Affiliates Controls as of the Effective Date or during the Agreement Term </font><font style="display:inline;font-family:Times New Roman,Times,serif;">to the extent used by Roche or its Affiliates to perform activities under this Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (including Roche Sole IP and Roche&#x2019;s interest in Joint IP) (but excluding Supplemental Studies unless BPM opts-in pursuant to Section 7.2), and (b) with respect to Program 2 and Program 4, any Patent Rights that Roche or its Affiliates uses in Exploiting any Licensed Products for Program 2 and Program 4 (as applicable) (but excluding Supplemental Studies unless Roche opts-in pursuant to Section 7.2), and in each case (a) and (b) that are necessary or useful to perform the activities under this Agreement.&nbsp;&nbsp;The Patent Rights identified in Appendix&nbsp;1.114 (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Excluded Patent Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) are specifically excluded from the Roche Patent Rights.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238594"></a><a name="_Toc442266240"></a><a name="_Toc445390082"></a><a name="_Toc450305463"></a><a name="_Toc362302580"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.115&nbsp;&nbsp;Roche Sole IP</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Roche Sole IP&#x201D; shall mean all Patent Rights and Know-How arising from a Roche Invention and all </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238595"></a><a name="_Toc442266241"></a><a name="_Toc445390083"></a><a name="_Toc450305464"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.116&nbsp;&nbsp;Roche Territory</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Roche Territory&#x201D; shall mean (a) in the case of Program 1, Program 3, and Program 5, all countries of the world, and (b) in the case of Program 2 and Program 4, ROW.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238596"></a><a name="_Toc442266242"></a><a name="_Toc445390084"></a><a name="_Toc450305465"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.117&nbsp;&nbsp;ROW</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;ROW&#x201D; shall mean all countries of the world excluding the US.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440523633"></a><a name="_Toc442238597"></a><a name="_Toc442266243"></a><a name="_Toc445390085"></a><a name="_Toc450305466"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.118&nbsp;&nbsp;Royalty Term</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Royalty Term&#x201D; shall mean, for each Licensed Product, on a country-by-country basis, the period of time beginning with First Commercial Sale of a Licensed Product in a country and ending on the latest of (i) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after First Commercial Sale in such country of such Licensed Product, (ii) the last to expire Composition of Matter Claim, and (iii) the end of any regulatory exclusivity for such Licensed Product. To the extent the only Valid Claim in the Collaboration Compound IP or BPM IP or any patent rights owned or in-licensed by Roche (only pursuant to Program 2 or Program 4) Covers an approved use of a Licensed Product, the Royalty Term shall expire on a country-by-country basis on the later of (a) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after First Commercial Sale in such country of such Licensed Product or (b) the end of the first Calendar Quarter in which a Generic Product enters the market in such country.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">18</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302581"></a><a name="_Ref417128076"></a><a name="_Toc442238598"></a><a name="_Toc442266244"></a><a name="_Toc445390086"></a><a name="_Toc450305467"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.119&nbsp;&nbsp;Sales</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Sales&#x201D; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">shall mean, for a Licensed Product in a particular period, the sum of (i) and (ii):</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;the amount stated in the Roche Holding AG &#x201C;Sales&#x201D; line of its externally published audited consolidated financial statements with respect to such Licensed Product for such period (excluding sales to any Sublicensees that are not Affiliates of Roche). This amount reflects the gross invoice price at which such Licensed Product was sold or otherwise disposed of (other than for use as clinical supplies or free samples) by Roche and its Affiliates to such Third Parties (excluding sales to any Sublicensees that are not Affiliates of Roche) in such period reduced by gross-to-net deductions, if not previously deducted from such invoiced amount, taken in accordance with the then currently used IFRS.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">By way of example, the gross-to-net deductions taken in accordance with IFRS as of the Effective Date include the following:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;credits, reserves or allowances granted for (i)&nbsp;damaged, outdated, returned, rejected, withdrawn or recalled Licensed Product, (ii)&nbsp;wastage replacement and short-shipments; (iii)&nbsp;billing errors and (iv)&nbsp;indigent patient and similar programs (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, price capitation);</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;governmental price reductions and government mandated rebates;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chargebacks, including those granted to wholesalers, buying groups and retailers;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;customer rebates, including cash sales incentives for prompt payment, cash and volume discounts; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 66pt;text-indent: -30pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;taxes and any other governmental charges or levies imposed upon or measured by the import, export, use, manufacture or sale of a Licensed Product (excluding income or franchise taxes).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For purposes of clarity, sales by Roche and its Affiliates to any Sublicensee shall be excluded from &#x201C;Sales&#x201D;.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;&nbsp;for Sublicensees that are not Roche Affiliates (and excluding Compulsory Sublicensees), the sales amounts reported to Roche and its Affiliates in accordance with the Sublicensee contractual terms and their then-currently used accounting standards. For the purpose of clarity, any such Sublicensee sales as reported to Roche in accordance with Compulsory Sublicense agreements shall be excluded from the sales amount. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238599"></a><a name="_Toc442266245"></a><a name="_Toc445390087"></a><a name="_Toc450305468"></a><a name="_Toc362302582"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.120&nbsp;&nbsp;Screening</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Screening&#x201D; shall mean the activities performed jointly by Roche and BPM at the beginning of Part 2 in accordance with this Agreement. The JRC shall approve the Screening plan and any changes thereto.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238600"></a><a name="_Toc442266246"></a><a name="_Toc445390088"></a><a name="_Toc450305469"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.121&nbsp;&nbsp;Screening Hit</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Screening Hit&#x201D; shall mean any Library Compound identified as a hit after Screening.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">19</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238601"></a><a name="_Toc442266247"></a><a name="_Toc445390089"></a><a name="_Toc450305470"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.122&nbsp;&nbsp;Sublicensee</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Sublicensee&#x201D; shall mean an entity to which Roche or BPM, as applicable, has licensed or sublicensed rights (through one or multiple tiers), other than through a Compulsory Sublicense, pursuant to this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238602"></a><a name="_Toc442266248"></a><a name="_Toc445390090"></a><a name="_Toc450305471"></a><a name="_Ref266256514"></a><a name="_Ref266437496"></a><a name="_Toc362302583"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.123&nbsp;&nbsp;Target</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Target&#x201D; shall mean any protein identified by its Entrez/HUGO number, including all splice variants, mutants, natural variants, and the like reasonably associated with such Entrez/HUGO number, which may be inhibited or modulated by Library Compounds, Other Compounds, Collaboration Compounds, Products, and/or Licensed Products. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238603"></a><a name="_Toc442266249"></a><a name="_Toc445390091"></a><a name="_Toc450305472"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.124&nbsp;&nbsp;Target Hypothesis</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Target Hypothesis&#x201D; shall mean any hypothesis for a Screening Hit established by both Parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440441568"></a><a name="_Toc442238604"></a><a name="_Toc442266250"></a><a name="_Toc445390092"></a><a name="_Toc450305473"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.125&nbsp;&nbsp;Target Validation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Target Validation&#x201D; shall mean the activities, including further </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">in vitro</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> assays, performed jointly by Roche and BPM following Screening in Part 2 to achieve validation of the Collaboration Targets for which a Target Hypothesis has been established. The JRC shall approve the Target Validation plan and any changes thereto. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390093"></a><a name="_Toc450305474"></a><a name="_Toc442238605"></a><a name="_Toc442266251"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.126&nbsp;&nbsp;Terminated Target</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Terminated Target&#x201D; shall mean any Collaboration Target that has under Section 21.3.1 become a &#x201C;Terminated Target.&#x201D;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390094"></a><a name="_Toc450305475"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.127&nbsp;&nbsp;Territory</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Territory&#x201D; shall mean (i) with respect to Roche, the Roche Territory, and (ii) with respect to BPM, the BPM Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302584"></a><a name="_Toc442238606"></a><a name="_Toc442266252"></a><a name="_Toc445390095"></a><a name="_Toc450305476"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.128&nbsp;&nbsp;Third Party</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Third Party&#x201D; shall mean </font><font style="display:inline;font-family:Times New Roman,Times,serif;">a person or entity other than (i)&nbsp;BPM or any of its Affiliates or (ii)&nbsp;a member of the Roche Group.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302585"></a><a name="_Toc442238607"></a><a name="_Toc442266253"></a><a name="_Toc445390096"></a><a name="_Toc450305477"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.129&nbsp;&nbsp;US</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;US&#x201D; or &#x201C;United States&#x201D; shall mean the United States of America and its territories and possessions.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302586"></a><a name="_Toc442238608"></a><a name="_Toc442266254"></a><a name="_Toc445390097"></a><a name="_Toc450305478"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.130&nbsp;&nbsp;US$</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;US$&#x201D; shall mean US dollars.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302587"></a><a name="_Toc442238609"></a><a name="_Toc442266255"></a><a name="_Toc445390098"></a><a name="_Toc450305479"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.131&nbsp;&nbsp;Valid Claim</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The term &#x201C;Valid Claim&#x201D; shall mean a claim in any (i) unexpired and issued patent that has not been disclaimed, revoked or held invalid by a final non-appealable decision of a court of competent jurisdiction or government agency, or (ii) pending patent application being prosecuted in good faith and has been pending for no more than </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> from the earliest priority date.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">20</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc257733349"></a><a name="_Toc362302589"></a><a name="_Toc442238610"></a><a name="_Toc442266256"></a><a name="_Toc445390099"></a><a name="_Toc450305480"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.132&nbsp;&nbsp;Additional Definitions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each of the following definitions is set forth in the Section of this Agreement indicated below: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.08%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<a name="_Toc148947684"></a><a name="_Toc362302590"></a><a name="_Toc442238611"></a><a name="_Toc442266257"></a><a name="_Toc445390100"></a><a name="_Toc450305481"></a><a name="_Toc148520682"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Definition</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Section</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">AAA</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Accounting Period</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Acquired Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.2.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Alliance Director</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Allowable Exception</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Arbitral Tribunal</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.3.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Bankruptcy Code</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">22</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Biomarker IP</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Deferral Election</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Invention </font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.62</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Member</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Other Program</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Specific Patent Rights </font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.5(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM Trademarks</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM&#x2019;s Portion</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.82</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Breaching Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.2.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Chairperson</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Compulsory Profit Share Percentage</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.9.8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Compulsory Sublicense</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.33</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Compulsory Sublicensee</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.33</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">CREATE Act</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Decision Period</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Deferrable Amount</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Development Event</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Disclosing Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.34</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Excluded Patent Rights</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.114</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Exclusive Terms Period</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Expedited Arbitration</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.3.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Expedited Dispute</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">23.3.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Expert Committee</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.9.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Finance Officers</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.5</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Global Trademarks</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">GLP Tox Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.60</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">H-W Suit Notice</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.13</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Indemnified Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">18.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Indemnifying Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">18.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Initiating Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Insulated Chemistry Expert</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">4.1.5</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Joint Invention</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.62</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Label Pursuit</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Members</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.3</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">21</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.08%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Definition</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Section</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Non-Acquired Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.2.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Non-Breaching Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.2.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Non-Selling Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">11.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Option Exercise Fee</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Other Component</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.27(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Other Compound IP</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Patent Term Extensions</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.14</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Payment Currency</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Peremptory Notice Period</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.2.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Pool</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">4.1.6</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 1</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.105</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 2</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.105</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 3</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.105</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 4</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.105</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 5</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.105</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Publishing Notice</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Publishing Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Receiving Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.34</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Redacted Agreement</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">20.5</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Register</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Relative Commercial Value</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">12.9.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Reversion License</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.3.1(f)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Reversion Product</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.3.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Basel</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Invention</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1.62</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Member</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">8.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Transfer Activities</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.3.4.4(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche US</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Samples</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.3.4.4(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Selling Party</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">11.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Sensitive Information</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">21.2.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Settlement</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Shared Development Cost Budget</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">SPCs</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.14</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Suit Notice</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">16.10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Supplemental Study</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Supplemental Study Opt-In Right</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Supply Agreement</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">9.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Switch</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">3.1.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Technology Transfer</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">9.2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:313.80pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Third Party Acquisition</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:132.10pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.4</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant of License</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> and Exclusivity</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">22</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref266782291"></a><a name="_Ref285808158"></a><a name="_Toc362302591"></a><a name="_Toc442238612"></a><a name="_Toc442266258"></a><a name="_Toc445390101"></a><a name="_Toc450305482"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">s</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442027539"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.1.1&nbsp;&nbsp;&nbsp;Research Cross Licenses</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of this Agreement, Roche hereby grants to BPM a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.3.2), non-exclusive license under Roche Know-How and Roche Patent Rights for BPM to perform its research activities under the Research Plans and development activities under the Phase I Plans, in each case in the Field and during the Research and Development Term. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of this Agreement, BPM hereby grants to Roche a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.3.1), non-exclusive license under BPM IP and Collaboration Compound IP for Roche to perform its research activities under the Research Plans and development activities under the Phase I Plans, in each case in the Field and during the Research and Development Term.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440533303"></a><a name="_Ref442027503"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.1.2&nbsp;&nbsp;&nbsp;Development and Commercial License</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> for Program 1, Program 3 and Program 5</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to Roche exercising its Option Right with regard to a Collaboration Target for Program 1, Program 3 or Program 5 (as applicable) as set forth in Section 3.1, BPM hereby grants to Roche, effective upon the Option Exercise Date for such Collaboration Target, a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.3.1), exclusive (even as to BPM but subject to BPM&#x2019;s retained rights, as applicable) license under BPM IP and Collaboration Compound IP to Exploit Licensed Products and Companion Diagnostics for Program 1, Program 3 or Program 5 (as applicable) in the Field in the Roche Territory. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">With respect to the Excluded Field, under this Agreement, Roche shall not (and shall require its Affiliates and Sublicensees to not) research, develop, manufacture or commercialize any Library Compound, Collaboration Compound, Other Compound, Product or Licensed Product for Program 1, Program 3 or Program 5 (as applicable) in the Excluded Field.&nbsp;&nbsp;For clarity, the foregoing restriction does not apply to any of Roche&#x2019;s or its Affiliate&#x2019;s or Sublicensee&#x2019;s research, development, manufacture or commercialization programs or activities outside of this Agreement. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding any other provision of this Agreement, for the purposes of the license grants under this Section 2.1.2 with respect to any Licensed Product that is a Combination Product, (i) such license will only include a license with respect to the Collaboration Compound in such Combination Product, and (ii) in no event is a license granted hereunder with respect to any Other Component of a Combination Product.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc269738949"></a><a name="_Toc285806876"></a><a name="_Toc286399383"></a><a name="_Toc286399626"></a><a name="_Toc269738950"></a><a name="_Toc285806877"></a><a name="_Toc286399384"></a><a name="_Toc286399627"></a><a name="_Toc269738952"></a><a name="_Toc285806879"></a><a name="_Toc286399386"></a><a name="_Toc286399629"></a><a name="_Toc269738957"></a><a name="_Toc285806884"></a><a name="_Toc286399391"></a><a name="_Toc286399634"></a><a name="_Toc184036039"></a><a name="_Toc184036040"></a><a name="_Toc184036041"></a><a name="_Toc184036042"></a><a name="_Ref442027505"></a><a name="_Ref266959418"></a><a name="_Toc362302595"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.1.3&nbsp;&nbsp;&nbsp;Development and Commercial Licenses for Program 2 and Program 4</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to Roche exercising its Option Right with regard to a Collaboration Target for Program 2 or Program 4 (as applicable) as set forth in Section 3.1, BPM hereby grants to Roche, effective upon the Option Exercise Date for such Collaboration Target, a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.3.2), exclusive (even as to BPM but subject to BPM&#x2019;s retained rights, as applicable) license under BPM IP and Collaboration Compound IP to Exploit Licensed Products and Companion Diagnostics for Program 2 or Program 4 (as applicable) in the Field in the Roche Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the foregoing, for Program 2 or Program 4, BPM retains the right under the BPM IP and Collaboration Compound IP, with the right to grant licenses through multiple tiers, to </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">23</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">develop each Product or Licensed Product (as applicable) in the Field anywhere in the world, in each case solely as and to the extent permitted in any Phase I Plan or Development Plan or as otherwise permitted under Section 7.2 or elsewhere under this Agreement, and in each case, solely for Regulatory Approval and commercialization in the BPM Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">With respect to the Excluded Field, under this Agreement, Roche shall not (and shall require its Affiliates and Sublicensees to not) research, develop, manufacture or commercialize any Library Compound, Collaboration Compound, Other Compound, Product or Licensed Product for Program 2 or Program 4 in the Excluded Field.&nbsp;&nbsp;For clarity, the foregoing restriction does not apply to any of Roche&#x2019;s or its Affiliate&#x2019;s or Sublicensee&#x2019;s research, development, manufacture or commercialization programs or activities outside of this Agreement. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding any other provision of this Agreement, for the purposes of the license grants under this Section 2.1.3 with respect to any Licensed Product that is a Combination Product, (i) such license will only include a license with respect to the Collaboration Compound in such Combination Product, and (ii) in no event is a license granted hereunder with respect to any Other Component of a Combination Product.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to Roche exercising its Option Right with regard to a Collaboration Target for Program 2 or Program 4 (as applicable), Roche hereby grants to BPM, effective upon the Option Exercise Date for such Collaboration Target, a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.2 and Section 2.3.2), exclusive (even as to Roche but subject to Roche&#x2019;s retained rights, as applicable) license, under Roche Know-How and Roche Patent Rights to Exploit Licensed Products and Companion Diagnostics for Program 2 or Program 4 (as applicable) in the Field in the BPM Territory.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref443313583"></a><a name="_Ref442052674"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.1.4&nbsp;&nbsp;&nbsp;Manufacturing Licenses</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of this Agreement, BPM hereby grants to Roche a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.3.1), worldwide, non-exclusive license under BPM IP and Collaboration Compound IP for Roche to manufacture and have manufactured Collaboration Compounds, Products and Licensed Products solely to perform its activities under Section 9.1.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of this Agreement, Roche hereby grants to BPM a non-transferable (except as provided in Section 23.4), sublicensable (subject to Sections 9.3 and 9.4), worldwide, non-exclusive license under Roche Patent Rights, Roche Know-How and [&#x2026;***&#x2026;] for BPM to manufacture and have manufactured Collaboration Compounds, Products and Licensed Products solely to perform its activities under Section 9.1. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of this Agreement, Roche hereby grants to BPM a non-transferable (except as provided in Section 23.4), sublicensable (subject to Sections 9.3 and 9.4), worldwide, non-exclusive license under [&#x2026;***&#x2026;] for BPM to manufacture and have manufactured Other Compounds and any derivatives thereof.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442008479"></a><a name="_Toc442238613"></a><a name="_Toc442266259"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.1.5&nbsp;&nbsp;&nbsp;Licenses to Conduct Supplemental Studies</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of this Agreement, BPM hereby grants to Roche a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.3.1), </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">24</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">worldwide, non-exclusive license under BPM IP and Collaboration Compound IP for Roche to conduct Supplemental Studies in compliance with Section 7.3.2.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of this Agreement, Roche hereby grants to BPM a non-transferable (except as provided in Section 23.4), sublicensable (subject to Section 2.3.2), worldwide, non-exclusive license under Roche Patent Rights and Roche Know-How for BPM to conduct Supplemental Studies in compliance with Section 7.3.2.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref444781787"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.1.6&nbsp;&nbsp;&nbsp;Rights of Reference</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party hereby grants to the other Party, and at the request of the other Party will grant to the other Party&#x2019;s Affiliates, a &#x201C;Right of Reference&#x201D;, as that term is defined in 21 C.F.R. &#xA7;&nbsp;314.3(b) (or any successor rule or analogous law recognized outside of the United States), to, and a right to copy, access, and otherwise use, all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical Studies or upon exercise of the Supplemental Study Opt-In Right, Supplemental Studies, or early access/named patient programs for the applicable Products or Licensed Products) included in or used in support of any regulatory filing, Regulatory Approval, drug master file or other regulatory documentation (including orphan drug applications and designations) maintained on behalf of such Party (or its Affiliates) that relates to any Product or Licensed Product, to the extent necessary or useful to obtain Regulatory Approval of a Product or Licensed Product in the BPM Territory or the Roche Territory, as applicable, and such Party will provide a signed statement to this effect, if requested by the other Party, in accordance with 21 C.F.R. &#xA7; 314.50(g)(3) (or any successor or analogous law outside of the United States).&nbsp;&nbsp;In addition, upon reasonable request of either Party (on behalf of itself or a Sublicensee), the other Party will obtain and provide to the requesting Party certificates or other formal or official attestations concerning the regulatory status of the Products or Licensed Products in the BPM Territory or the Roche Territory, as applicable (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, Certificates of Free Sale, Certificates for Export, Certificates to Foreign Governments), at the requesting Party&#x2019;s request, and provided further that such attestations are reasonably necessary for the requesting Party to exercise its rights under this Agreement.&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement other than for safety concerns, neither Party will withdraw or inactivate any regulatory filing that the other Party references or otherwise uses pursuant to this Section&nbsp;2.1.6.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref443910354"></a><a name="_Ref444487076"></a><a name="_Toc445390102"></a><a name="_Toc450305483"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right of First </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Negotiation</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;color:#000000;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">During the Agreement Term, if BPM elects to sublicense or divest to a Third Party part or all of its development or commercialization rights in the BPM Territory pursuant to Program 2 and/or Program 4, then BPM shall promptly notify Roche of its decision to do so and Roche shall have a right of first negotiation to enter into an exclusive negotiation period with BPM in order to reach agreed terms for such a sublicense or divestment.&nbsp;&nbsp;Roche shall inform BPM within </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after receipt of notification from BPM (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exclusive Terms Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">as to whether Roche is interested in entering into an exclusive negotiation period. If Roche provides written notice to BPM during the Exclusive Terms Period, then the Parties shall negotiate a term sheet within an additional </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> period. If the Parties are able to agree upon a term sheet within the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> period, then the Parties shall negotiate a definitive agreement within an additional </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> negotiation period.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If the Parties are unable to reach terms on a term sheet in such </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> period or on a definitive agreement in the additional </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> negotiation period, then, at BPM&#x2019;s written election, BPM shall have the right to either (a) negotiate and, subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, enter into a sublicense or divestment agreement with a Third Party in accordance with Section 2.3.2, or (b) commence Expedited </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">25</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Arbitration proceedings by providing written notice to Roche to resolve any disputed terms in such term sheet or definitive agreement.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;If Roche provides written notice to discontinue such Expedited Arbitration proceedings within such </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> period, then </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall terminate and BPM shall have the right to negotiate and enter into a sublicense or divestment agreement with a Third Party in accordance with Section 2.3.2.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If BPM negotiates a sublicense or divestment agreement with a Third Party after either (1) the Parties are unable to reach terms of a term sheet within the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> period or terms of a definitive agreement within the additional </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> negotiation period and either (x) BPM does not exercise its right to commence Expedited Arbitration proceedings or (y) BPM provides written notice to discontinue such Expedited Arbitration proceedings, or (2) Roche does not exercise such right of first negotiation during the Exclusive Terms Period, then </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In all events, this Section 2.1.5 will not apply to (A) any Change of Control of BPM or other permitted assignment of this Agreement under Section 23.4, (B) any bona fide agreement with a CRO, under which such CRO performs contract services on behalf of BPM or any of its Affiliates for the research, development, manufacture or commercialization of any Collaboration Compound, Other Compound, Product or Licensed Product as permitted under this Agreement on a fee-for-services basis, it being understood that under an agreement for such fee-for-services, fees paid to the Third Party for such services may include milestones or royalties, (C) any agreement permitted in compliance with the terms of this Agreement with any academic institution or other not-for-profit Third Party regarding any Collaboration Compound, Other Compound, Product or Licensed Product, or (D) any agreement with a distributor regarding any Licensed Product for Program 2 and Program 4 in the BPM Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If Roche does not exercise such right of first negotiation during the Exclusive Terms Period, then BPM shall have the right to negotiate and, subject to [&#x2026;***&#x2026;] enter into a sublicense or divestment agreement with a Third Party in accordance with Section 2.3.2. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442030791"></a><a name="_Toc442238614"></a><a name="_Toc442266260"></a><a name="_Toc445390103"></a><a name="_Toc450305484"></a><a name="_Ref441049325"></a><a name="_Ref266780884"></a><a name="_Ref266781118"></a><a name="_Ref266960192"></a><a name="_Toc362302596"></a><a name="_Toc148947685"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicenses</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442100347"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.3.1&nbsp;&nbsp;&nbsp;Roche&#x2019;s Scope of Permissible Sublicensing</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The license granted by BPM to Roche in Section 2.1.2 and Section 2.1.3 may be sublicensed by Roche through multiple tiers, provided that (i) Roche will ensure that the financial terms included in Section 12 that are applicable to the scope of the sublicense granted remain unchanged, (ii) BPM&#x2019;s obligations to such sublicensed Affiliate or Sublicensee will be no broader than BPM&#x2019;s obligations were to Roche under this Agreement prior to Roche&#x2019;s grant of such a sublicense, (iii) Roche will be liable for any act or omission of any such sublicensed Affiliate or Sublicensee that is a breach of any of Roche&#x2019;s obligations under this Agreement as though the same were a breach by Roche, and BPM will have the right to proceed directly against Roche without any obligation to first proceed against such sublicensed Affiliate or Sublicensee, (iv) Roche will ensure that Roche receives from the Sublicensee all rights necessary for Roche to grant to BPM the rights and licenses upon termination of the Agreement set forth in Section 21.3 and (v) such sublicensed Affiliate or Sublicensee will undertake obligations of confidentiality and non-use regarding Confidential Information that are at least as protective as those undertaken by Roche with respect to Confidential Information pursuant to Section 20 hereof.&nbsp;&nbsp;Roche, as soon as reasonably practicable thereafter, shall provide BPM with a copy of any executed sublicense agreement with a Third Party other than [&#x2026;***&#x2026;], or a Third Party acting only as a distributor (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 2.3.1).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">26</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">The license granted by BPM to Roche in Section 2.1.1 may be sublicensed by Roche to a permitted CRO to perform Roche&#x2019;s assigned responsibilities under the Research Plans and Phase I Plans upon prompt written notice to BPM.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The license granted by BPM to Roche in Section 2.3.1 may be sublicensed by Roche to a permitted CRO to perform Roche&#x2019;s assigned responsibilities under Section 9.1.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442051761"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.3.2&nbsp;&nbsp;&nbsp;BPM&#x2019;s Scope of Permissible Sublicensing</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The license granted by Roche to BPM in Section 2.1.3 may be sublicensed by BPM through multiple tiers, provided that (i) BPM will ensure that the financial terms included in Section 12 that are applicable to the scope of the sublicense granted remain unchanged, (ii) Roche&#x2019;s obligations to such sublicensed Affiliate or Sublicensee will be no broader than Roche&#x2019;s obligations were to BPM under this Agreement prior to BPM&#x2019;s grant of such a sublicense, and (iii) BPM will be liable for any act or omission of any such sublicensed Affiliate or Sublicensee that is a breach of any of BPM&#x2019;s obligations under this Agreement as though the same were a breach by BPM, and Roche will have the right to proceed directly against BPM without any obligation to first proceed against such sublicensed Affiliate or Sublicensee, (iv) BPM will ensure that BPM receives from the Sublicensee all rights necessary for BPM to grant to Roche the rights and licenses upon termination of the Agreement set forth in Section 21.3 and (v) such sublicensed Affiliate or Sublicensee will undertake in writing obligations of confidentiality and non-use regarding Confidential Information that are at least as protective as those undertaken by BPM with respect to Confidential Information pursuant to Section 20 hereof.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The license granted by Roche to BPM in Section 2.1.1 may be sublicensed by BPM to a permitted CRO to perform BPM&#x2019;s assigned responsibilities under the Research Plans and Phase I Plans upon written notice to Roche.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442050297"></a><a name="_Toc442238615"></a><a name="_Toc442266261"></a><a name="_Toc445390104"></a><a name="_Toc450305485"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.4&nbsp;&nbsp;&nbsp;&nbsp;BPM Third Party Payments</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM will be responsible for all payments associated with any agreements related to the BPM IP that exist as of the Effective Date, except as otherwise agreed to in writing.&nbsp;&nbsp;For clarity, to the extent payments under those agreements are incurred by BPM pursuant to the Research Plan or Phase I Plan, such payments will not be reimbursed by Roche unless they are specifically included under the Research Plan budget or Phase I Plan budget as an amount to be reimbursed by Roche.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event that, after the Effective Date and prior to any Change of Control of BPM, BPM in-licenses BPM IP that would be deemed Controlled for purposes of the licenses granted to Roche under Section 2.1 but for BPM owing payments under the agreement for such in-licensed BPM IP on account of any sublicense granted thereunder to Roche or its Affiliates or Sublicensees, BPM will notify Roche of the existence of and anticipated amounts of such payments and Roche will have the right to decline a sublicense to such in-licensed BPM IP or take such sublicense, in which case Roche agrees to comply with any obligations under such agreement of BPM that apply to Roche and of which Roche was informed by BPM, including any obligation to make such payments.&nbsp;&nbsp;In the event Roche elects to take such sublicense, Roche will make such payments to BPM within thirty (30) days of receiving an invoice from BPM for the same.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">27</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442053147"></a><a name="_Toc442238616"></a><a name="_Toc442266262"></a><a name="_Toc445390105"></a><a name="_Toc450305486"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exclusivity</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442030979"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.5.1&nbsp;&nbsp;&nbsp;BPM Exclusivity with regard to Collaboration Targets</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, BPM and its Affiliates shall work exclusively with Roche during the Option Period with respect to such Collaboration Target. BPM and its Affiliates shall continue to work exclusively with Roche on each Collaboration Target for which Roche exercises its Option Right until the earliest of (i) (a) for Program 1, Program 3 and Program 5, the First Commercial Sale by the Roche Group in the Roche Territory of the first Licensed Product with respect to such Collaboration Target, or (b) for Program 2 and Program 4, the First Commercial Sale by the Roche Group or the BPM Group in the Territory of the first Licensed Product with respect to such Collaboration Target, (ii) such Collaboration Target becomes a Leftover Target, or (iii) such Collaboration Target becomes a Terminated Target.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442030980"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.5.2&nbsp;&nbsp;&nbsp;BPM Exclusivity with regard to Cancer Immunotherapy</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM and its Affiliates shall work exclusively with Roche in the field of cancer immunotherapy until Target Validation for Part 2 is completed and the Pool is established by the JRC, but in any event for no more than thirty (30) months after the Effective Date. [&#x2026;***&#x2026;]&nbsp;&nbsp;Excluded Targets and Leftover Targets (and research and development activities with respect thereto), and customary screening and early-stage chemistry and biology work performed by and on behalf of BPM in the ordinary course, shall not be subject to or otherwise prohibited by this Section 2.5.2.&nbsp;&nbsp;The conduct of general screening activities by or on behalf of BPM or its Affiliates shall not be deemed a breach of this Section 2.5.2 unless and until BPM or its Affiliates decides to pursue a Target for additional development.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442265688"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.5.3&nbsp;&nbsp;&nbsp;BPM Rights if Roche is not Exclusive for a Collaboration Target</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If Roche or its Affiliates gain access (such as through licensing or acquisition from a Third Party) to a compound or product targeting a Collaboration Target prior to exercising its Option Right for such Collaboration Target, then Roche shall immediately notify BPM in writing and BPM shall have the right upon written notice to Roche to terminate (i) Roche&#x2019;s Option Right to such Collaboration Target and (ii) all activities under the Research Plan and Phase I Plan for such Collaboration Target.&nbsp;&nbsp;If BPM opts for such termination, then such Collaboration Target will become a Leftover Target and all associated Collaboration Compounds and Products will become Reversion Products.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If Roche or its Affiliates gain access (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, via licensing or acquisition or internal program, or any other way) to a compound or product targeting a Collaboration Target after exercising its Option Right for such Collaboration Target, then without affecting the rights and obligations of the parties under this Agreement, for clarity, BPM shall have no right of termination as set forth above and Roche shall continue to use Commercially Reasonable Efforts to develop and commercialize Licensed Products corresponding to such Collaboration Target.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the case of Program 2 or Program 4, if Roche or its Affiliates gain access (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, via licensing or acquisition or internal program, or any other way) to a compound or product targeting a Collaboration Target of such Program 2 or Program 4 and exercises its Option Right for such Collaboration Target (before or after gaining such access), and such compound or product has initiated (i.e., </font><font style="display:inline;font-family:Times New Roman,Times,serif;">the date that a human is first dosed with the compound or product in a human clinical study)</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (i) a Phase II Study in the case of a compound or product accessed from a Third Party or internally (other than from </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) or (ii) a Phase III Study in the case of a compound or product </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">28</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">accessed from [&#x2026;***&#x2026;], then BPM&#x2019;s obligation of exclusivity under Section 2.5.1 with respect to such Collaboration Target shall automatically and immediately terminate. Roche shall as soon as practicable notify BPM in writing upon any such initiation of such Phase II Study or Phase III Study (as applicable).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442032303"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.5.4&nbsp;&nbsp;&nbsp;Limitations on BPM Exclusivity Obligations</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Parties hereby acknowledge and agree that (I) after expiration of the obligations set forth in Section 2.5.2, Sections 2.5.1 and 2.5.2 will not apply to any compound or product that is intended to modulate (including inhibit) any target(s) other than a Collaboration Target; and (II) BPM retains (for itself and its Affiliates and licensees and subcontractors) (A) the right to research (but not preclinically or clinically develop or commercialize) Collaboration Compounds, Products and Licensed Products outside of the applicable Research Plans, (B) the right, solely to the extent reasonably necessary for any such research, to manufacture Collaboration Compounds, Products and Licensed Products outside of the applicable Research Plans, and (C) the rights under the license grants in Section 2.1 or elsewhere in this Agreement or elsewhere retained under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding Section </font><font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.1 and Section 2.5.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and subject to the next paragraph, in the event that BPM or its Affiliates acquire a Third Party or a portion of the business of a Third Party (whether by merger, stock purchase, purchase of assets, in-license or other means) (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Third Party Acquisition</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) that is, prior to such Third Party Acquisition, conducting a research, development or commercialization program or activities that, if conducted by BPM at such time, would be a breach of BPM&#x2019;s exclusivity obligation in Section </font><font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.1 or Section&nbsp;2.5.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM Other Program</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), BPM may elect </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;BPM will not be deemed in breach of Section </font><font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.1 and Section 2.5.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> with respect to such BPM Other Program so long as BPM complies with the terms of Section </font><font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.1 and Section&nbsp;2.5.2 </font><font style="display:inline;font-family:Times New Roman,Times,serif;">and provided that such BPM Other Program is conducted independently of BPM&#x2019;s activities under this Agreement and without any use of any Roche Know-How, Roche Patent Rights or Roche Confidential Information or material use (other than the retained rights above) of the Collaboration Compounds. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event of a Change of Control of BPM, the exclusivity obligations of BPM set forth in Section </font><font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.1 and Section&nbsp;2.5.2 </font><font style="display:inline;font-family:Times New Roman,Times,serif;">will not apply to any research, development or commercialization program or activities that, if conducted by BPM at such time would be a breach of BPM&#x2019;s exclusivity obligations in Section </font><font style="display:inline;font-family:Times New Roman,Times,serif;">2.5.1 or Section&nbsp;2.5.2,</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (I) is owned, in-licensed or otherwise controlled by a Third Party described in the definition of &#x201C;Change of Control&#x201D; or its Affiliates prior to the closing of such Change of Control or (II) becomes owned, in-licensed or otherwise controlled by such Third Party or its Affiliates (other than by BPM or any of its direct or indirect subsidiary Affiliates) after the closing of such Change of Control, in each case ((I) and (II)) if such BPM Other Program is conducted independently of BPM&#x2019;s activities under this Agreement and without any use of any Roche Know-How, Roche Patent Rights or Roche Confidential Information or material use (other than the retained rights above) of the Collaboration Compounds.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">With respect to the two preceding paragraphs of this Section 2.5.4, BPM and its Affiliates (including such Third Party and its Affiliates under the preceding paragraph) will adopt reasonable procedures (which include appropriate administrative, physical and technical safeguards, including underlying operating system and network security controls and other firewalls) to prevent the use of any Roche Know-How, Roche Patent Rights or Roche Confidential Information or material use (other than the retained rights above) of the Collaboration Compounds in a manner that is not in compliance with the two preceding paragraphs of this Section 2.5.4.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">29</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238617"></a><a name="_Toc442266263"></a><a name="_Toc445390106"></a><a name="_Toc450305487"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Option of Roche</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302597"></a><a name="_Ref442030753"></a><a name="_Ref442128279"></a><a name="_Toc442238618"></a><a name="_Toc442266264"></a><a name="_Toc445390107"></a><a name="_Toc450305488"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Option Right</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref266959485"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.1.1&nbsp;&nbsp;&nbsp;General</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, Roche is granted up to five (5) exclusive Option Rights to obtain an exclusive or co-exclusive license to Exploit Products containing a Collaboration Compound directed to the Collaboration Target to which the Option Right pertains in the Field in the Territory.&nbsp;&nbsp;Once the Option Right for a Collaboration Target is exercised, such Products become &#x201C;Licensed Products&#x201D; and the program for the development and commercialization of such Licensed Products becomes a &#x201C;Program.&#x201D;&nbsp;&nbsp;The designation of a Program as Program 1, Program 2, Program 3, Program 4 or Program 5 will occur as specified in the definition of Program. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.1.2&nbsp;&nbsp;&nbsp;Grant of Option Right</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, BPM hereby grants to Roche during the Option Period an exclusive Option Right for each Collaboration Target to obtain the licenses set forth in Section 2.1.2, Section 2.1.3 and Section&nbsp;2.1.4 with respect to such Collaboration Target, Licensed Products and Program.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref266781269"></a><a name="_Ref442094856"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.1.3&nbsp;&nbsp;&nbsp;Exercise of Option Right</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event the Option Data Package Trigger is determined pursuant to Section 1.83(a),for each Collaboration Target, within </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after the Option Data Package Trigger, (i) each Party will deliver its portion of the Option Data Package with respect to such Collaboration Target, and (ii) BPM will afford Roche the information rights under Section 3.2.&nbsp;&nbsp;In the event that Roche determines that BPM&#x2019;s Portion of an Option Data Package for a Collaboration Target is incomplete or insufficient, then Roche shall provide written notice to BPM identifying all such deficiencies.&nbsp;&nbsp;If BPM disputes the existence of any such deficiencies, BPM may, at its election, refer such dispute for resolution in accordance with Section 8.8.3.&nbsp;&nbsp;If BPM&#x2019;s Portion of such Option Data Package for a Collaboration Target is determined to be incomplete or insufficient, BPM shall promptly upon curing all deficiencies re-deliver an updated version of BPM&#x2019;s Portion of such Option Data Package for such Collaboration Target to Roche; provided that Roche may not request a further updated version of BPM&#x2019;s Portion of such Option Data Package for such Collaboration Target for a period of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, Roche shall have the right to exercise its Option Right during the Option Period for a given Collaboration Target.&nbsp;&nbsp;Roche will exercise an Option Right for a Collaboration Target, if at all, by properly delivering an Option Exercise Notice for such Collaboration Target at any time during the Option Period for such Collaboration Target. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event the Option Data Package Trigger is not determined pursuant to Section 1.83(a), the JDC will set a cut-off date for the data resulting from the Phase I Studies conducted by the Parties for each Collaboration Target so that such data may be included in an Option Data Package for such Collaboration Target in a timely fashion. Such cut-off date shall be determined as follows:&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">30</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">In the event that (a) a Product is for a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, (b) such Product satisfies all Option Data Criteria other than the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and (c) Roche wishes to extend the Option Period for such Collaboration Target until all of the Option Data Criteria are satisfied (but in any event no longer than the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> anniversary of the date the MTD for the first Combination Product for such </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> is confirmed by the JDC plus </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), then Roche shall provide written notice to BPM of Roche&#x2019;s election to extend the Option Period and pay to BPM an Option Period extension fee equal to (v) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for the first Collaboration Target for which Roche exercises its extension right under this Section 3.1.3, (w) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for the second Collaboration Target for which Roche exercises its extension right under this Section 3.1.3, (x) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for the third Collaboration Target for which Roche exercises its extension right under this Section 3.1.3, (y) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for the fourth Collaboration Target for which Roche exercises its extension right under this Section 3.1.3, and (z) </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for the fifth Collaboration Target for which Roche exercises its extension right under this Section 3.1.3.&nbsp;&nbsp;Such Option Period extension fee shall be due and payable by Roche to BPM within thirty (30) days after the determination that such Product satisfies all Option Data Criteria other than the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Parties agree that </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of any such Option Period extension fee payment </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in accordance with Section 12.4, provided that (i) each Option Period extension fee payment </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> only if Roche exercises its Option Right for such Collaboration Target, and (ii) any amounts that are </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in accordance with Section 12.4 (but may not be applied to any other payments under this Agreement).&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for each Collaboration Target </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> will be due and payable after Roche&#x2019;s exercise of its Option Right for such Collaboration Target in accordance with Section 12.4.&nbsp;&nbsp;In the event that (a) a Product is for a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, (b) such Product satisfies all Option Data Criteria other than the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and (c) Roche does not pay the Option Period extension fee as set forth above, then such </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall be a Terminated Target.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For any Collaboration Target to which Roche does not timely exercise its Option Right, then, effective as of the expiration of the Option Period for such Collaboration Target, (a) all research and development activities with respect to such Collaboration Target shall terminate, (b) such Collaboration Target shall become a Leftover Target, (c) BPM shall retain all rights, title and interest in and to all Library Compounds, Other Compounds, Collaboration Compounds and Products for such Collaboration Target, (d) all rights and obligations (including the licenses to Roche) under this Agreement with respect to such Collaboration Target shall terminate, (e) the right of first negotiation and matching right under Section 2.2 with respect to such Collaboration Target shall terminate, and (f) the exclusivity provisions under Section 2.5 shall terminate.&nbsp;&nbsp;For clarity, if Roche does not timely exercise its Option Right related to a given Collaboration Target, and BPM desires to continue to research, develop or commercialize such Collaboration Compound or Product in combination with a Roche Clinical Compound or</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Roche Marketed Products, then Roche will consider, at its sole discretion, supplying such Roche Clinical Compound or Roche Marketed Products to BPM or its designee pursuant to a supply agreement on terms and conditions to be agreed upon by the Parties in good faith. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref441059647"></a><a name="_Ref445371181"></a><a name="_Ref442222256"></a><a name="_Toc442238619"></a><a name="_Toc442266265"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.1.4&nbsp;&nbsp;&nbsp;One Time Program Switch Right</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">After Roche&#x2019;s receipt of the first Option Data Package for a Collaboration Target or at the end of the Option Period for the first Collaboration Target, Roche shall have a one-time right to exercise its Option Right for such Collaboration Target by declaring such Collaboration Target as &#x201C;Program 2&#x201D;, thereby declaring the next most advanced Collaboration Target as designated by the JRC or JDC (as applicable) as &#x201C;Program 1&#x201D; (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Switch</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;If Roche elects to make the Switch, then Roche shall provide written notice to BPM prior to expiration of the Option Period for the first Collaboration Target of Roche&#x2019;s election to make the Switch and identify the Collaboration Target </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">31</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">that will be &#x201C;Program 2&#x201D; and the Collaboration Target that will be &#x201C;Program 1&#x201D;.&nbsp;&nbsp;If Roche makes the Switch, then Roche shall pay both the Program 1 Option Exercise Fee and the Program 2 Option Exercise Fee as set forth in Section 12.4, subject to the limitations in the following paragraph.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event that Products for Program 1 and Program 2 are each being developed or planned to be developed in Phase I Studies as Products for a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> pursuant to Section 5.1.3, then, simultaneously with the Switch, Roche shall exercise its Option Right with respect to the next most advanced Collaboration Target as designated by the JRC or JDC (as applicable) making it &#x201C;Program 1&#x201D;.&nbsp;&nbsp;The Program 1 Option Exercise Fee shall be payable as set forth in Section 12.4, i.e. </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> within </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after Roche exercises its Option Right and receipt of an invoice from BPM.&nbsp;&nbsp;If such next most advanced Collaboration Target has reached MTD more than </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> prior to the Switch election, then the Program 2 Option Exercise Fee (i.e., </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) shall be payable at the same time as the Program 1 Option Exercise Fee.&nbsp;&nbsp;If such next most advanced Collaboration Target has either not yet reached MTD or not reached MTD within </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> preceding the Switch, then the Program 2 Option Exercise Fee (i.e., </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) shall be payable only (i)&nbsp;after BPM has provided Roche with the Option Data Package for the Collaboration Target declared as Program 1 as per the Switch, and Roche has determined, within </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after Roche receives the Option Data Package, to not exercise its termination right with respect to the Collaboration Target declared as Program 1 as per the Switch, or (ii)&nbsp;upon Roche Initiating a Clinical Study of a Product or Licensed Product against the Collaboration Target declared as Program 1 as per the Switch. For clarity, if either Program 1 or Program 2 or both are being developed as a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and Roche elects to make the Switch, payments of the Option Exercise Fee for each such Program shall be in accordance with Section 3.1.3 and Section 12.4.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref443490332"></a><a name="_Toc445390108"></a><a name="_Toc450305489"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information Sharing for Option Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">After the Option Data Package Trigger for each Collaboration Target and for the remainder of the Option Period with respect to such Collaboration Target, (i) Roche shall have the right to perform reasonable due diligence (including visits to the facilities in which the data were generated and interviews with the persons generating the data) with respect to such Collaboration Target and the applicable Collaboration Compounds and Products, and (ii) representatives of Roche shall have the opportunity to ask questions of and receive answers from representatives of BPM related to the work that has been conducted and the data that have been generated with respect to such Collaboration Target and the applicable Collaboration Compounds and Products. BPM shall respond to Roche&#x2019;s inquiries in a timely fashion and without delay and shall not withhold any material information regarding such Collaboration Target and the applicable Collaboration Compounds and Products from Roche in response to Roche&#x2019;s inquiries.&nbsp;&nbsp;For clarity, the disclosure and use of any structures or structural information of the Collaboration Compounds and Products pursuant to this Section 3.2 will be subject to the terms of Section 4.1.4, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">mutatis mutandis</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc269738966"></a><a name="_Toc285806893"></a><a name="_Toc286399400"></a><a name="_Toc286399643"></a><a name="_Toc362302600"></a><a name="_Toc442238620"></a><a name="_Toc442266266"></a><a name="_Toc445390109"></a><a name="_Toc450305490"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research Collaboration</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302601"></a><a name="_Toc442238621"></a><a name="_Toc442266267"></a><a name="_Toc445390110"></a><a name="_Toc450305491"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conduct of the Research</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.1.1&nbsp;&nbsp;&nbsp;Scope</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, BPM shall have lead responsibility for the conduct of all research of Library Compounds, Other Compounds and Collaboration Compounds in the Field in the Territory.&nbsp;&nbsp;The activities conducted under each Research Plan will be overseen by the JRC.&nbsp;&nbsp;For clarity, prior to exercise of its Option Right for a Collaboration Target, </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">32</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Roche and its Affiliates shall not conduct any research activities under this Agreement with respect to such Collaboration Target except as expressly permitted in the Research Plans.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">It is understood and agreed that (a)&nbsp;Roche shall not, under this Agreement, research, develop, manufacture or commercialize any Library </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Compounds, Other Compounds or Collaboration Compounds</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (and corresponding Products) unless such activities are included in a Research Plan or Phase I Plan, and (b)&nbsp;on a Collaboration Target-by-Collaboration Target basis, </font><font style="display:inline;font-family:Times New Roman,Times,serif;">upon the start of the first GLP Tox Study of a Collaboration Compound satisfying the CCS Criteria for such Collaboration Target (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, the most advanced such Collaboration Compound for such Collaboration Target), </font><font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall not be required under this Agreement to conceive or make any new compounds as potential Collaboration Compounds for such Collaboration Target.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.1.2&nbsp;&nbsp;&nbsp;Diligent Efforts</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, Roche and BPM shall each use Commercially Reasonable Efforts to perform their respective tasks and obligations in conducting all activities ascribed to it in the then-current Research Plan for such Collaboration Target in the Field, in accordance with the time parameters set forth therein.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref269451325"></a><a name="_Ref445477345"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.1.3&nbsp;&nbsp;&nbsp;Research Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">s</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Unless decided otherwise by the JRC, the Research Plans will be updated at least annually by the JRC and approved by the JRC. The Research Plans will set forth (i)&nbsp;the scope of the research and the resources that will be dedicated to the activities contemplated, including the responsibilities of each Party, (ii)&nbsp;specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRC as research progresses, and (iii) key deliverables for each Party. The Parties shall prepare a Research Plan for (a) the first three (3) Collaboration Targets (each of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), within thirty (30) days after the Effective Date, and (b) for each additional Collaboration Target, within thirty (30) days after the designation of such Target as a Collaboration Target, which the JRC shall minute.&nbsp;&nbsp;The JRC shall review the Research Plans on an ongoing basis and may amend the Research Plans.&nbsp;&nbsp;Any such changes shall be reflected in written amendments to the Research Plans.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440535013"></a><a name="_Ref442226147"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.1.4&nbsp;&nbsp;&nbsp;Backup Compounds</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JRC and JDC shall ensure that the Research Plan and Phase I Plan for each Collaboration Target contains a plan for the research and development of Backup Compounds.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;].</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;Progress of up to </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Collaboration Compounds satisfying CCS Criteria through GLP Tox Studies for a Collaboration Target shall be at BPM&#x2019;s sole expense.&nbsp;&nbsp;Additional Backup Compounds may be progressed through a GLP Tox Study at Roche&#x2019;s sole discretion and expense (including any supply thereof) as part of the Research Plan and under the supervision of the JRC, provided that BPM will have the right to conduct (or have conducted) any such GLP Tox Study, and if BPM elects such right then Roche shall reimburse BPM for any personnel costs, Allocable Overhead or Out of Pocket Expenses incurred by BPM with respect thereto.&nbsp;&nbsp;All Phase I Development Costs for the first Backup Compound for a Collaboration Target in a Phase I Study shall be shared as set forth in Section&nbsp;12.5 (including subject to the cap stated therein); provided that BPM shall only be obligated to fund one (1) Collaboration Compound for a Collaboration Target at a time in a Phase I Study.&nbsp;&nbsp;Thereafter, all Phase I Development Costs for any Backup Compound for a Collaboration Target in a Phase I Study shall be at Roche&#x2019;s sole expense and discretion (including any supply thereof) as part of the Phase I Plan and under the supervision of the JDC, provided that BPM will have the right to conduct (or have conducted) any such Phase I</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">33</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Study, and if BPM elects such right then Roche shall reimburse BPM for any Phase I Development Costs incurred by BPM with respect thereto.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref443499353"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.1.5&nbsp;&nbsp;&nbsp;Part 1 Activities</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In Part 1, the Parties will work on the three (3) specified Collaboration Targets: </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. Prior to the JRC determining that </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> has satisfied </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, the Parties may upon mutual written agreement replace </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> with another Collaboration Target. The Parties will select an additional two (2) Collaboration Targets in Part 2, as described in Section&nbsp;4.1.6.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For each Collaboration Target, BPM will select Library Compounds of different scaffolds offering different starting chemistry points, and exhibiting adequate kinase potency, activity in binding, enzyme and/or biochemical and cell-based assays, kinase selectivity, and ADME characteristics.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Such Library Compounds shall be derivatized by BPM to improve potency, selectivity and ADME profile characteristics (via application of applicable kinase binding assays, cellular target engagement measurements, and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">in vitro</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> ADME profiling), and thereby establish structure-activity relationships of different compound series, including Other Compounds and Collaboration Compounds. </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Further optimization of potency, selectivity and ADME profile characteristics of Library Compounds, Collaboration Compounds and Other Compounds by BPM during Lead Optimization shall enable </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">in vivo</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Animal POC experiments of selected Collaboration Compounds by Roche or a CRO (provided that Roche shall continue to bear responsibility for the conduct of such experiments). Additional ADME/PK/safety/stability testing and pre-formulation activities performed by BPM during Lead Optimization shall help identify Collaboration Compounds meeting CLS Criteria and finally CCS Criteria. The JRC shall discuss the use of CROs for such activities. Any CRO recommended by the JRC shall either be listed in Appendix 1.38 or otherwise approved by Roche (such approval not be unreasonably withheld, conditioned or delayed). </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. At Lead Nomination and/or during Lead Optimization, as per Section 8.4, the JRC will also recommend whether Roche&#x2019;s chemistry resources should be included in Lead Optimization to address issues including BPM resource constraints or to assist with problem-solving. In summary, the work during Lead Optimization is being performed by BPM, with Roche providing protein crystallography and modeling support and input to the preclinical evaluation, and the JRC recommending further Roche contributions including chemistry resources.&nbsp;&nbsp;For clarity, except as provided for in Section 21.2.3, the Roche Group is granted no right under this Agreement to perform any medicinal chemistry activities with respect to Library Compounds, Other Compounds, Collaboration Compounds, Products or Licensed Products under this Agreement unless authorized by the JRC or by the mutual agreements of the Parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">A chemistry expert at Roche (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Insulated Chemistry Expert</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) shall be designated in writing by Roche to review structures of Other Compounds and Collaboration Compounds at the start of the collaboration and throughout the Lead Nomination phase. The Insulated Chemistry Expert shall independently handle the structural information and no structures provided by BPM to the Insulated Chemistry Expert can be shared with any other individuals within Roche other than members of senior management specified on Appendix 4.1.5 acting in their decision making capacity. For clarity, these structures cannot be used for any other purpose, including any research purpose.&nbsp;&nbsp;Appropriate safeguards will be established by Roche that are intended to prevent any inadvertent disclosure or improper use of these structures and any structural information related to such structures. From Lead Nomination onwards and throughout Lead Optimization, the structures of Other Compounds and Collaboration Compounds in the Lead</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">34</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Optimization phase shall be shared with the Roche project team members (including Collaboration Compounds meeting Lead Series Identified Criteria, CLS Criteria and CCS Criteria).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In order to enable manufacture of batches of selected Collaboration Compounds for GLP Tox Studies, BPM or Roche (as determined by the JRC) shall initiate activities for manufacturing process optimization (including establishment of an entry into GLP Tox manufacturing process), entry into GLP Tox formulations, GLP analytics including establishment of specifications for drug substance and drug product at the appropriate time point after CLS, with specifications aligned by the JRC in accordance with Section&nbsp;8.4. </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> At the meeting of CCS Criteria, an entry-into-human formulation strategy shall also be available and aligned by the JRC.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to Section 4.1.4, GLP Tox Studies, after confirmation of Collaboration Compound exposure with the GLP Tox batch, shall be performed by BPM in both rodent and non-rodent species </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, at BPM&#x2019;s expense, as a final step of the preclinical phase at a CRO approved by Roche (such approval not to be unreasonably withheld, conditioned or delayed) unless the CRO is already listed in Appendix 1.38.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref441721739"></a><a name="_Ref442188268"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Part 2 Activities</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Part 2 shall start with Screening of Library Compounds selected by both Parties (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, the diversity set comprised in BPM Technology) in both assays performed by BPM (Jurkat-cell based) and by Roche (</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), and the screening and validation phase of Part 2 shall end on the earlier of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. It is anticipated that the Screening phase will last approximately </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. Screening Hits shall be selected by the JRC and taken forward into Target Validation, with the Target Validation plan approved by the JRC, including any Library Compound derivatization during the Target Validation phase to test Library Compounds, Other Compounds and Collaboration Compounds. It is anticipated that at least </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> as a shared effort between BPM and Roche with studies being performed by both Parties. Target Validation aims to deliver a pool of validated Collaboration Targets as determined by the JRC (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Pool</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). For Collaboration Targets selected in Part 2, a Research Plan will be established prior to initiating Lead Nomination Activities based on Library Compounds, Other Compounds or Collaboration Compounds identified during the respective Target Validation. The JRC shall select the Collaboration Targets from the Pool to be further pursued in Part 2 for Lead Nomination. If the JRC is unable to reach consensus on the selection of Collaboration Targets to pursue in Part 2, then Roche and BPM shall each select one (1) Collaboration Target for Part 2.&nbsp;&nbsp;Activities from Lead Nomination onwards for such selected Part 2 Collaboration Targets shall follow the outline described under Part 1 activities. If Collaboration Compounds for a given Target from this Part 2 fail no later than in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">in vivo</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Animal POC experiments performed by or on behalf of Roche, and provided there are additional Collaboration Targets remaining in the Pool, then the JRC may replace a Collaboration Target with another Collaboration Target from the Pool. The JRC&#x2019;s replacement right shall not exceed two (2) Collaboration Target replacements, and shall not extend beyond completion of Animal POC experiments for such Collaboration Targets. If the JRC is unable to reach consensus on a replacement for a Collaboration Target, then </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;After the JRC&#x2019;s right to replace Collaboration Targets from the Pool has ended pursuant to this Section 4.1.6, all Collaboration Targets still then within the Pool shall automatically become Leftover Targets, and both Parties shall have rights to further research and develop compounds and products related to any Leftover Targets outside of the Agreement without any financial obligations owed to the other Party.&nbsp;&nbsp;For clarity, (a) the JRC shall have the right to replace </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> as set forth in Section 4.1.5, (b) the JRC shall have the right to replace the fourth or fifth Collaboration Targets no later than in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">in vivo</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Animal POC experiments for such Collaboration Target as set forth in this Section 4.1.6, and (c) the JRC shall have no right to replace </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">35</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238622"></a><a name="_Toc442266268"></a><a name="_Toc445390111"></a><a name="_Toc450305492"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.2&nbsp;&nbsp;&nbsp;Records; Reports</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.2.1&nbsp;&nbsp;&nbsp;Progress Reports</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">At least quarterly during the Research and Development Term, (i) BPM shall prepare and provide to the JRC a detailed summary of the progress of the work performed by BPM under the Research Plans during the preceding Calendar Quarter and (ii)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall update the JRC with a detailed summary of the progress of the work performed by Roche under the Research Plans during the preceding Calendar Quarter.&nbsp;&nbsp;Promptly upon expiry of the Research and Development Term, each Party shall provide a final written report to the JRC summarizing its activities under the Research Plans and the results thereof. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.2.2&nbsp;&nbsp;&nbsp;Research Records</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall maintain records of all research conducted under the Research Plans (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of activities under the Research Plans. All laboratory notebooks shall be maintained for no less than the term of any Patent Rights issuing therefrom.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238623"></a><a name="_Toc442266269"></a><a name="_Toc445390112"></a><a name="_Toc450305493"></a><a name="_Toc362302602"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conduct of the Phase I Program</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390113"></a><a name="_Toc450305494"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase I Program</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.1.1&nbsp;&nbsp;&nbsp;Scope</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, BPM shall have the lead responsibility for the conduct of all Phase I Studies (even if Roche elects to exercise its Option Right before the completion of Phase I Studies), other than those Phase I Studies involving Roche Clinical Compounds or Roche Marketed Products, in accordance with the Phase I Plans.&nbsp;&nbsp;Roche shall have the right to conduct all Phase I Studies involving Roche Clinical Compounds or Roche Marketed Products in accordance with the Phase I Plans. The activities conducted in connection with the Phase I Program will be overseen by the JDC.&nbsp;&nbsp;For clarity, Roche and its Affiliates shall not conduct any Phase I Studies with respect to such Collaboration Target except as expressly permitted in the Phase I Plans.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.1.2&nbsp;&nbsp;&nbsp;Diligent Efforts</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For each Collaboration Target, Roche and BPM shall each use Commercially Reasonable Efforts to perform their respective tasks and obligations in conducting all activities ascribed to it in the then-current Phase I Plan for such Collaboration Target, in accordance with the time parameters set forth therein.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref444871868"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.1.3&nbsp;&nbsp;&nbsp;Phase I Plan</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JDC shall strive by consensus to prepare a Phase I Plan for each Collaboration Target no later than thirty (30) days after the start of GLP Tox Studies for such Collaboration Target.&nbsp;&nbsp;Each Collaboration Target will be designated by the JDC as either a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> or a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in the applicable Phase I Plan.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, the JDC shall amend the Phase I Plan for such Collaboration Target (if needed).&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">36</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall prepare the initial draft of each Phase I Plan for any </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, unless the combination is with a Roche Clinical Compound or Roche Marketed Product, in which case Roche shall prepare the initial draft of each such Phase I Plan.&nbsp;&nbsp;The JDC shall review each Phase I Plan on an ongoing basis and may amend such Phase I Plan.&nbsp;&nbsp;Any such changes shall be reflected in written amendments to such Phase I Plan. The Parties will conduct the Phase I Program in accordance with the Phase I Plans. Each Phase I Plan will set forth (i)&nbsp;the scope of the initial Phase I Studies for such Collaboration Target and the resources that will be dedicated to the activities contemplated within the scope of such Phase I Studies, including the responsibilities of each Party, (ii) projected patient enrollment rates consistent with Roche&#x2019;s historic enrollment rates for similar drug candidates in Phase I Studies, (iii)&nbsp;specific objectives for Calendar Year end in which such initial Phase I Studies are conducted, which objectives will be updated or amended, as appropriate, by the JDC as development progresses, and (iv)&nbsp;a rolling two (2) year budget for such anticipated activities to be performed during the then-current Calendar Year and the next Calendar Year, and a forecast of the budgets for each subsequent Calendar Year thereafter through completion of all development activities set forth in such Phase I Plan; provided that BPM shall have no obligation to incur any Phase I Development Costs in excess of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for all Phase I Studies for each Phase I Plan for each Collaboration Target as further described in Section&nbsp;12.5. </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref442046763"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.1.4&nbsp;&nbsp;&nbsp;Phase I Studies</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall keep Roche informed and consult with Roche as needed through the JDC on the progress of Phase I Studies conducted by BPM.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445034768"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.1.5&nbsp;&nbsp;&nbsp;Duration</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Collaboration Target-by-Collaboration Target basis, the Phase I Program for a Collaboration Target shall commence on the start of the first Phase I Plan for such Collaboration Target and shall continue until the expiration of the Option Period for such Collaboration Target.&nbsp;&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238624"></a><a name="_Toc442266270"></a><a name="_Toc445390114"></a><a name="_Toc450305495"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Records; Reports</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.2.1&nbsp;&nbsp;&nbsp;Progress Reports</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">At least quarterly during the Phase I Program, (i) BPM shall prepare and provide to the JDC a detailed summary of the progress of the work performed by BPM under the Phase I Plans during the preceding Calendar Quarter and (ii) Roche shall prepare and provide to the JDC a detailed summary of the progress of the work performed by Roche under the Phase I Plans during the preceding Calendar Quarter. Promptly upon expiry of the Research and Development Term, each Party shall provide a final written report to the JDC summarizing its activities under the Phase I Plans and the results thereof. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.2.2&nbsp;&nbsp;&nbsp;Phase I Records</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall maintain records of all Phase I Studies conducted under the Phase I Plans (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of activities under the Phase I Plans.&nbsp;&nbsp;All laboratory notebooks shall be maintained for no less than the term of any Patent Rights issuing therefrom.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">37</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302603"></a><a name="_Toc442238625"></a><a name="_Toc442266271"></a><a name="_Toc445390115"></a><a name="_Toc450305496"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diligence</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall use Commercially Reasonable Efforts in the conduct of each Research Plan and Phase I Plan.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For any Collaboration Target for which Roche exercises its Option Right, Roche shall use Commercially Reasonable Efforts to further develop (pursuant to the agreed Development Plan) and commercialize at least one (1) Licensed Product in at least one (1) Indication in the Field in the Roche Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For Program 2 and Program 4, BPM shall use Commercially Reasonable Efforts to further develop (pursuant to the agreed Development Plan) and commercialize at least one (1) Licensed Product in at least one (1) Indication in the Field in the BPM Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302604"></a><a name="_Ref417228732"></a><a name="_Ref442231512"></a><a name="_Toc442238626"></a><a name="_Toc442266272"></a><a name="_Ref445310233"></a><a name="_Toc445390116"></a><a name="_Toc450305497"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc445390117"></a><a name="_Toc450305498"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scope</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref266780710"></a><a name="_Toc362302608"></a><font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms of this Section 7, after exercise of its Option Right for a Collaboration Target and other than with respect to the Phase I Program, (i) subject to Section 7.3, Roche shall have responsibility for the conduct of all clinical development for Licensed Products in the Field in the Territory subject to the applicable sharing of Phase I Development Costs and Development Costs, (ii) Roche shall have responsibility for the design and conduct of all research and development of Companion Diagnostics for Licensed Products in the Field in the Territory, and (iii) Roche shall have the responsibility for the design of, and the right to conduct, all Clinical Studies for a given Collaboration Target involving Roche Clinical Compounds or Roche Marketed Products. Clinical development of Licensed Products in the Field in the Territory shall be overseen by the JDC subject to Section&nbsp;7.3. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440983782"></a><a name="_Ref442214044"></a><a name="_Toc442238628"></a><a name="_Toc442266274"></a><a name="_Ref442263188"></a><a name="_Ref442263202"></a><a name="_Ref442304562"></a><a name="_Toc445390118"></a><a name="_Toc450305499"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For development of Licensed Products in Program 1, Program 3, and Program 5, Roche shall keep BPM informed of clinical development activities for Licensed Products in the Field in the Roche Territory and share the Development Plan through the JDC. Roche shall be responsible for all decision making with respect to clinical development of Licensed Products in Program 1, Program 3 and Program 5 in the Field in the Roche Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref443289206"></a><a name="_Toc445390119"></a><a name="_Toc450305500"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development of Program 2 and Program 4</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445115280"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.3.1&nbsp;&nbsp;&nbsp;Consensus and Label Pursuits</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For development of Licensed Products in Program 2 and Program 4, the Parties shall strive to reach consensus on the Development Plan through the JDC with the intent to establish a global clinical plan that benefits both Parties in their respective regions for commercialization. If the JDC is unable to agree on elements of the Development Plan (as to Indications, Label Pursuits, or design of the global Clinical Studies), then Roche shall have final say with respect to the Development Plan where such Development Plan shall include no more than a total of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Label Pursuit</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) of which no more than a total of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Label Pursuits may include simultaneous Pivotal&nbsp;&nbsp;Studies) unless the Parties mutually agree otherwise, provided that if the Parties mutually agree to co-formulate a Combination Product involving Roche Clinical Compounds or Roche Marketed Products, then the Parties shall mutually agree to the applicable portion of the Development Plan. By way of example, triple negative breast cancer and hormone-receptor positive breast cancer shall be considered two (2) distinct Label Pursuits.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">38</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445115291"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.3.2&nbsp;&nbsp;&nbsp;Supplemental Studies</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall have responsibility for the conduct of all Clinical Studies for Licensed Products in the Field in the Territory pursuant to the Development Plan other than Supplemental Studies.&nbsp;&nbsp;In addition, after the first Regulatory Approval for a Licensed Product, to the extent that (a) a Party desires to conduct any Clinical Studies in a Label Pursuit for such Licensed Product that is not included in the Development Plan, (b) a Party desires to conduct any Clinical Studies for such Licensed Product that are specific to a Party&#x2019;s portion of the Territory, or (c) a Party desires to conduct any Post-Marketing Studies or other post-marketing commitments as mandated or agreed to be conduct with a Regulatory Authority for such Licensed Product, in each case ((a)-(c)) for such Licensed Product that the other Party does not desire to co-fund (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Supplemental Study</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), the Party desiring to conduct such Supplemental Study(ies) may do so at its own cost and expense in its Territory or in the other Party&#x2019;s Territory, subject to the following limitations in this Section 7.3.2. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If a Party wants to conduct a Supplemental Study for a Licensed Product in the other Party&#x2019;s Territory, such Supplemental Study shall require the consent of such other Party, which consent shall not be unreasonably withheld by such other Party; provided that such consent may be reasonably withheld by such other Party if such other Party determines in good faith using industry-reasonable criteria that such Supplemental Study would likely cause commercial harm to such other Party or its Affiliates or Sublicensees in such other Party&#x2019;s respective Territory.&nbsp;&nbsp;At the request of the Party proposing to conduct such Supplemental Study, such other Party shall explain at the JDC the basis for its determination to withhold its consent to such Supplemental Study in such other Party&#x2019;s Territory.&nbsp;&nbsp;If the Party proposing to conduct the Supplemental Study believes that it is impractical or such Party will be unable to fulfill a post-marketing commitment mandated or agreed to with a Regulatory Authority unless such Supplemental Study is conducted in the other Party&#x2019;s Territory, the Party proposing to conduct such Supplemental Study shall have the burden of demonstrating that it is impractical or unable to conduct such Supplemental Study unless such Supplemental Study is conducted in the other Party&#x2019;s Territory. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The other Party shall have the right (but not the obligation) (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Supplemental Study Opt-In Right</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to access any study reports and data of such Supplemental Study(ies) that such other Party did not co-fund for purposes of Filing for Regulatory Approval in such other Party&#x2019;s Territory by paying </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of the Development Costs incurred by the Party conducting such Supplemental Study.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For clarity, for Program 2 and Program 4 (i) conduct of Clinical Studies (including Supplemental Studies) in non-oncology Indications shall require mutual agreement of the Parties, and (ii) conduct of Clinical Studies (including Supplemental Studies) using Roche Marketed Products shall require the written consent of Roche.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445115316"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.3.3&nbsp;&nbsp;&nbsp;Shared Development Costs</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Within sixty (60) days after exercising its Option Right with respect to each of Program 2 and Program 4, Roche shall provide BPM with an initial Development Plan and a budget for such Program outlining the planned activities and related Development Costs (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Shared Development Cost Budget</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) for such Development Plan. The Shared Development Cost Budget shall include the anticipated Development Costs pursuant to the Development Plan for the remainder of the then current Calendar Year and each of the next two (2) Calendar Years expected to be incurred by each Party and in total. Thereafter, annually, the Development Plan and the Shared Development Cost Budget shall be updated by the JDC such that the Shared Development Cost </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">39</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Budget shall always reflect the planned activities under the Development Plan for three (3) Calendar Years. If a Party&#x2019;s actually incurred Development Costs for the current Calendar Year exceeds </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of its portion of the Shared Development Cost Budget, such excess portion of Development Costs shall be entirely borne by the Party that exceeded its portion of the Shared Development Cost Budget provided that (A) BPM approved the amount included in the Shared Development Cost Budget specifically attributable to the activities conducted by BPM under such Shared Development Cost Budget, and (B)&nbsp;the JDC shall have the right during a Calendar Year to update the Shared Development Cost Budget in the event of (i) faster than planned Clinical Study enrollment, (ii) written guidance or requirements from a Regulatory Authority that would result in amendments to the Development Plan or (iii) mutual agreement by the Parties to amend the Development Plan, each of (i), (ii) and (iii) an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Allowable Exception</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;.&nbsp;&nbsp;Additional Development Costs incurred in a Calendar Year resulting from an Allowable Exception shall be subject to sharing of Development Costs pursuant to Section 12.6.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref445115375"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.3.4&nbsp;&nbsp;&nbsp;Deferrable Amounts</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If the annual update to the Development Plan for such Program results in the Shared Development Cost Budget for the first remaining Calendar Year of the Shared Development Cost Budget increasing by more than </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> from the then current Shared Development Cost Budget for the then-current Calendar Year or the second remaining Calendar Year increasing by more than </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> from the then current Shared Development Cost Budget for such Program for the then-current Calendar Year, after taking into consideration any Allowable Exceptions, then BPM shall have the right to elect not to pay its share of actually incurred Development Costs for such Program for such Calendar Year exceeding such percentage of the previous Shared Development Cost Budget for such Program for such Calendar Year (such amount a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Deferrable Amount</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; and such election a (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM Deferral Election</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;)). If BPM makes a BPM Deferral Election, Roche may elect to either (i) deduct or withhold payments payable to BPM under Section 12.7, 12.8 or 12.9 until </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of the Deferrable Amount is repaid to Roche or (ii) increase the royalty rates payable by BPM to Roche under Section 12.9.3 by </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (e.g., the first royalty tier would become </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) until </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of the Deferrable Amount is repaid to Roche, provided that at any time BPM may elect to repay </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of such Deferrable Amount in part or in full to Roche in cash.&nbsp;&nbsp;Notwithstanding the foregoing, BPM shall not have the right to make a BPM Deferral Election for any Calendar Year after the First Commercial Sale in the United States for any Licensed Product under this Agreement. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The following is an example that illustrates a possible scenario involving a Licensed Product for a </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In this example, the Shared Development Cost Budget was provided to BPM in June 2019 in millions of US dollars (US$ Millions) and BPM approved the costs of activities performed by BPM.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">June-Dec 2019 (budgeted)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2020 (budgeted)</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2021 (budgeted)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Total</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:25.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">40</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">The Shared Development Cost Budget was provided to BPM for 2020, 2021 and 2022 in millions of US dollars (US$ Millions) and BPM approved costs of activities performed by BPM.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">June-Dec 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2020</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2021</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2022</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Actual)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Budgeted)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Budgeted)</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Budgeted)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Total</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:20.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">As a consequence:</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- For 2019, both parties share </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> the amount of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;+</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;"> [&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;=</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;"> [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- For 2019, Roche bears on its own the amount of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, which </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of the originally budgeted amount of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- BPM can elect the BPM Deferral Election for 2020 because the increase in total budget from </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> to </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> is </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(For the below sections we assume that BPM made such election.)</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- No Deferral Election can be made for 2021 because the increase in total budget from </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> to </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> is </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Shared Development Cost Budget provided to BPM for 2021, 2022 and 2023 in millions of US dollars (US$ Millions) and BPM approved costs of activities performed by BPM.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Century;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">June-Dec 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2020</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2021</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2022</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jan-Dec 2023</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Actual)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Actual)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Budgeted)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Budgeted)</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Budgeted)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Total</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">As a consequence:</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- For 2020, because of BPM&#x2019;s deferral election, both parties share </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> the amount of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- BPM pays on its own the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, which exceeds the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> % of the previously budgeted amount of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">41</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">- Roche pays on its own the remaining </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;(</font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> total less </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">shared costs less </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> solely borne by BPM)</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- Roche is entitled to a repayment of </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> % of BPM's share of the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- BPM's share of the </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> equals </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and Roche's reimbursement equals </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;][&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- No Deferral Election for 2021 because the increase in total budget from </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> to </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> is </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">- No Deferral Election for 2022 because the increase in total budget from </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> to </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> is </font><font style="display:inline;font-family:Times New Roman,Times,serif;background-color: #FFFFFF;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.3.5&nbsp;&nbsp;&nbsp;Updates </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For Program 2 and Program 4, each Party will periodically provide to the JDC, on a Calendar Quarter basis, or more frequently as reasonably requested by the JDC, an update regarding development activities conducted by or on behalf of such Party with respect to Licensed Products for such Program, as well as any Supplemental Studies, conducted by or on behalf of such Party with respect to Licensed Products for such Program.&nbsp;&nbsp;The Parties will periodically report to the JDC, but in no event less than on a Calendar Quarter basis, regarding their respective activities conducted under the Development Plan for Licensed Products for such Program. In addition, each Party will promptly share with the other Party all material developments and information that it comes to possess relating to the development of any Licensed Products for such Program and all other data and information that either Party may reasonably request to support Filings in a mutually agreed format, including (a) safety concerns for Licensed Products for such Program, and (b) study reports and data generated from Clinical Studies of such Licensed Products for such Program; provided however, that excluding safety concerns or as required under the Pharmacovigilance Agreement, a Party will not be obligated to share any study reports and data generated from Supplemental Studies conducted by or on behalf of such Party unless the non-proposing Party has not exercised its Supplemental Study Opt-In Right other than to permit the non-proposing Party to determine whether to exercise its Supplemental Study Opt-in Right.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.3.6&nbsp;&nbsp;&nbsp;Records</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442238629"></a><font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party will maintain scientific records, in sufficient detail and in sound scientific manner appropriate for Patent and regulatory purposes and in compliance with cGCP with respect to activities intended to be submitted in regulatory filings (including INDs and BLAs), which will fully and accurately reflect all work done and results achieved in the performance of the Development activities, Clinical Studies (including Supplemental Studies) with respect to Licensed Products by such Party.</font><a name="_Toc441059909"></a><a name="_Toc441060147"></a><a name="_Toc441059910"></a><a name="_Toc441060148"></a><a name="_Toc441059911"></a><a name="_Toc441060149"></a><a name="_Ref441563572"></a>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc442266275"></a><a name="_Ref442289894"></a><a name="_Toc445390120"></a><a name="_Toc450305501"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governance</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Toc362302609"></a><a name="_Toc442238630"></a><a name="_Toc442266276"></a><a name="_Ref442369880"></a><a name="_Toc445390121"></a><a name="_Toc450305502"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Research Committee</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Within thirty (30) days after the Effective Date, the Parties shall establish a JRC to oversee all activities under the Research Plans.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<a name="_Ref440977592"></a><a name="_Toc442238631"></a><a name="_Toc442266277"></a><a name="_Toc445390122"></a><a name="_Toc450305503"></a><a name="_Ref266775257"></a><a name="_Ref266775392"></a><a name="_Toc362302610"></a><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JDC</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Within thirty (30) days after the first Collaboration Compound achieving CLS Criteria, the Parties shall establish a JDC to oversee development of Products and Licensed Products.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">42</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Members</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JRC and JDC shall each be composed of six (6) persons (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Members</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). Roche and BPM each shall be entitled to appoint three (3) Members with appropriate seniority, responsibilities and functional expertise within the applicable Party to make decisions arising within the scope of the JRC&#x2019;s or JDC&#x2019;s, as applicable (each such appointee of Roche, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche Member</font><font style="display:inline;font-family:Times New Roman,Times,serif;">,&#x201D; and each such appointee of BPM, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM Member</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;); provided that one Roche Member shall have CMC-related decision-making authority on behalf of Roche at all times. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least ten (10) days prior to the next scheduled meeting of the JRC or JDC, as applicable. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part or the whole meeting with prior written notification to the JRC or JDC, as applicable. Members may be represented at any meeting by another person designated by the absent Member. Each committee is chaired by a Member (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Chairperson</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The JRC shall be chaired by a BPM Member.&nbsp;&nbsp;The JDC shall be chaired by a Roche Member.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibilities of the JRC</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JRC shall have the responsibility and authority to: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approve each Research Plan and any revisions thereto;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review and oversee the execution of the Research Plans;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approve the Screening plan and any changes thereto;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;select Screening Hits for Target Validation;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;select Collaboration Targets in Part 2 in accordance with Section 4.1.6;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approve the Target Validation plan and any changes thereto;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approve validated Collaboration Targets to be allocated to the Pool in Part 2;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maintain a list of Collaboration Targets;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;establish timelines for research decision points;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine Compound Criteria;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine whether criteria have been met (Compound Criteria, Lead Series Identified Criteria, CLS Criteria, CCS Criteria);</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;select all Backup Compounds;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maintain a list of all Collaboration Compounds, including Backup Compounds;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine and maintain a list of all Collaboration Targets in order of advancement of status;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review the research efforts of the Parties;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;identify appropriate resources necessary to conduct the Research Plans (including recommending whether Roche&#x2019;s chemistry resources should be included in Lead Optimization, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in order to increase the number of parallel activities on multiple series in a Research Plan or for multiple Research Plans or to address specific optimization questions in Lead Optimization);</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine when and where to perform any pre-formulation activities, salt screening, and polymorph screening in accordance with CLS Criteria and CCS Criteria;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">43</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;align on the drug substance and drug product specifications for the batches used for the GLP Tox Studies;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;align on the drug substance and drug product strategy, including stability program, and its execution for the drug product used for the GLP Tox Studies and Phase I Studies;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine whether drug substance and/or drug product batches for Phase I Studies shall be made at a CRO acceptable to Roche or by Roche itself using its facilities;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;oversee manufacture and release of drug substance and drug product batches to be used for Phase I Studies;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review the GLP Tox Study protocol </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> with respect to study design, dose selection or GLP exposure measurements;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine whether drug substance and/or drug product batches for GLP-Tox Studies&nbsp;&nbsp;shall be made at a CRO acceptable to Roche or by Roche itself using its facilities;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;oversee manufacture and release of drug substance and drug product batches to be used in GLP-Tox Studies;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;establish, set expectations and mandates for, oversee and disband JOTs;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recommend action items to each Party&#x2019;s respective decision making bodies; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;attempt to resolve any disputes on an informal basis.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JRC shall have all responsibility and authority regarding overseeing activities under the Research Plans, other than as expressly set forth in this Agreement. The JRC shall have no responsibility and authority other than that expressly set forth in this Section, unless mutually agreed by the Parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibilities of the JDC</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JDC shall have the responsibility and authority to: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;develop and approve initial Phase I Plans and any revisions thereto;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approve Development Plans and any revisions thereto;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review and oversee the execution of the Phase I Plans and Development Plans;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;oversee the initial Phase I Studies for Products prior to Roche&#x2019;s exercise of an Option Right;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine and maintain a list of all Collaboration Targets in order of advancement of status;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designate the MTD for each Product;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designate the cut-off date for the data resulting from the Phase I Studies conducted by the Parties for each Collaboration Target in accordance with Section 3.1.3;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;oversee development of Licensed Products after Roche&#x2019;s exercise of an Option Right;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;establish timelines and criteria for development decision points;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine whether development criteria have been met;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review the development efforts of the Parties, including for Companion Diagnostics;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;identify appropriate resources necessary to conduct the Phase I Plans and Development Plans;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">44</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review and approve Phase I Development Costs and Development Costs in accordance with the allocations set forth in Sections&nbsp;12.5 and 12.6;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;depending on the Clinical Studies following Phase I Studies, devise at the latest upon start of Phase I Studies the appropriate CMC-strategy for drug substance and drug product to be used in either Phase II Studies or Phase III Studies and oversee its execution (with Roche deciding where such manufacture of Phase II and Phase III Study supply, both for drug substance and drug product, should occur (including prior to Roche exercising its Option Right);</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;define the drug substance and drug product specifications for the batches used for Phase I Studies and any batches made prior to Roche exercising its Option Right for the subsequent Phase II Studies and/or Phase III Studies after Option Right exercise;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determine whether a [&#x2026;***&#x2026;] or should be re-designated pursuant to Section 5.1.3;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;establish, set expectations and mandates for, oversee and disband JOTs;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recommend action items to each Party&#x2019;s respective decision making bodies; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;attempt to resolve any disputes on an informal basis.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JDC shall have all responsibility and authority regarding the clinical development of Products and Licensed Products, other than as expressly set forth in this Agreement. The JDC shall have no responsibility and authority other than that expressly set forth in this Section, unless mutually agreed by the Parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Chairperson or his/her delegate will be responsible for sending invitations and agendas for all JRC or JDC, as applicable, meetings to all Members of each committee at least ten (10) days before the next scheduled meeting of the JRC or JDC, as applicable. During the Research and Development Term, the venue for the meetings shall be agreed by the JRC or JDC, as applicable. The JRC or JDC, as applicable shall hold meetings at least once per Calendar Quarter, either in person or by tele-/video-conference, and in any case as frequently as the Members of the JRC or JDC, as applicable may agree shall be necessary, but not more than six (6) times each Calendar Year. After the Research and Development Term the JDC shall meet once per Calendar Quarter, provided that if there is no on-going development for either Program 2 or Program 4, the JDC shall meet twice per Calendar Year. The Alliance Director of each Party may attend the JRC and/or JDC meetings as a permanent participant.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Minutes</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Chairperson of a committee will be responsible for designating a Member to record in reasonable detail and circulate draft minutes of meetings to all members of the committee for comment and review within twenty (20) days after the relevant meeting. The Members of the committee shall have ten (10) days to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the committee within thirty-five (35) days of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">45</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decisions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.8.1&nbsp;&nbsp;Decision Making Authority</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JRC shall decide matters within its responsibilities set forth in Section&nbsp;8.4.&nbsp;&nbsp;The JDC shall decide matters within its responsibilities set forth in Section 8.5.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.8.2&nbsp;&nbsp;Consensus; Good Faith</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In general, the Parties intend to govern this collaboration through empowered joint committees that operate by consensus while making its decisions with speed. The Parties recognize that there may be exceptions to this principle where reaching consensus is not possible and one Party will need to make a final decision on a given matter in order to preserve the importance of progressing with speed.&nbsp;&nbsp;With this in mind, the Members of a committee shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by that committee. The Parties shall endeavor to make decisions by consensus.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.8.3&nbsp;&nbsp;Pre-Exercise of Option Right Escalation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If the JRC or JDC is unable to decide a matter arising before Roche&#x2019;s exercise of its Option Right by consensus, then such matter shall be referred to the Chief Executive Officer of BPM or equivalent position or his/her nominee and the Head of Roche Partnering or equivalent position or his/her nominee for resolution, who together shall use reasonable and good faith efforts to reach a decision by consensus within thirty (30) days after the date such matter is referred to them. If the Parties still fail to reach a decision within such thirty (30) days, then the final decision shall be BPM&#x2019;s in the case of a decision by the JRC and Roche&#x2019;s in the case of a decision by the JDC, which shall be exercised in good faith. Any such decision shall constitute a decision of the JRC or JDC, as applicable.&nbsp;&nbsp;Notwithstanding the above, (a) decisions that impact the payment of fees under Section 12.2, the use of Roche facilities or resources pursuant to Section 4.1.5 or Section 8.4 or the use of each Party&#x2019;s resources outside of the scope of this Agreement shall require consensus and shall not be subject to this Section 8.8.3, (b) Roche shall have the final decision-making authority with respect to the design of each Phase I Plan, (c) Roche shall have the final decision-making authority with respect to the conduct of any Clinical Studies of a Product or Licensed Product in combination with either a Roche Marketed Product or a Roche Clinical Compound that Roche elects to conduct, and (d) BPM shall have the final decision-making authority with respect to the conduct of all other Phase I Clinical Studies. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information Exchange</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM and Roche shall exchange the information in relation to its activities under this Agreement through the JRC or JDC, as applicable, and BPM and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto and each Party shall give due consideration to the other Party&#x2019;s input. Notwithstanding the above, a committee may determine other routes of information exchange.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.10&nbsp;&nbsp;&nbsp;&nbsp;Alliance Director</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall appoint one (1) person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each, an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Alliance Director</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The Alliance Directors shall be permanent participants of committee meetings (but not Members of the committees) and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the committees to reach consensus and avert escalation of such issues or potential disputes.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">46</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations of Authority</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">No committee shall have any authority to amend or waive any terms of this Agreement, nor shall any committee have the authority to determine whether a Party is in breach of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JRC, JDC and any other committees established under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lifetime</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The JRC shall exist for so long as work is being conducted under a Research Plan in accordance with this Agreement.&nbsp;&nbsp;The JDC shall exist for so long as a Product or Licensed Product remains in clinical development under a Development Plan. The lifetime of any other committee established pursuant to Section&nbsp;8.14 will be agreed to by the Parties at the time of inception.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Committees</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Parties may mutually agree to establish such additional joint committees as deemed necessary to achieve the objectives and intent of this Agreement. Any additional committees shall be required to consist at all times of an equal number of BPM Members and Roche Members.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacture and Supply</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.1&nbsp;&nbsp;Manufacturing Right</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to Roche&#x2019;s exercise of its Option Right for a Collaboration Target, the JRC will determine which Party has responsibility for the manufacture of Collaboration Compounds and Products, subject to the oversight of the JRC, in accordance with the applicable Research Plan and Phase I Plan for such Collaboration Target.&nbsp;&nbsp;If requested by a Party, the other terms under which a Party will manufacture and supply Collaboration Compounds and Products to the other Party will be set forth in one or more manufacturing and supply agreements to be entered into between the Parties (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Supply Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;Such Supply Agreements will contain customary terms and conditions, including quality and supply failure remedies, and otherwise be consistent with this Agreement and Roche quality standards.&nbsp;&nbsp;If the Parties cannot agree to the terms of a Supply Agreement within ninety (90) days of initiation of discussions, such matter will be decided by the Expert Committee in accordance with the terms and conditions set forth in Section 12.9.4, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">mutatis mutandis</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">After Roche&#x2019;s exercise of its Option Right for a Collaboration Target, subject to the oversight of the JDC, Roche shall have the right to manufacture all Licensed Products for such Collaboration Target throughout the Territory, subject to this Section 9.1. For Licensed Products in the BPM Territory pursuant to Program 2 and Program 4, (i) Roche, at its option, can elect to transfer the manufacturing process to BPM (or a CRO that is reasonably acceptable to Roche) whereby BPM (or such CRO) would then have responsibility to manufacture its own supply of such Licensed Product at its own costs; or (ii) BPM, at its option, can elect to use a CRO that is acceptable to Roche to perform such manufacturing activities on behalf of BPM in the BPM Territory if such CRO provides a price that is at least </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> lower than the per unit cost for a Licensed Product than offered by Roche taking into account projected supply volume discounts. The costs of any such manufacturing process transfer pursuant to clause (i) of the preceding sentence shall be shared equally by the Parties, and pursuant to clause (ii) of the preceding sentence shall be borne solely by BPM. For Licensed Products supplied to BPM by Roche in the United States pursuant to Program 2 and Program 4, Roche shall supply such Licensed Products for clinical supply at </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">47</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and for commercial supply at </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;][&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. The other terms under which Roche will manufacture and supply Licensed Products to BPM will be set forth in one or more Supply Agreements.&nbsp;&nbsp;Such Supply Agreements will contain customary terms and conditions, including quality and supply failure remedies, and otherwise be consistent with this Agreement and Roche quality standards.&nbsp;&nbsp;If the Parties cannot agree to the terms of a Supply Agreement within ninety (90) days of initiation of discussions, such matter will be decided by the Expert Committee in accordance with the terms and conditions set forth in Section 12.9.4, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">mutatis mutandis</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;At BPM&#x2019;s request, the Parties will include provisions in such Supply Agreements relating to the manufacture and supply of Companion Diagnostics or Roche Marketed Products for use with Licensed Products for Program 2 and Program 4. Either Party shall have the right to manufacture at risk, or have a CRO approved by Roche manufacture at risk, a Product prior to Roche exercising its Option Right for a Collaboration Target.&nbsp;&nbsp;If Roche exercises its Option Right for a Collaboration Target and Roche accepts the quality of a batch of the applicable Product, then the cost to manufacture such batch shall be a Development Cost.&nbsp;&nbsp;If Roche does not exercise its Option Right for a Collaboration Target, then the cost to manufacture such batch of the applicable Product shall be borne by the Party that manufactured or had manufactured the batch.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology Transfer</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall have the right, but not obligation, to request a Technology Transfer (as defined below) at any time however no later than [&#x2026;***&#x2026;] after exercising its Option Right for a given Program. Within [&#x2026;***&#x2026;] upon such request of Roche, BPM shall complete the transfer of all its Know-How within the BPM IP relating to the manufacturing of the Collaboration Compounds, Products and Licensed Products to Roche and/or one or more CROs designated by and contracting directly with Roche with the goal of enabling Roche and/or its designated CRO to manufacture Collaboration Compounds, Products and Licensed Products (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Technology Transfer</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The Parties will agree in good faith on a Technology Transfer protocol defining the scope and conditions of transfer. The cost of such Technology Transfer shall be shared equally. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall maintain in full force and effect all agreements relating to the manufacture of Collaboration Compounds and Products with Third Parties in effect as of the date of Roche&#x2019;s request of transfer so that Roche has uninterrupted access to clinical supply prior to and during any manufacturing transition from BPM to Roche.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inspection Right</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall have the right, at any time prior to exercising its Option Right to conduct an inspection (including a cGMP audit) of BPM&#x2019;s manufacturing sites at BPM or at the CRO&#x2019;s facility, as applicable and, with respect to CROs, subject to confidentiality obligations.&nbsp;&nbsp;BPM shall cooperate in good faith in all respects to allow Roche to expediently complete its due diligence.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Review of Draft CRO Agreements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to entering into any new CRO agreements for manufacturing, including supply and quality agreements, related to Collaboration Compounds or Products, BPM shall provide Roche with any draft agreements with CROs for Roche to review and comment. BPM shall consider in good faith all reasonable comments of Roche.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.1&nbsp;&nbsp;Responsibility</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to Roche&#x2019;s exercise of its Option Right for a Collaboration Target, (a) BPM shall own and file all INDs and hold the regulatory responsibility under each Phase I Plan for each Collaboration Target that is designated as a [&#x2026;***&#x2026;], and for each [&#x2026;***&#x2026;] not involving a Roche Marketed Product or a Roche Clinical Compound and (b) Roche shall own and file all INDs and hold the</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">48</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">regulatory responsibility under each Phase I Plan for each Collaboration Target that is designated as a [&#x2026;***&#x2026;] that involves a Roche Marketed Product or a Roche Clinical Compound; provided in each case ((a) and (b)) that a Party shall only file an IND pursuant to the JDC deciding to do so.&nbsp;&nbsp;The responsible Party shall be responsible for pursuing, compiling and submitting the IND and all related Filing documentation, and for interacting with Regulatory Authorities, for such Collaboration Target; provided that the other Party shall have the right to review and comment on any material Filing prior to submission to the relevant Regulatory Authority, and, if the other Party exercises such right, the responsible Party will reasonably consider to consult with and address any concerns raised by the other Party in connection with such activities.&nbsp;&nbsp;Additionally, promptly following submission of any material Filing, the responsible Party shall provide the other Party with the technical format data, the case file and any regulatory dossiers containing information necessary or useful to the responsible Party in connection with its Filings for all Licensed Products including, but not limited to Clinical Study dossiers, regulatory correspondence, Regulatory Authority meeting minutes and study reports from completed non-clinical and Clinical Studies in a format that is agreed to by the Parties.&nbsp;&nbsp;The responsible Party or its Affiliates shall own and file in their discretion all Filings and INDs for such Collaboration Target in the Field in all countries. For all completed study reports, the responsible Party shall provide necessary documentation to confirm data reliability, as required by Article 43 of the Japanese Pharmaceutical Affairs Law Enforcement Regulations and related notifications, including, but not limited to original author signatures, raw data lists, GLP and GCP compliance information. The responsible Party shall supply the other Party with a copy of all material communications related to such Collaboration Target in the Field to or from the Regulatory Authorities for all Major Countries. Upon request of the other Party, the responsible Party shall supply the other Party with a copy of all such communications to or from the Regulatory Authorities for all Major Countries.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">After Roche&#x2019;s exercise of its Option Right for a Collaboration Target, subject to Sections 7.2, 12.5 and 12.6, Roche shall be solely responsible for all regulatory affairs related to Licensed Products in the Field in the Roche Territory including the preparation and Filings, as well as any or all Regulatory Approvals required to Exploit Licensed Products in the Field in the Roche Territory. Roche shall be responsible for pursuing, compiling and submitting all Filing documentation, and for interacting with Regulatory Authorities, for all Licensed Products in all countries in the Roche Territory; provided that for Program 2 and Program 4, BPM shall have the right to review and comment on any material Filing for Program 2 or Program 4 prior to submission to the relevant Regulatory Authority, and, if BPM exercises such right, Roche will reasonably consider to consult with and address any concerns raised by BPM in connection with such activities.&nbsp;&nbsp;Roche will use Commercially Reasonable Efforts, to the extent reasonably practicable, to permit BPM to have, at BPM&#x2019;s expense, one (1) mutually acceptable representative of BPM attend, solely as a non-participating observer, material, substantive meetings, including pre-IND and end of Phase II Study meetings, with the Regulatory Authorities pertaining to all Licensed Products in Program 2 or Program 4.&nbsp;&nbsp;Additionally, promptly following submission of any material Filing for Program 2 or Program 4, Roche shall provide BPM with the technical format data, case file and any regulatory dossiers containing information necessary or useful to BPM in connection with its Filings for all Licensed Products including, but not limited to Clinical Study dossiers, regulatory correspondence, Regulatory Authority meeting minutes and study reports from completed non-clinical and Clinical Studies in a format that is agreed to by the Parties.&nbsp;&nbsp;Roche or its Affiliates shall own and file in their discretion all Filings and Regulatory Approvals for all Licensed Products in the Field in all countries of the Roche Territory. </font><font style="display:inline;font-family:Times New Roman,Times,serif;">For all completed study reports, BPM shall provide necessary documentation to confirm data reliability, as required by Article&nbsp;43 of the Japanese Pharmaceutical Affairs Law Enforcement Regulations and related notifications, including, but not limited to original author signatures, raw data lists, GLP and GCP compliance information.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Roche shall supply BPM with a copy of all material communications related to Licensed Products in the </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">49</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Field to or from the Regulatory Authorities for all Major Countries in the Roche Territory. Upon request of BPM, Roche shall supply BPM with a copy of any communications to or from the Regulatory Authorities for all Major Countries in the Roche Territory.&nbsp;&nbsp;Such terms shall apply </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">mutatis mutandis</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> with respect to Licensed Products for Program 2 and Program 4 in the BPM Territory (i.e., BPM shall have all such rights and obligations in lieu of Roche), other than Combination Products in Program 2 or Program 4 that include a Roche Marketed Product, in which case Roche shall be solely responsible for all regulatory affairs worldwide related to such Combination Product in Program 2 or Program 4 as set forth above.&nbsp;&nbsp;For Combination Products in Program 2 or Program 4 that include a Roche Marketed Product, Roche will provide BPM with reasonable advance notice of all substantive meetings with the Regulatory Authorities pertaining to each such Combination Product, or with as much advance notice as practicable under the circumstances.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to Roche&#x2019;s starting Clinical Study enrollment activities for Licensed Products, BPM shall transfer to Roche all relevant historical clinical safety data.&nbsp;&nbsp;Safety information on serious adverse events shall be provided in CIOMS format and safety information on non-serious adverse events shall be provided in English Line Listing format.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">At a date to be defined by Roche after exercise of an Option Right for a Collaboration Target, BPM shall transfer and assign to Roche all INDs with respect to Products for such Collaboration Target in the Field in its possession and control, except for filings with a US Regulatory Authority in the case of Program 2 and Program 4. Prior to the transfer, BPM shall provide to Roche copies of all material correspondence with the Regulatory Authorities with respect to such Products for such Collaboration Target. In addition, at a date defined by Roche after exercise of an Option Right for a Collaboration Target, BPM shall transfer and assign to Roche any regulatory dossiers containing information necessary or useful to Roche in connection with its Filings for all Licensed Products for such Collaboration Target in the Field in the Roche Territory, including, but not limited to Clinical Study dossiers, regulatory correspondence, Regulatory Authority meeting minutes and study reports from completed non-clinical and Clinical Studies. For all completed study reports for Licensed Products for such Collaboration Target in the Roche Territory, BPM shall provide to Roche necessary documentation to confirm data reliability, as required by Article&nbsp;43 of the Japanese Pharmaceutical Affairs Law Enforcement Regulations and related notifications, including original author signatures, raw data lists, GLP and GCP compliance information. All documentation is to be provided in English.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting Adverse Events</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.2.1&nbsp;&nbsp;Report</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Parties agree to inform each other about serious adverse events occurring or having occurred in connection with the use of a Product or Licensed Product that comes into its knowledge. The Parties agree to handle data and information about adverse events occurring or having occurred in connection with the use of a Product or Licensed Product according to the guidelines in the respective territory, for example, those recited in the FDCA and the similar requirements of the Canadian or European regulatory authorities, requirements of the Regulatory Authority and/or requirements of any other relevant Regulatory Authority in the Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall be solely responsible for reporting adverse drug experiences to Regulatory Authorities in the BPM Territory in the case of Program 2 and Program 4. In all other cases, Roche, as the party owning the Filings and Regulatory Approvals shall be solely responsible for reporting adverse drug experiences to the regulatory authorities in the Roche Territory.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">50</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.2.2&nbsp;&nbsp;Pharmacovigilance Agreement</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Parties mutually agree to execute a separate Pharmacovigilance Agreement as deemed applicable by the Parties specifying the procedures and timeframes for compliance with Applicable Law pertaining to safety reporting of each Product and Licensed Product and their related activities. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercialization</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">11.1&nbsp;&nbsp;Responsibility</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche, at its own expense, shall have sole responsibility and decision making authority for the marketing, promotion, sale and distribution of Licensed Products in the Roche Territory and shall book all Sales in the Roche Territory.&nbsp;&nbsp;For Program 2 and Program 4, BPM, at its own expense, shall have sole responsibility and decision making authority for the marketing, promotion, sale and distribution of Licensed Products in the BPM Territory and shall book all Sales in the BPM Territory subject to Section 12.9.4.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">11.2&nbsp;&nbsp;Updates </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Upon request of the Party not selling a Licensed Product in a particular region (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Non-Selling Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), the Party selling the Licensed Product in the particular regions (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Selling Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) shall update the Non-Selling Party regarding the commercialization of the Licensed Product (i) in the Roche Territory in the Field by Roche, its Affiliates and Sublicensees, in the case where Roche is the Selling Party, or (ii) in the BPM Territory in the Field by BPM, its Affiliates and Sublicensees, in the case where BPM is the Selling Party. By November 15 of each Calendar Year, the Selling Party also shall provide a non-binding forecast of its annual sales of Licensed Products to the Non-Selling Party for the subsequent Calendar Year. If the Non-Selling Party requests an update, the Selling Party shall provide a high level summary, in writing and/or through a meeting (face to face/ tele-presence/videoconference or telephone). The Non-Selling Party shall not request an update more frequently than once per Calendar Year. In addition, upon reasonable request by the Non-Selling Party in connection with financing, partnering, other strategic transaction or Non-Selling Party's reporting obligations under securities laws, the Selling Party shall provide a high level summary regarding the commercialization of the Licensed Product in the Roche Territory or BPM Territory, as applicable, in the Field by the Selling Party, its Affiliates and Sublicensees.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">11.3&nbsp;&nbsp;Recalls, Market Withdrawals or Corrective Actions.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event that any Regulatory Authority issues or requests a recall or takes a similar action in connection with a Licensed Product in the Field in the Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal of a Licensed Product in the Field in its Territory, the Party notified of such recall or similar action, or the Party that desires such recall or similar action, will as promptly as possible, notify the other Party by telephone or e-mail.&nbsp;&nbsp;Each Party, in consultation with the other Party, will decide whether to conduct a recall of a Licensed Product in its own Territory and the manner in which any such recall will be conducted (except in the case of a government mandated recall, when such Party may act without such advance notice but will notify the other Party as soon as possible thereafter).&nbsp;&nbsp;Except as may otherwise be agreed to by the Parties, each Party will bear the expense of any such recall in its own Territory.&nbsp;&nbsp;Each Party will make available all of its pertinent records that may be reasonably requested by the other Party in order for a Party to effect a recall of a Licensed Product in its Territory. The Parties&#x2019; rights and obligations under this Section&nbsp;11.3 will be subject to the terms of any Supply Agreement(s) and any Pharmacovigilance Agreement entered into between the Parties.&nbsp;&nbsp;In the event of a conflict between the provisions of any such Supply Agreements and Pharmacovigilance Agreement and </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">51</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">this Section&nbsp;11.3, the provisions of such Supply Agreement and Pharmacovigilance Agreement will govern.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.1&nbsp;&nbsp;Initiation Payment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Within [&#x2026;***&#x2026;] after the Effective Date and receipt of an invoice from BPM, Roche shall pay to BPM forty-five million US dollars (US$45,000,000). Such payment will be non-refundable, non-creditable and not subject to set-off.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.2&nbsp;&nbsp;Pre-Option Exercise Fees</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall pay to BPM up to a total of </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> US dollars </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, upon the achievement of milestone events with respect to Products. The event payments under this Section&nbsp;12.2 shall be paid by Roche according to the following schedule of events.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="top" style="width:314.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">op</font></p>
				</td>
				<td colspan="2" valign="top" style="width:130.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:314.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Event</font></p>
				</td>
				<td colspan="2" valign="top" style="width:130.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">US Dollars (in </font><br /><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">millions)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:314.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 3.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:130.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:314.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 3.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:130.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:314.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 3.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (per each Collaboration Target, up to </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in total payments for all five Collaboration Targets)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:130.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:314.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 3.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (per each Collaboration Target, up to </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in total payments for all five Collaboration Targets)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:130.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:314.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 3.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (per each Collaboration Target, up to </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in total payments for all five Collaboration Targets)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:130.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Any such payments shall be paid by Roche to BPM within [&#x2026;***&#x2026;] after the occurrence of the applicable event and receipt of an invoice from BPM.&nbsp;&nbsp;Each payment will be non-refundable, non-creditable and not subject to set-off.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.3&nbsp;&nbsp;Costs for Work Conducted Under Research Plans</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Except as otherwise provided in this Agreement, each Party shall be responsible for its own costs incurred in the conduct of each Research Plan.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.4&nbsp;&nbsp;Option Exercise Fee</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If Roche exercises its Option Right with respect to a Collaboration Target, then Roche shall pay to BPM a fee (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Option Exercise Fee</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to exercise such Option Right as follows: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:280.00pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exercise of Option Right</font></p>
				</td>
				<td valign="top" style="width:165.45pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">US Dollars (in millions)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:280.00pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 1</font></p>
				</td>
				<td valign="top" style="width:165.45pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:280.00pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 2</font></p>
				</td>
				<td valign="top" style="width:165.45pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:280.00pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 3</font></p>
				</td>
				<td valign="top" style="width:165.45pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:280.00pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 4</font></p>
				</td>
				<td valign="top" style="width:165.45pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:280.00pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 5</font></p>
				</td>
				<td valign="top" style="width:165.45pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">52</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the provisions of Sections 3.1.3 and 3.1.4, any such payments shall be paid by Roche to BPM </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> after the occurrence of the applicable event and receipt of an invoice from BPM.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Each Option Exercise Fee will be non-refundable, non-creditable and not subject to set-off.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.5&nbsp;&nbsp;Phase I Development Cost Share </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All Phase I Development Costs will be shared [&#x2026;***&#x2026;] by BPM and [&#x2026;***&#x2026;] by Roche; provided that BPM shall only be responsible for up to a maximum of [&#x2026;***&#x2026;] of Phase I Development Costs for all Phase I Studies conducted pursuant to a Phase I Plan for each Collaboration Target (it being understood that such [&#x2026;***&#x2026;] cap shall apply on a Collaboration Target-by-Collaboration Target basis and thus to all Products (including any Backup Compounds) for any such Collaboration Target), and any Phase I Development Costs in excess of such [&#x2026;***&#x2026;] cap for a Collaboration Target shall be </font><font style="display:inline;font-family:Times New Roman,Times,serif;">at Roche&#x2019;s sole expense; provided that if (a) there is a failure of a Product in a Phase I Study prior to the designation of the MTD for such Product for a Collaboration Target and (b) the Parties conduct a Phase I Study with a Backup Compound for a Collaboration Target, then the cap for such Collaboration Target shall be increased to a maximum of </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">(it being understood that such [&#x2026;***&#x2026;] cap shall apply on a Collaboration Target-by-Collaboration Target basis and thus to all Products (including any Backup Compounds) for any such Collaboration Target), and any Phase I Development Costs in excess of such [&#x2026;***&#x2026;] cap for a Collaboration Target shall be </font><font style="display:inline;font-family:Times New Roman,Times,serif;">at Roche&#x2019;s sole expense</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;For clarity, the allocation of Phase I Development Costs set forth in this Section 12.5 will apply regardless of whether Roche has exercised its Option Right for a Collaboration Target. Commencing the first Calendar Quarter immediately following initiation of the Phase I Program, within fifteen (15) days after the end of each Calendar Quarter during which either Party incurs any Phase I Development Costs, both Parties shall submit to a finance officer designated by BPM and a finance officer designated by Roche (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Finance Officers</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) a report setting forth a good faith estimate of the Phase I Development Costs it incurred in such Calendar Quarter, as detailed in the Phase I Plans, as approved by the JDC.&nbsp;&nbsp;Within forty-five (45) days following the end of such Calendar Quarter, each Party shall update such report to reflect the final amount of Phase I Development Costs incurred by such Party; provided that if there are any Phase I Development Costs incurred in such Calendar Quarter that a Party is unable to timely include in such financial report, then such amount shall be included and reconciled in the financial report in a future Calendar Quarter.&nbsp;&nbsp;Each such report shall specify in reasonable detail costs incurred and shall include reasonably detailed supporting information. Within fifteen (15) days after receipt of such reports, the Finance Officers shall confer and agree in writing on whether a reconciliation payment is due from one Party to the other Party, and if so, the amount of such reconciliation payment, so that the Parties share Phase I Development Costs in accordance with this Section&nbsp;12.5.&nbsp;&nbsp;The Party required to pay such reconciliation payment shall make such payment to the other Party within sixty (60) days after the end of each Calendar Quarter; provided, however, that in the event of any disagreement with respect to the calculation of such reconciliation payment, any undisputed portion of such reconciliation payment shall be paid in accordance with the foregoing timetable and the remaining, disputed portion shall be paid within ten (10) Business Days after the date on which the Parties, using good faith efforts, resolve the dispute.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.6&nbsp;&nbsp;Development Cost Share </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All Development Costs for each Program will be shared by BPM and Roche as summarized in the following table.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">53</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:259.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exercise of Option Right</font></p>
				</td>
				<td valign="top" style="width:186.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Development Cost Share</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:259.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 1, Program 3, and Program 5</font></p>
				</td>
				<td valign="top" style="width:186.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">100% paid by Roche</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:259.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Program 2 and Program 4</font></p>
				</td>
				<td valign="top" style="width:186.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;] (Roche: BPM)</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Roche:BPM) </font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the foregoing, Developments Costs after the preparation of the initial regulatory dossier for a Licensed Product for Program 2 and Program 4, costs related to preparing and filing subsequent Filings with respect to such Licensed Product (including associated filing fees, translation expenses, and legal and other professional service fees) will be the responsibility of each Party in its respective Territory with respect to such Licensed Products. After receipt of Regulatory Approval for such Licensed Product in a country, all costs and expenses incurred will be the responsibility of each Party in its respective Territory with respect to such Licensed Product.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For clarity, the allocation of Development Costs set forth in this Section 12.6 will apply regardless of whether Roche has exercised its Option Right for a Collaboration Target.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Commencing the first Calendar Quarter immediately following a Party incurring Development Costs under this Agreement and continuing thereafter so long as a Party incurs Development Costs under this Agreement for which reconciliation will be provided, within fifteen (15) days after the end of each Calendar Quarter during which either Party incurs any Development Costs, each Party shall submit to a finance designee of the other Party a report setting forth a good faith estimate of the Development Costs it incurred in such Calendar Quarter for such Collaboration Target, as detailed in the Development Plan, as approved by the JDC.&nbsp;&nbsp;Within forty-five (45) days following the end of such Calendar Quarter, each Party shall update such report to reflect the final amount of Development Costs incurred by such Party; provided that if there are any Development Costs incurred in such Calendar Quarter that a Party is unable to timely include in such financial report, then such amount shall be included and reconciled in the financial report in a future Calendar Quarter.&nbsp;&nbsp;Each such report shall specify in reasonable detail costs incurred and shall include reasonably detailed supporting information. Within fifteen (15) days after receipt of such reports, the finance designees from both Parties shall confer and agree in writing on whether a reconciliation payment is due from one Party to the other Party, and if so, the amount of such reconciliation payment, so that the Parties share Development Costs in accordance with this Section&nbsp;12.6.&nbsp;&nbsp;The Party required to pay such reconciliation payment shall make such payment to the other Party within sixty (60) days after the end of each Calendar Quarter; provided, however, that in the event of any disagreement with respect to the calculation of such reconciliation payment, any undisputed portion of such reconciliation payment shall be paid in accordance with the foregoing timetable and the remaining, disputed portion shall be paid within ten (10) Business Days after the date on which the Parties, using good faith efforts, resolve the dispute.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.7&nbsp;&nbsp;Development Event Payments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For each of Program 1, Program 3, and Program 5, Roche shall pay BPM the following one-time milestone event payments for the first achievement of each of the corresponding milestone events (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Development Event</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) by the first Licensed Product for such Program to achieve such event:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:291.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Development Event for First Licensed Product</font></p>
				</td>
				<td valign="top" style="width:153.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">US Dollars (in millions)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:291.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:291.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:291.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">54</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:292.20pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:292.20pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:292.20pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:292.20pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:292.20pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:292.20pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="middle" style="width:153.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:292.20pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Total</font></p>
				</td>
				<td valign="middle" style="width:153.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the foregoing, for the purposes of construing the payments specified in the above table, if a Development Event is skipped (i.e., a later Development Event payment is payable before an earlier Development Event payment), or if Regulatory Approval is achieved in any jurisdiction with respect to a Licensed Product for a Collaboration Target without all of the preceding Development Event payments applicable to a Licensed Product having been achieved, then the skipped Development Event(s) will be deemed to have been achieved upon the achievement of the subsequent Development Event(s) or upon Regulatory Approval as applicable.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Upon the achievement of a Development Event, Roche shall timely notify BPM and Development Event payments shall be paid by Roche to BPM [&#x2026;***&#x2026;] from occurrence of the applicable event and receipt of an invoice from BPM.&nbsp;&nbsp;Subject to Section 7.3 and Section 12.9.6, each Development Event Payment will be non-refundable, non-creditable and not subject to set-off with respect to undisputed amounts.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.8&nbsp;&nbsp;Sales Based Event</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For the first Licensed Product pursuant to each of Program 1, Program 3, and Program 5, Roche shall pay BPM the following one-time milestone event payment for the first achievement of such milestone event by the first Licensed Product for such Program to achieve such event: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:279.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:165.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:279.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Calendar Year Net Sales Threshold</font></p>
				</td>
				<td valign="top" style="width:165.95pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">US Dollars (in millions)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:279.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Calendar Year Net Sales in the Territory of a Licensed Product exceed </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:165.95pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each sales milestone payment shall be deemed earned upon achievement of the corresponding sales milestone, and Roche shall make the corresponding sales milestone payment within [&#x2026;***&#x2026;] after the end of the Calendar Year in which the sales milestone threshold was achieved. Subject to Section 7.3, each sales milestone payment will be non-refundable, non-creditable and not subject to set-off with respect to undisputed amounts.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9&nbsp;&nbsp;Royalty Payments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">12.9.1&nbsp;&nbsp;Royalty Term</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Royalties shall be payable by the Selling Party on Net Sales or BPM Net Sales, as applicable, of Licensed Products until the expiry of the Royalty Term. Thereafter, on a Licensed Product-by-Licensed Product and country-by-country basis, the licenses granted shall be fully paid up, irrevocable and royalty-free.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">55</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9.2&nbsp;&nbsp;Royalty Rates on Licensed Products for the Program 1, Program 3, and Program 5</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall, on a Licensed Product-by-Licensed Product basis for each Licensed Product for Program 1, Program 3 or Program 5, pay to BPM royalties on Calendar Year Net Sales of a given Licensed Product in the Roche Territory as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Portion of Calendar Year Net Sales of a Licensed Product:</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Rate:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;] and up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;] and up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For example, if worldwide Net Sales of a Licensed Product for Program 1 for a given Calendar Year are </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, then royalties payable to BPM on such Net Sales of such Licensed Product for that Calendar Year shall equal </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> calculated as follows:</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For the purpose of calculating royalties payable on a Licensed Product for Program 1, Program 3 or Program 5, Calendar Year Net Sales and the royalty rates shall be subject to the adjustments under Sections 12.9.4 - 12.9.6 below, as applicable.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9.3&nbsp;&nbsp;Royalty Rates on Licensed Products for Program 2 and Program 4</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall, on a Licensed Product-by-Licensed Product basis for each Licensed Product for Program 2 or Program 4, pay to BPM royalties on Calendar Year Net Sales of a given Licensed Product in the Roche Territory as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Portion of Calendar Year Net Sales of a Licensed Product:</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Rate:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;] and up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;] and up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:371.70pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:73.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to Section 7.3, BPM shall, on a Licensed Product-by-Licensed Product basis for each Licensed Product for Program 2 and Program 4, pay to Roche royalties on Calendar Year BPM Net Sales of a given Licensed Product in the BPM Territory as follows:</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:377.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:68.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:377.10pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Portion of Calendar Year BPM Net Sales of a Licensed Product:</font></p>
				</td>
				<td valign="top" style="width:68.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Rate:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:377.10pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:68.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:377.10pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;] and up to [&#x2026;***&#x2026;] </font></p>
				</td>
				<td valign="top" style="width:68.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:377.10pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;] and up to [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:68.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:377.10pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">More than [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:68.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.25pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For the purpose of calculating royalties of a Licensed Product, Calendar Year Net Sales or BPM Net Sales, as applicable, and the royalty rates shall be subject to the adjustments under Sections 12.9.4 - 12.9.6 below, as applicable.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">56</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9.4&nbsp;&nbsp;Combination Product</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If the Selling Party or its Affiliates intend to sell a Combination Product, then the Parties shall meet approximately one (1) year prior to the anticipated First Commercial Sale of such Combination Product in the Territory to negotiate in good faith and agree to an appropriate adjustment to Net Sales to reflect the relative commercial value contributed by the components of the Combination Product (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Relative Commercial Value</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;If, after such good faith negotiations not to exceed ninety (90) days, the Parties cannot agree to an appropriate adjustment, the dispute shall be initially referred to the executive officers of the Parties in accordance with Section&nbsp;23.2. Should the Parties fail to agree within sixty (60) days of such referral, then the Relative Commercial Value shall be determined by the Expert Committee under the procedures set forth below.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If the Parties are unable to agree on the Relative Commercial Value, then Roche will select one (1) individual who would qualify as an Expert, BPM will select (1) individual who would qualify as an Expert, and those two (2) individuals shall select one (1) individual who would qualify as an Expert and who shall be chairman of a committee of the three Experts (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Expert Committee</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), each with a single deciding vote. The Expert Committee will promptly hold a meeting to review the issue under review, at which it will consider memoranda submitted by each Party at least fifteen (15) days before the meeting, as well as reasonable presentations that each Party may present at the meeting. The determination of the Expert Committee as to the issue under review will be binding on both Parties. The Parties will share equally in the costs of the Expert Committee. Unless otherwise agreed to by the Parties, the Expert Committee may not decide on issues outside the scope mandated under terms of this Agreement.&nbsp;&nbsp;If the Expert Committee is unable to come to a determination within sixty (60) days of such meeting, the matter will be decided pursuant to Section 23.3.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9.5&nbsp;&nbsp;Royalty Reductions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If royalties on a Licensed Product are payable only on the basis of clause (i) of the Royalty Term definition in Section 1.118 in a country, then the royalties in such country payable on Net Sales or BPM Net Sales, as applicable, for such Licensed Product shall be reduced by [&#x2026;***&#x2026;].&nbsp;&nbsp;The royalty rate tier applicable to the Calendar Year Net Sales or BPM Net Sales, as applicable, of such Licensed Product in such country will be applied </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">pro rata</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> on a Calendar Quarter-by-Calendar Quarter basis, with reference to the aggregate worldwide Calendar Year Net Sales or BPM Net Sales, as applicable, for each Licensed Product. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the foregoing, in addition, on a country-by-country basis, upon the first entry in a country of a Generic Product with respect to a Licensed Product, the applicable royalty rate for Calendar Year Net Sales or BPM Net Sales, as applicable, in such country for such Licensed Product shall be reduced as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If at any time after entry of a Generic Product in a country there has been a decline of the quarterly Net Sales of the applicable Licensed Product in such country greater than [&#x2026;***&#x2026;] of the average level of the quarterly Net Sales of such Licensed Product achieved in the [&#x2026;***&#x2026;] consecutive Calendar Quarters immediately prior to such entry, then the royalty payments due to BPM or Roche, as applicable, for such Licensed Product in such country shall be reduced by [&#x2026;***&#x2026;] for the remainder of the Royalty Term.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">57</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If at any time after entry of a Generic Product in a country there has been a decline of the quarterly Net Sales of the applicable Licensed Product in such country greater than [&#x2026;***&#x2026;] of the average level of the quarterly Net Sales of such Licensed Product achieved in the [&#x2026;***&#x2026;] consecutive Calendar Quarters immediately prior to such entry, then the royalty payments due to BPM or Roche, as applicable, for such Licensed Product in such country shall be reduced by [&#x2026;***&#x2026;] for the remainder of the Royalty Term.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9.6&nbsp;&nbsp;Third Party Payments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If Roche (or BPM in the US in the case of Program 2 or Program 4) is obligated to remit payments to a Third Party in relation to Third Party issued patents that would allegedly be infringed by the marketing of a Licensed Product, then Roche (or BPM) shall be permitted to offset up to [&#x2026;***&#x2026;] of any payments paid to such Third Party against any royalty payments and Development Event payments after the first NDA Filing Development Event payment for such Licensed Product otherwise payable by Roche to BPM (or by BPM to Roche in the case of Program 2 or Program 4) for such Licensed Product in the applicable Calendar Quarter. Roche&#x2019;s ability to make such deductions to Development Event payments pursuant to Section 12.7 shall be limited to [&#x2026;***&#x2026;] of any individual Development Event payment after the first NDA Filing Development Event payment for such Licensed Product.&nbsp;&nbsp;For clarity, amounts paid by Roche to BPM (or by BPM to Roche in the case of Program 2 or Program 4) for such Licensed Product with respect to any Calendar Quarter will not be reduced as a result of this Section 12.9.6 below [&#x2026;***&#x2026;] of the amount that would otherwise have been payable hereunder. [&#x2026;***&#x2026;] owed by Roche to BPM (or by BPM to Roche in the case of Program 2 or Program 4) for such Licensed Product. For any payments made by Roche (or BPM) to Third Parties in relation to Third Party issued patents that are (i) used by Roche (or BPM) for both Licensed Products and other products (including Roche Clinical Compounds or Roche Marketed Products) or applications, the Parties will agree on an equitable apportionment of such payments to reflect the fair value attributable to the Licensed Products under this Section 12.9.6 as compared to other products (including Roche Clinical Compounds or Roche Marketed Products) or applications, so that Roche&#x2019;s or BPM&#x2019;s right [&#x2026;***&#x2026;] under this Section 12.9.6 is limited to fair value attributable to the Licensed Products only.&nbsp;&nbsp;If the Parties are unable to agree on an equitable apportionment of such payments, then either Party may refer such dispute to Expedited Arbitration. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9.7&nbsp;&nbsp;Maximum Deductions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding anything foregoing, in no event shall the royalty paid for Net Sales of Licensed Products hereunder be reduced by more than an amount equal to </font><font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of the royalties otherwise due for Net Sales of such Licensed Products, per the applicable royalty rates set forth above. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.9.8&nbsp;&nbsp;Apportionment of Compulsory Sublicensee Consideration</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Compulsory Sublicense Compensation received by the Selling Party from a Compulsory Sublicensee shall be shared with the Non-Selling Party on an equivalent profit share percentage (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Compulsory Profit Share Percentage</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) calculated for the respective Calendar Year as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">At the end of the Calendar Year, the Selling Party shall pay to the Non-Selling Party the Compulsory Sublicense Compensation under a given country or region of the Territory multiplied </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">58</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">by the Compulsory Profit Share Percentage. For clarity, any sales or payments by Compulsory Sublicensees under a Compulsory Sublicense shall not be considered as Net Sales or BPM Net Sales, as applicable, and shall not give rise to any royalty payment under Section&nbsp;12.9.2 of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.10&nbsp;&nbsp;Disclosure of Payments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party acknowledges that the other Party may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law, including the US Sunshine Act.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.11&nbsp;&nbsp;Only One Royalty </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Only one royalty will be due with respect to the sale of the same unit of Licensed Product.&nbsp;&nbsp;Only one royalty will be due hereunder on the sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of such Licensed Product infringes more than one Composition of Matter Claim.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounting and reporting</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13.1&nbsp;&nbsp;Timing of Payments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Selling Party shall calculate royalties on Net Sales or BPM Net Sales, as applicable, quarterly as of March 31, June 30, September 30 and December 31 (each being the last day of an "</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Accounting Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) and shall pay royalties on Net Sales or BPM Net Sales, as applicable, [&#x2026;***&#x2026;] after the end of each Accounting Period in which such Net Sales or BPM Net Sales, as applicable, occur.&nbsp;&nbsp;Subject to Section 7.3 and Section 12.9.6, all payments of royalties are non-refundable, non-creditable and not subject to set-off with respect to undisputed amounts.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13.2&nbsp;&nbsp;Late Payment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at [&#x2026;***&#x2026;], as reported by Reuters from time to time, calculated on the number of days such payment is overdue.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13.3&nbsp;&nbsp;Method of Payment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Royalties on Net Sales and all other amounts payable hereunder shall be paid in US Dollars (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Payment Currency</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to account(s) designated by the Party to which payments are to be made.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13.4&nbsp;&nbsp;Currency Conversion</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">When calculating the Sales of any Licensed Product that occur in currencies other than the Payment Currency, Roche shall convert the amount of such sales into Swiss Francs and then into the Payment Currency using Roche&#x2019;s then-current internal foreign currency translation method actually used on a consistent basis in preparing its audited financial statements (at the Effective Date, YTD average rate as reported by Reuters).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13.5&nbsp;&nbsp;Reporting</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Within ten (10) days after the end of a Calendar Quarter for which royalties are payable to a Party under Section 12.9, the paying Party shall deliver to the other Party in writing for the relevant Calendar Quarter, on a Licensed Product-by-Licensed Product basis, an estimate of the Sales, in the case of Roche, or BPM gross sales for Licensed Products, in the case of BPM. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">With each payment Roche shall provide BPM in writing for the relevant Calendar Quarter on a Licensed Product-by-Licensed Product basis the following information:</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales in Swiss Francs;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">59</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Sales in Swiss Francs;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adjustments made pursuant to Section&nbsp;12.9.4;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Sales in Swiss Francs after adjustments made pursuant to Section&nbsp;12.9.3 in Swiss Francs;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;exchange rate used for the conversion of Net Sales from Swiss Francs to the Payment Currency pursuant to Section&nbsp;13.4;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Sales after adjustments made pursuant to Section&nbsp;12.9.4 in the Payment Currency;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;royalty rate pursuant to Section&nbsp;12.9.2;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adjustments made pursuant to Sections&nbsp;12.9.5 and 12.9.6 (subject to the cap in Section 12.9.7); </font>
		</p>
		<p style="margin:0pt 0pt 0pt 23.05pt;text-indent: -23.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;total royalty payable in the Payment Currency after adjustments made pursuant to Sections&nbsp;12.9.5 and 12.9.6 (subject to the cap in Section 12.9.7); and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;calculation and each Party&#x2019;s amount of the Compulsory Profit Share Percentage.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">With each payment BPM shall provide Roche in writing for the relevant Calendar Quarter on a Licensed Product-by-Licensed Product basis the following information with regard to Program 2 and Program 4:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BPM Sales in US dollars;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BPM Net Sales in US dollars;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments made pursuant to Section&nbsp;12.9.4;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BPM Net Sales in US dollars after adjustments made pursuant to Section&nbsp;12.9.4 in the US dollars;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;royalty rate pursuant to Section&nbsp;12.9.2;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adjustments made pursuant to Sections&nbsp;12.9.5 and 12.9.6 (subject to the cap in Section 12.9.7); </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;total royalty payable in US dollars after adjustments made pursuant to Sections&nbsp;12.9.5 and 12.9.6 (subject to the cap in Section 12.9.7); and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;calculation and each Party&#x2019;s amount of the Compulsory Profit Share Percentage.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">14.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Taxes</font></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Non-Selling Party shall pay all sales, turnover, income, revenue, value added, and other taxes levied on account of any payments accruing or made to the Non-Selling Party under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche may withhold from payments due to BPM amounts for payment of any withholding tax that is required by Applicable Law to be paid to any taxing authority with respect to such payments. Roche will provide BPM all relevant documents and correspondence, and will also provide to BPM any other cooperation or assistance on a reasonable basis as may be necessary to enable BPM to claim exemption from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Roche will give proper evidence from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Roche making payments from a single source in the US, where necessary and possible. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM may withhold from payments due to Roche amounts for payment of any withholding tax that is required by Applicable Law to be paid to any taxing authority with respect to such payments. BPM will provide Roche all relevant documents and correspondence, and will also provide to Roche any other cooperation or assistance on a reasonable basis as may be necessary to enable Roche to claim exemption from such withholding taxes and to receive a refund of such withholding </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">60</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">tax or claim a foreign tax credit. BPM will give proper evidence from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include BPM making payments from a single source in the US, where necessary and possible.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Apart from any such permitted withholding and those deductions expressly included in the definitions of Net Sales or BPM Net Sales, the amounts payable hereunder will not be reduced on account of any taxes, charges, duties or other levies.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Auditing</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">15.1&nbsp;&nbsp;Right to Audit</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Selling Party shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties payable under this Agreement. Each Party shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all Phase I Development Costs and Development Costs payable under this Agreement. Such books of accounts shall be kept at their principal place of business. At the expense of the auditing Party, the auditing Party shall have the right to engage an internationally recognized independent public accountant reasonably acceptable to the audited Party to perform, on behalf of the auditing Party, an audit of such books and records of the audited Party and its Affiliates that are deemed necessary by the independent public accountant to report on Net Sales of Licensed Product, Phase I Development Costs and/or Development Costs for the period or periods requested by the auditing Party and the correctness of any financial report or payments made under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Upon timely request and at least sixty (60) working days' prior written notice from the auditing Party, such audit shall be conducted in the countries specifically requested by the auditing Party, during regular business hours in such a manner as to not unnecessarily interfere with the audited Party's normal business activities. Such audit shall be limited to results in the three (3) Calendar Years prior to audit notification. Accordingly, if the auditing Party does not request an audit of a given Calendar Year for a given country on or before the third (3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">rd</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) anniversary of the end of such Calendar Year, then the audited Party will be deemed to have accepted the payments and reports for such country in such Calendar Year.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Such audit shall not be performed more frequently than once per Calendar Year nor more frequently than once with respect to records covering any specific period of time.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All information, data documents and abstracts herein referred to shall be used only for the purpose of verifying royalty statements, shall be treated as the audited Party&#x2019;s Confidential Information subject to the obligations of this Agreement and need neither be retained more than one (1) year after completion of an audit hereof, if an audit has been requested; nor more than two (2) years from the end of the Calendar Year to which each shall pertain; nor more than one (1) year after the date of termination of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">15.2&nbsp;&nbsp;Audit Reports</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The auditors shall only state factual findings in the audit reports and shall not interpret this Agreement. The auditors shall share all draft audit reports with the audited Party before the draft report is shared with the auditing Party and before the final document is issued. The final audit report shall be shared with the audited Party at the same time it is shared with the auditing Party.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">61</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">15.3&nbsp;&nbsp;Over- or Underpayment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If the audit reveals an overpayment, the auditing Party shall reimburse the audited Party for the amount of the overpayment within thirty (30) days. If the audit reveals an underpayment, the audited Party shall make up such underpayment with the next payment or, if no further payments are owed by the audited Party, then the audited Party shall reimburse the auditing Party for the amount of the underpayment within thirty (30) days. The auditing Party shall pay for the audit costs if the underpayment of the audited Party exceeds [&#x2026;***&#x2026;] of the aggregate amount of payments owed with regard to the statements subject to the audit. Section&nbsp;13.2 shall apply to this Section&nbsp;15.3.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intellectual Property</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.1&nbsp;&nbsp;Ownership of Inventions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The following terms and conditions shall apply to the ownership of Inventions unless provided for otherwise in this Agreement:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall remain owner of its Patent Rights and Know-How.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall solely own Inventions solely related to any improvements to the BPM Technology and all Patent Rights and Know-How relating thereto (which will be treated as BPM Technology).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to exercise of an Option Right for each Collaboration Target by Roche, all Collaboration Compounds and all Other Compounds for a given Collaboration Target or other Targets, including their methods of manufacture [&#x2026;***&#x2026;] and use, and all Patent Rights and Know-How relating thereto (including Collaboration Compound IP) shall be solely owned by BPM (with all of the foregoing that are not &#x201C;Collaboration Compounds&#x201D; or &#x201C;Collaboration Compound IP&#x201D; referred to herein as &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Other Compound IP</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;] </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All Patent Rights and Know-How generated under this Agreement to the extent related to biomarkers or bioreagents, including their methods of manufacture and use, (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Biomarker IP</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) shall be owned jointly by the Parties (with US rules on joint ownership to apply worldwide).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">After exercise of an Option Right for each Collaboration Target by Roche, all Patent Rights and Know-How arising from the development or commercialization of Licensed Products, including their methods of manufacture and use, that is generated by (i) either Party individually shall be owned by such generating Party or (ii) both Parties jointly shall be owned jointly by the Parties (with US rules on joint ownership to apply worldwide). </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subsequent to exercise of an Option Right for a given Collaboration Target, the Roche Group shall not generate additional compounds directed to such Collaboration Target under this Agreement.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the foregoing, all Patent Rights and Know-How generated under this Agreement to the extent related to Collaboration Targets, including their methods of manufacture and use (other than Collaboration Compound IP, BPM Technology, Other Compound IP, Biomarker IP or [&#x2026;***&#x2026;]), shall be owned jointly by the Parties (with US rules on joint ownership to apply worldwide).&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">62</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Inventorship for Inventions (including Patent Rights and Know-How) first made during the course of the performance of activities under this Agreement will be determined in accordance with United States patent laws for determining inventorship.&nbsp;&nbsp;BPM and Roche each shall require all of its employees, consultants and contractors to assign all Inventions conceived by them to Roche and/or BPM, to the extent required by this Agreement.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Except as specifically set forth herein, this Agreement shall not be construed, by estoppel, implication or otherwise, as (i)&nbsp;giving any of the Parties any license, right, title, interest in or ownership to any Confidential Information; (ii)&nbsp;granting any license or right under any Patent Rights or Know-How; or (iii)&nbsp;representing any commitment by either Party to enter into any additional agreement.&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, all in-licensed Patent Rights or Know-How Controlled by a Party hereto will be subject to the applicable Third Party agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.2&nbsp;&nbsp;Patent Rights Owned Jointly</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the licenses granted in this Agreement, all Joint Patent Rights shall be fully exploitable by both Parties without the consent of the other Party and without the need by either Party to account to the other Party for such exploitation.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">At the reasonable written request of a Party, the other Party will grant such consents in writing and confirm that no such accounting is required to effect the foregoing regarding any such jointly-owned Patent Rights.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to in all events to the rest of this Section&nbsp;16, </font><font style="display:inline;font-family:Times New Roman,Times,serif;">the Handling and enforcement of any Joint Patent Rights will be jointly managed by the Parties on mutually agreeable terms to be entered into by the Parties at the time any such Joint Patent Rights are first filed, and all recoveries and out-of-pocket costs and expenses arising from those activities, absent further agreement, will be shared equally by the Parties (provided that sufficient advance written notice of any such costs or expenses is given to the Party not incurring same), provided that if either Party elects not to pay any such costs or expenses for any such Patent, the Parties will meet and agree upon an equitable way to treat such Patent.&nbsp;&nbsp;In the event that one Party desires to proceed with any Handling or enforcement of a Joint Patent Right, and the other Party does not, then the Party desiring to proceed may proceed with such action at the proceeding Party&#x2019;s expense, and the proceeding Party may abandon such activities at any time without the consent of the other Party.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.3&nbsp;&nbsp;German Statute on Employee&#x2019;s Inventions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In accordance with the German Statute on Employees&#x2019; Inventions, each Party agrees to claim the unlimited use of any Invention conceived, reduced to practice, developed, made or created in the performance of, or as a result of, any research by employees of any German Affiliates or any other persons acting on behalf of such German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling the obligations towards their employees under the German Statute of Employee&#x2019;s Inventions. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.4&nbsp;&nbsp;Trademarks and Labeling </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall own the global trademarks, logos, slogans and service marks used on or in connection with Licensed Products (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Global Trademarks</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) worldwide, and shall, at its sole cost, be responsible for selection, procurement, maintenance, and defense of all trademarks used on or in connection with Licensed Products worldwide.&nbsp;&nbsp;For Program 2 and Program 4, BPM shall have the right to provide input for the Global Trademarks which Roche shall reasonably consider and BPM shall either use the Global Trademarks or may use other trademarks or logos of its own choosing and at its own expense on or in connection with Licensed Products in the BPM Territory.&nbsp;&nbsp;Roche shall have the first right to enforce the Global Trademarks in the Roche Territory.&nbsp;&nbsp;For Program 2 and Program 4, BPM shall have the first right to enforce the Global Trademarks in the BPM Territory.&nbsp;&nbsp;If BPM does not timely enforce the Global Trademarks in the BPM Territory, then </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">63</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall have the right to enforce the Global Trademarks in the BPM Territory.&nbsp;&nbsp;Prior to commercialization of any Licensed Product in the BPM Territory bearing a Global Trademark, the Parties will enter into a trademark license agreement setting forth customary terms and conditions for using the Global Trademarks and ensuring quality and good will associated with the Global Trademarks.&nbsp;&nbsp;Notwithstanding the foregoing, BPM shall not be obligated to use such Global Trademarks and may instead select and use its own trademarks, logos, slogans and service marks on or in connection with Licensed Products for Program 2 and Program 4 in the BPM Territory (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM Trademarks</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;If BPM elects to use BPM Trademarks, BPM shall, at its sole cost, be responsible for selection, procurement, maintenance, and defense of all such BPM Trademarks used on or in connection with Licensed Products.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall have the right to obtain the International Non-proprietary Name (INN) from the World Health Organization and the US Adopted Name (USAN) from the US adopted Names Council (USANC) as the generic name(s) for the Licensed Products worldwide.&nbsp;&nbsp;The Parties shall consult with each other regarding the INN and USAN prior to Roche obtaining the INN and USAN, and Roche shall in good faith consider BPM&#x2019;s input.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the case of Program 2 and Program 4, if BPM elects to use the Global Trademark, Roche shall grant BPM an exclusive, royalty-free license to use the Global Trademarks for the purpose of Exploiting the Licensed Products in the BPM Territory as permitted by this Agreement. Such trademark license shall be non-transferable, except that the BPM shall have the right to sublicense such rights to its Affiliates and Sublicensees in the BPM Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall maintain all registrations of such Global Trademarks worldwide, and BPM shall not file any identical or similar registrations or other filings in respect of any of such Global Trademarks without Roche&#x2019;s prior written consent.&nbsp;&nbsp;BPM shall maintain all registrations of such BPM Trademarks, and Roche shall not file any identical registrations or other filings in respect of any of such BPM Trademarks without BPM&#x2019;s prior written consent.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall use the Global Trademarks in accordance with sound trademark and trade name usage principles and in accordance with all Applicable Law as reasonably necessary to maintain the validity and enforceability of the Global Trademarks. BPM recognizes that Roche&#x2019;s Global Trademarks represent a valuable asset of Roche, and that substantial recognition and goodwill are associated with such name, logo and trademarks. BPM hereby agrees that, without prior written authorization of Roche, it shall not use such Global Trademarks for any purpose except as expressly permitted under this Agreement.&nbsp;&nbsp;Roche recognizes that BPM Trademarks represent a valuable asset of BPM, and that substantial recognition and goodwill are associated with such name, logo and trademarks. Roche hereby agrees that, without prior written authorization of BPM, it shall not use such BPM Trademarks for any purpose except as expressly permitted under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.5&nbsp;&nbsp;Prosecution by BPM</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;Subject to the remainder of this Section 16.5, BPM shall [&#x2026;***&#x2026;] (i)&nbsp;Handle all BPM Patent Rights and Patent Rights within Collaboration Compound IP, (ii)&nbsp;consult with Roche as to the Handling of such Patent Rights to the extent that, on a Collaboration Target-by-Collaboration Target, any such BPM Patent Rights Covers the chemical structure of any Collaboration Compound (collectively, for such Collaboration Target, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM Specific Patent Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), and (iii)&nbsp;furnish to Roche copies of all documents relevant to any such Handling for such BPM Specific Patent Rights. BPM shall furnish such documents and consult with Roche in sufficient time before any action by BPM is due to allow Roche to provide comments thereon, which comments BPM must consider but BPM shall retain </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">64</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">final decision-making authority with respect to such Handling. At BPM&#x2019;s reasonable request, Roche shall cooperate, in all reasonable ways with the Handling of all such Patent Rights. BPM agrees to file patent applications in all countries consistent with BPM&#x2019;s customary practices for its other internal programs. To the extent that Roche wishes for filings in additional countries, Roche shall provide BPM a list of such countries and BPM agrees to file patent applications in such additional countries [&#x2026;***&#x2026;].</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;Subject to Section&nbsp;16.10, after exercise of an Option Right for each Collaboration Target, (i)&nbsp;Roche shall Handle, either directly or using the mutually agreed outside counsel previously utilized by BPM [&#x2026;***&#x2026;] all Patent Rights within Collaboration Compound IP to the extent Covering a Licensed Product in the Field for the applicable Program 1, Program 3 and Program 5, (ii)&nbsp;Roche shall Handle in the Roche Territory, either directly or using the mutually agreed outside counsel used by BPM [&#x2026;***&#x2026;] all Patent Rights within Collaboration Compound IP to the extent Covering a Licensed Product in the Field for a given Collaboration Target for the applicable Program 2 and 4, and (iii)&nbsp;BPM shall Handle in the BPM Territory, using mutually agreed upon outside counsel in consultation with Roche [&#x2026;***&#x2026;] all Patent Rights within Collaboration Compound IP to the extent Covering a Licensed Product in the Field for a given Collaboration Target for the applicable Program 2 and 4.&nbsp;&nbsp;The controlling Party under this Section&nbsp;16.5(b) shall [&#x2026;***&#x2026;] (1)&nbsp;consult with the other Party as to the Handling of such Patent Rights, and (2)&nbsp;furnish to the other Party copies of all documents relevant to any such Handling for such Patent Rights.&nbsp;&nbsp;The controlling Party shall furnish such documents and consult with the other Party in sufficient time before any action by such controlling Party is due to allow such other Party to provide comments thereon, which comments such controlling Party must consider but the controlling Party shall retain final decision-making authority with respect to such Handling. At such controlling Party&#x2019;s reasonable request, the other Party shall cooperate, in all reasonable ways with the Handling of all such Patent Rights.&nbsp;&nbsp;Notwithstanding the foregoing in this Section&nbsp;16.5(b), before abandoning any such Patent Rights (including electing not to file any continuation Patent Rights upon issuance of any Patent Rights), the applicable Controlling Party shall notify the other Party in advance of such abandonment to allow such other Party to elect to Handle such Patent Rights [&#x2026;***&#x2026;].</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.6&nbsp;&nbsp;Prosecution of Other Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall [&#x2026;***&#x2026;] Handle all Roche Patent Rights and Patent Rights within Roche Sole IP other than Joint Patent Rights (which Joint Patent Rights will be Handled under Section&nbsp;16.5 if applicable or otherwise under Section&nbsp;16.2).&nbsp;&nbsp;Subject to Section&nbsp;16.5, BPM shall [&#x2026;***&#x2026;] Handle all Patent Rights within BPM Sole IP other than Joint Patent Rights (which Joint Patent Rights will be Handled under Section&nbsp;16.5 if applicable or otherwise under Section&nbsp;16.2).</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.7&nbsp;&nbsp;Patent Coordination Team</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Where the Parties need to consult with each other on the Handling of Patent Rights, the Parties shall establish a patent coordination team and shall adopt procedures for interacting on patent matters.&nbsp;&nbsp;The patent coordination team shall be subject to the oversight of the JDC.&nbsp;&nbsp;The patent coordination team also shall serve as a forum for promptly notifying the other Party when an Invention is made by a Party.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.8&nbsp;&nbsp;Unified Patent Court (Europe)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">At any time prior to the end of the &#x201C;transitional period&#x201D; as such term is used in Article&nbsp;83 of the Agreement on a Unified Patent Court between the participating Member States of the European Union, for a given relevant EU Patent Right, Roche may request in writing that BPM either (i)&nbsp;opt out from the exclusive competence of the Unified Patent Court or (ii)&nbsp;if applicable, withdraw a </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">65</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">previously-registered opt-out, and BPM shall notify the Registry, pay any such registry fee and take such other action as may be necessary to effect the opt-out or opt-out withdrawal (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Register</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;BPM shall Register within five (5) days of receipt of Roche&#x2019;s written request, or such other time parameters specified by Roche. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.9&nbsp;&nbsp;CREATE Act </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">It is the intention of the Parties that this Agreement is a &#x201C;joint research agreement&#x201D; as that phrase is defined in the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. &#xA7; 103(c)(2)-(c)(3) (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">CREATE Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the CREATE Act when exercising its rights under this Agreement, but with respect to any Patent Rights with the BPM IP or Collaboration Compound IP, only with the prior written consent of BPM in its sole discretion, and with respect to any Patent Rights within the Roche IP, only with the prior written consent of Roche in its sole discretion.&nbsp;&nbsp;In the event that a Party intends to invoke the CREATE Act, once agreed to by the other Party if required by the preceding sentence, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to any filings or other activities in support thereof.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.10&nbsp;&nbsp;Infringement</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall promptly provide written notice to the other Party during the Agreement Term of any (i)&nbsp;known infringement or suspected infringement by a Third Party of any BPM IP, Patent Rights within Collaboration Compound IP, Roche Patent Rights or Joint Patent Rights, or (ii)&nbsp;known or suspected unauthorized use or misappropriation by a Third Party of any BPM Know-How, Roche Know-How or Joint Know-How, in each case if and to the extent involving any commercialization of any Licensed Product (or other compounds that satisfy the Compound Criteria) for the applicable Collaboration Target in the Field, and shall provide the other Party with all evidence in its possession and Control supporting such infringement or unauthorized use or misappropriation.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Within ten (10) Business Days after a Party provides or receives such written notice (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Decision Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), such Party in its Territory (i.e., Roche in the Roche Territory and BPM in the BPM Territory), in its sole discretion, shall decide whether or not to initiate a suit or action in the Territory regarding such infringement or unauthorized use or misappropriation and shall notify the other Party in writing of its decision in writing (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Suit Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If Roche decides to bring a suit or take action in the Roche Territory with respect to such infringement or unauthorized use or misappropriation, once the applicable Suit Notice is provided, Roche may immediately commence such suit or take such action in the Roche Territory. In the event that Roche (i)&nbsp;does not in writing advise BPM within the Decision Period that Roche will commence suit or take action, or (ii)&nbsp;fails to commence suit or take action within a reasonable time after providing Suit Notice, BPM shall thereafter have the right to commence suit or take action in the Roche Territory and shall provide written notice to Roche of any such suit commenced or action taken by BPM. If BPM decides to bring a suit or take action in the BPM Territory with respect to such infringement or unauthorized use or misappropriation, once the applicable Suit Notice is provided, BPM may immediately commence such suit or take such action in the BPM Territory. In the event that BPM (i)&nbsp;does not in writing advise Roche within the Decision Period that BPM will commence suit or take action, or (ii)&nbsp;fails to commence suit or take action within a reasonable time after providing Suit Notice, Roche shall thereafter have the right to commence suit or take action in the BPM Territory and shall provide written notice to BPM of any such suit commenced or action taken by Roche.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">66</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Upon written request, the Party bringing suit or taking action (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Initiating Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) shall keep the other Party informed of the status of any such suit or action and shall provide the other Party with copies, to the extent the Initiating Party is lawfully permitted to do so, of all substantive documents or communications filed in such suit or action. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action, and any actions that otherwise would have been Handled with respect to any Patent Rights subject to this Section&nbsp;16 will be controlled by the Initiating Party to the extent reasonably related to such suit or action.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Initiating Party shall, except as provided below, pay all expenses of the suit or action, including the Initiating Party&#x2019;s attorneys&#x2019; fees and court costs. Any damages, settlement fees or other consideration received as a result of such suit or action shall be allocated as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;First, to reimburse the Initiating Party for its costs and, if any remains, to the other Party for any advisory counsel fees and costs; and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Second, the balance, if any, (1) to the extent a lost profits award, shall be treated as Net Sales and subject to royalty obligations under this Agreement, and (2) to the extent a royalty or other type of award, will be paid [&#x2026;***&#x2026;].</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If the Initiating Party believes it is reasonably necessary or desirable to obtain an effective remedy, upon written request the other Party agrees to be joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At the Initiating Party&#x2019;s written request, the other Party shall offer reasonable assistance to the Initiating Party in connection therewith at no charge to the Initiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance. The other Party shall have the right to participate and be represented in any such suit or action by its own counsel at its own expense.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Initiating Party may settle, consent judgment or otherwise voluntarily dispose of the suit or action (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Settlement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) without the written consent of the other Party but only if such Settlement can be achieved without adversely affecting the other Party (including any of its Patent Rights). If a Settlement could adversely affect the other Party, then the written consent of the other Party would be required, which consent shall not be unreasonably withheld, conditioned or delayed.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.11&nbsp;&nbsp;Defense</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If an action for infringement of Patent Rights or trade secrets misappropriation is commenced against either Party, its licensees or its sublicensees related to the conduct of the activities within the scope of the Research Plan, or the development, manufacture, use or sale of a Product in the Roche Territory, then Roche shall have the right (but not the obligation) to defend such action at its own expense, and BPM shall assist and cooperate with Roche, at Roche&#x2019;s expense, to the extent necessary in the defense of such suit. Roche shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long as such settlement or adverse judgment does not adversely affect the rights of the BPM Group (including any Patent Rights owned or in-licensed by any of them). Roche shall assume full responsibility for the payment of any award for damages, or any amount due pursuant to any settlement entered into by it with such Third Party. If an action for infringement of Patent Rights or trade secrets misappropriation is commenced against either Party, its licensees or its sublicensees related to the development, manufacture, use or sale of a Product in the BPM Territory, then BPM shall have the right (but not the obligation) to defend such action at its own expense, and Roche shall assist and cooperate with BPM, at BPM&#x2019;s expense, to the extent necessary in the defense of such suit. BPM shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">67</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">as such settlement or adverse judgment does not adversely affect the rights of the Roche Group (including any Patent Rights owned or in-licensed by any of them). BPM shall assume full responsibility for the payment of any award for damages, or any amount due pursuant to any settlement entered into by it with such Third Party.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Parties shall cooperate with each other in connection with any such claim, suit or proceeding and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the above, neither Party shall enter into any settlement of any such claim under this Section&nbsp;16.11 without the prior written consent of the other Party if such settlement would require such other Party to be subject to an injunction or to make any monetary payment to such Party or any Third Party, or admit any wrongful conduct by such other Party or its Affiliates, or would limit or restrict the claims of or admit any invalidity and/or unenforceability of any of the Patent Rights owned or in-licensed by such other Party, or have any impact on activities outside the Field.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.12&nbsp;&nbsp;Common Interest Disclosures</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">With regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of the activities under the Research Plans or Library Compounds, Other Compounds, Collaboration Compounds, Products or Licensed Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the conduct of the activities under the Research Plans or Library Compounds, Other Compounds, Collaboration Compounds, Products or Licensed Products. Accordingly, the Parties agree that all such information and materials obtained by BPM and Roche from each other will be used solely for purposes of the Parties&#x2019; common legal interests with respect to the conduct of this Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party&#x2019;s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against the other Party.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.13&nbsp;&nbsp;Hatch-Waxman</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding anything herein to the contrary, should a Party receive a certification for a Licensed Product pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417, known as the Hatch-Waxman Act), as amended, or its equivalent in a country other than the US, with respect to any activities under this Agreement in the Field, then such Party shall immediately provide the other Party with a copy of such certification. For each Licensed Product, Roche in the Roche Territory, and BPM in the BPM Territory, shall have thirty (30) days from date on which it receives or provides a copy of such certification to provide written notice to the other Party (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">H-W Suit Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) whether such first Party will bring suit, at its expense, within a forty-five (45) day period from the date of such certification. Should such thirty (30) day period expire without such first Party bringing suit or providing such H-W Suit Notice, then such other Party shall be free to immediately bring suit in its name.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">68</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.14&nbsp;&nbsp;Patent Term Extensions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">With respect to Patent Rights within the Collaboration Compound IP with application in the Field, the Parties shall use Commercially Reasonable Efforts to obtain all available patent term extensions, adjustments or restorations, or supplementary protection certificates (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SPCs</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;, and together with patent term extensions, adjustments and restorations, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Patent Term Extensions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;, in each case for such Patent Rights within Collaboration Compound IP with Field applicability). For Licensed Products with application in the Field in the Roche Territory, BPM shall execute such authorizations and other documents and take such other actions as may be reasonably requested by Roche to obtain such Patent Term Extensions, including designating Roche as its agent for such purpose as provided in 35 USC &#xA7;&nbsp;156.&nbsp;&nbsp;BPM shall retain those rights for Licensed Products in the BPM Territory.&nbsp;&nbsp;All filings for such Patent Term Extensions shall be made by Roche for Licensed Products in the Roche Territory and by BPM for Licensed Products in the BPM Territory; provided, that in the event that the lead Party elects not to file for a Patent Term Extension, the lead Party shall (a)&nbsp;promptly inform the other Party of its intention not to file and (b)&nbsp;grant BPM the right to file for such Patent Term Extension. Each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. The Parties shall cooperate with each other in gaining patent term restorations, extensions and/or SPCs wherever applicable to such Patent Rights within Collaboration Compound IP.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.1&nbsp;&nbsp;Third Party Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;] represents and warrants, as of the Effective Date, that it has no knowledge of the existence of any patent or patent application owned by or licensed to any Third Party that could prevent the activities contemplated by this Agreement in the Territory.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.2&nbsp;&nbsp;Ownership of Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]represents and warrants, as of the Effective Date, that it is the exclusive owner of all right, title and interest in, or is the exclusive licensee of, the [&#x2026;***&#x2026;].</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.3&nbsp;&nbsp;Inventors</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]represents and warrants, as of the Effective Date, that (a) it has obtained the assignment of, or an exclusive license under, all interest and all rights or licenses thereunder with respect to the [&#x2026;***&#x2026;] necessary to grant the licenses granted hereunder and (b) all of its employees, officers and consultants have executed agreements requiring assignment to it of all Inventions made by such individuals during the course of and as a result of their association with it.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.4&nbsp;&nbsp;Grants</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">To its knowledge and belief, each of BPM and Roche represents and warrants, as of the Effective Date, that it has the lawful right to grant Roche or BPM, respectively, and each of their Affiliates the rights and licenses described in this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.5&nbsp;&nbsp;Authorization</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each of BPM and Roche represents and warrants, as of the Effective Date, that its execution, delivery and performance of this Agreement and all instruments and documents to be delivered by it hereunder: (i)&nbsp;are within its corporate power and authority; (ii)&nbsp;have been duly authorized by all necessary or proper corporate action; (iii)&nbsp;are not in contravention of any provision any of its formation or governance documents; (iv)&nbsp;to its knowledge, will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (v)&nbsp;will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which it is a party </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">69</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">or by which it or any of its property is bound, which violation would have an adverse effect on its financial condition&nbsp;&nbsp;or on its ability to perform its obligations hereunder; and (vi)&nbsp;do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other Person, which has not been made or obtained previously.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.6&nbsp;&nbsp;Validity of Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;] represents and warrants, as of the Effective Date, that it is not in possession of information that could render invalid and/or unenforceable any claims that are in any of the [&#x2026;***&#x2026;].&nbsp;&nbsp;[&#x2026;***&#x2026;] has no knowledge of any inventorship disputes concerning any [&#x2026;***&#x2026;].</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.7&nbsp;&nbsp;Ownership and Validity of Know-How</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;] represents and warrants, as of the Effective Date, that its Know-How is legitimately in its possession and, to its knowledge, has not been misappropriated from any Third Party. [&#x2026;***&#x2026;] has taken reasonable measures to protect the confidentiality of its Know-How.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.8&nbsp;&nbsp;No Claims</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each of BPM and Roche represents and warrants, as of the Effective Date, that there are no claims or investigations, pending or threatened against it or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect its ability to perform its obligations hereunder.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.9&nbsp;&nbsp;No Conflict</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">To its knowledge, each of BPM and Roche represents and warrants, as of the Effective Date that neither it nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of BPM&#x2019;s obligations hereunder.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.10&nbsp;&nbsp;No Other Representations</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF PRODUCTS.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">18.1&nbsp;&nbsp;Indemnification by Roche</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall indemnify, hold harmless and defend BPM and its directors, officers, employees and agents from and against any and all Third Party liabilities, losses, expenses, cost of defense (including without limitation attorneys' fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts BPM becomes legally obligated to pay because of breach of contract by Roche or any claim or claims against it to the extent that such claim or claims arise out of Roche&#x2019;s and its Affiliates&#x2019; actions or inactions in connection with activities under this Agreement, including the Exploitation of any Library Compounds, Other Compounds, Collaboration Compounds, Products or Licensed Products, except to the extent such liabilities, losses, expenses, costs and amounts are due to the breach of this Agreement by BPM or the gross negligence or willful misconduct or failure to act of BPM.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">18.2&nbsp;&nbsp;Indemnification by BPM</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall indemnify, hold harmless and defend Roche and its directors, officers, employees and agents from and against any and all Third Party liabilities, losses, expenses, cost of defense </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">70</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">(including without limitation attorneys' fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche becomes legally obligated to pay because of breach of contract by BPM or any claim or claims against it to the extent that such claim or claims arise out of BPM&#x2019;s and BPM&#x2019;s Affiliates&#x2019; actions or inactions in connection with activities under this Agreement, including the Exploitation of any Library Compounds, Other Compounds, Collaboration Compounds, Products or Licensed Products, except to the extent such liabilities, losses, expenses, costs and amounts are due to the breach of this Agreement by Roche or the gross negligence or willful misconduct or failure to act of Roche.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">18.3&nbsp;&nbsp;Procedure</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event of a claim by a Third Party against a Party entitled to indemnification under this Agreement ("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Indemnified Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">"), the Indemnified Party shall promptly notify the other Party ("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Indemnifying Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">") in writing of the claim and the Indemnifying Party shall undertake and solely manage and control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party&#x2019;s written consent. The Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liability</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">19.1&nbsp;&nbsp;Limitation of Liability</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to Section&nbsp;19.2, neither Party shall be liable to the other Party as a result of failure or delay to develop and/or commercialize any Collaboration Compound, Product or Licensed Product, as applicable, including but not limited to, (a)&nbsp;a delay in timelines, (b)&nbsp;delay or failure to recruit patients, (c)&nbsp;a change in its respective study protocols, or (d)&nbsp;failure of the other Party to obtain Regulatory Approval for any Collaboration Compound, Product or Licensed Product, as applicable.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">19.2&nbsp;&nbsp;Disclaimer</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. BPM AND ROCHE DISCLAIM ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. EXCEPT FOR INDEMNIFICATION UNDER ARTICLE 18 AND BREACH OF NON-DISCLOSURE AND NON-USE UNDER ARTICLE 20, IN NO EVENT SHALL EITHER BPM OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation Not to Disclose Confidential Information</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">20.1&nbsp;&nbsp;Non-Use and Non-Disclosure</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the remainder of this Section&nbsp;20, during the Agreement Term and for five (5) years thereafter, a Receiving Party shall (i)&nbsp;treat Confidential Information provided by Disclosing Party as it would treat its own information of a similar nature, (ii)&nbsp;take all reasonable precautions not to </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">71</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">disclose such Confidential Information to Third Parties, without the Disclosing Party&#x2019;s prior written consent, and (iii)&nbsp;not use such Confidential Information other than for fulfilling its obligations or exploit its licenses and other rights under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">20.2&nbsp;&nbsp;Permitted Disclosure</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the obligation of non-use and non-disclosure set forth in Section&nbsp;20.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">20.3&nbsp;&nbsp;Press Releases</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Parties may, individually or jointly, issue a press release announcing the existence and selected key terms of this Agreement, in a form substantially similar to the template attached as Appendix&nbsp;20.3.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Roche shall issue press releases in accordance with its internal policy that typically does not issue a second press release until Phase I proof of concept has been achieved for a Product and Roche has exercised its Option Right with respect to the Collaboration Target. Roche shall provide BPM with a copy of any draft press release related to the activities contemplated by this Agreement at least two (2) weeks prior to its intended publication for BPM's review. BPM may provide Roche with suggested modification to the draft press release. Roche shall consider BPM's suggestions in issuing its press release.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">BPM shall only issue press releases related to the activities contemplated by this Agreement that have either (i)&nbsp;been approved by Roche or (ii)&nbsp;are required to be issued by BPM as a matter of law and BPM has received a competent legal opinion to that effect. In all circumstances, BPM shall provide Roche with a draft press release at least two (2) weeks prior to its intended publication for Roche's review, unless a shorter time period is required as a matter of law and BPM has received a competent legal opinion to that effect. During such period, Roche shall (a)&nbsp;approve the draft press release and permit BPM to issue the press release, (b)&nbsp;contact BPM to discuss modification to the draft press release, or (c)&nbsp;contact BPM and disapprove the press release. If Roche asks for modification, then BPM shall either make such modification or work with Roche to arrive at a press release that Roche approves. Notwithstanding any of the foregoing, BPM may issue a press release upon the achievement of any milestone event (including the amount and payment of such milestone payment for any such milestone event) without obtaining the consent of Roche announcing the achievement of such event.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">To ensure communication alignment, responses (if any) to inquiries by media or other Third Parties after issuance of a permitted press release by BPM (solely or jointly with Roche) shall consist solely of the press release language or shall follow the response guidelines that may be mutually developed by the Parties except to the extent additional or varying disclosure is required by a Regulatory Authority, including the United States Securities and Exchange Commission (or foreign equivalent) to comply with either Party&#x2019;s disclosure obligations as a public company.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">20.4&nbsp;&nbsp;Publications</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential Information in any publication or presentation:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with their internal guidelines. Roche, in accordance with its internal policies and procedures, shall have the right to publish all studies, clinical trials and results thereof on the clinical trial registries that are maintained by or on behalf of Roche. BPM shall not publish </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">72</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">any studies, clinical trials or results thereof on its clinical trial registry, provided however, that Roche&#x2019;s clinical trial registry can be accessed via a link from BPM&#x2019;s clinical trial registry.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">A Party ("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Publishing Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">") shall provide the other Party with a copy of any proposed material publication or presentation at least thirty (30) days (or sixty (60) days in the case of a manuscript) prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies ("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Publishing Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;">") the Publishing Party in writing, within such thirty (30) day period (or sixty (60) day period in the case of a manuscript) after receipt of the copy of the proposed publication, presentation, or manuscript, that such publication or presentation in its reasonable judgment (i)&nbsp;contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (ii)&nbsp;could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than ninety (90) days from the date of the Publishing Notice.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">20.5&nbsp;&nbsp;Commercial Considerations</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Nothing in this Agreement shall prevent a Receiving Party or its Affiliates from disclosing Confidential Information of the Disclosing Party and the existence and terms of this Agreement to (i)&nbsp;governmental agencies to the extent required or desirable to secure government approval for the development, manufacture or commercialization of a Product or Licensed Product in the Territory or to obtain patents in accordance with this Agreement; provided that such Confidential Information will be disclosed only to the extent reasonably necessary to do so, and where permitted, subject to confidential treatment, (ii)&nbsp;Third Parties acting on behalf of the Receiving Party, to the extent reasonably necessary for the Receiving Party to perform its obligations or exercise its rights under this Agreement, (iii) Third Parties requesting Clinical Study data information (in accordance with the Receiving Party&#x2019;s then-current data sharing policy), (iv)&nbsp;Third Parties to the extent reasonably necessary to market the Licensed Products in the Territory, (v) its Affiliates, consultants, CROs, licensees or Sublicensees, and its and their directors, officers, employees, agents or advisors (including accountants, attorneys, consultants, bankers, financial advisors and members of advisory boards) who reasonably require Confidential Information, are informed of the confidential nature of such information and are bound by non-use and confidentiality obligations with respect to such Confidential Information, and (vi) any bona fide potential or actual sources of debt or equity financing or parties to a merger, acquisition or similar transaction (including attorneys, accountants, consultants, bankers or financial advisors of the foregoing) who reasonably require such Confidential Information as part of their due diligence investigations and who are informed of the confidential nature of such information and this Agreement and are bound by obligations of non-use and confidentiality with respect to such Confidential Information. The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Law, including the rules and regulations of the U.S. Securities and Exchange Commission (or equivalent foreign agency) or a securities exchange on which its or its Affiliate&#x2019;s securities are listed (or to which an application for listing has been submitted), to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party, such Confidential Information is disclosed only to the extent reasonably necessary to do so and, </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">73</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">to the extent practicable, takes reasonable and lawful actions to minimize the degree of such disclosure.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Parties acknowledge that either or both Parties may be obligated to make a filing (including to file a copy of this Agreement) with the U.S. Securities and Exchange Commission (or equivalent foreign agency) or a governmental authority.&nbsp;&nbsp;Each Party will be entitled to make such a required filing, provided that it will (a) submit in connection with such filing the redacted copy of this Agreement in a form mutually agreed to by the Parties (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Redacted Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), (b) request, and use commercially reasonable efforts consistent with Applicable Laws to obtain, confidential treatment of all terms redacted from this Agreement, as reflected in the Redacted Agreement, for a period of at least ten (10) years, (c) promptly deliver to the other Party any written correspondence received by it or its representatives from the U.S. Securities and Exchange Commission (or equivalent foreign agency) or a governmental authority with respect to such confidential treatment request and promptly advise the other Party of any other material communications between it or its representatives with the U.S. Securities and Exchange Commission (or equivalent foreign agency) or a governmental authority with respect to such confidential treatment request, (d) upon the written request of the other Party, if legally justifiable, request an appropriate extension of the term of the confidential treatment period, and (e) if the U.S. Securities and Exchange Commission (or equivalent foreign agency) or a governmental authority requests any changes to the redactions set forth in the Redacted Agreement, use commercially reasonable efforts consistent with Applicable Laws to support the redactions in the Redacted Agreement as originally filed and not agree to any changes to the Redacted Agreement without, to the extent practical, first discussing such changes with the other Party and taking the other Party&#x2019;s comments into consideration when deciding whether to agree to such changes (provided that a Party will only be required to make such efforts to support such redactions once).&nbsp;&nbsp;Each Party will be responsible for its own legal and other external costs in connection with any such filing, registration or notification.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term and Termination</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.1&nbsp;&nbsp;Commencement and Term</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Agreement shall commence upon the Effective Date and continue for the Agreement Term.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.2&nbsp;&nbsp;Termination</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.2.1&nbsp;&nbsp;Termination for Breach</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">A Party (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Non-Breaching Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) shall have the right to terminate this Agreement in its entirety or on a Collaboration Target-by-Collaboration Target or Program-by-Program basis, in the event the other Party (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Breaching Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) is (i) in material breach of any of its material obligations under this Agreement with respect to Program 1, Program 3, or Program 5, or (ii) in material breach of any of its material obligations under this Agreement in a manner that fundamentally frustrates the transactions contemplated by this Agreement with respect to Program 2 or Program 4, in either (i) or (ii) to this Agreement or such Collaboration Target or Program (as applicable).&nbsp;&nbsp;The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach and the Collaboration Target(s) or Program(s) for which, the Non-Breaching Party intends to have this Agreement terminate. The Breaching Party shall have a period of ninety (90) days after such written notice is provided (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Peremptory Notice Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to cure such breach. If the alleged Breaching Party has a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">bona fide</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> dispute as to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party within the Peremptory Notice Period, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section&nbsp;23.2. Upon a determination of breach or failure to cure, the Breaching Party may have </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">74</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party&#x2019;s request for termination, this Agreement shall terminate in its entirety or with respect to such Collaboration Target(s) or Program(s) effective as of the expiration of the Peremptory Notice Period.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.2.2&nbsp;&nbsp;Insolvency</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">A Party shall have the right to terminate this Agreement if the other Party incurs an Insolvency Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing thereof.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.2.3&nbsp;&nbsp;Effects of Change of Control</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If there is a Change of Control, then the Party experiencing such Change of Control (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Acquired Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) shall provide written notice to the other Party (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Non-Acquired Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) at least thirty (30) days prior to completion of such Change of Control, subject to any confidentiality obligations of the Acquired Party then in effect (but in any event shall notify the Non-Acquired Party within fifteen (15) days after completion of such Change of Control).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Change of Control Group in connection with such Change of Control shall not utilize any of the Non-Acquired Party&#x2019;s solely owned (with respect to the Acquired Party) Know-How or Patent Rights licensed to the Acquired Party under this Agreement, or Inventions or Confidential Information (but not Joint Know-How, Joint Patent Rights or Joint Inventions) (such solely-owned items, collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Sensitive Information</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), except as otherwise permitted by the Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Following closing of the Change of Control, the Acquired Party and the Change of Control Group shall adopt in writing reasonable procedures to prevent the disclosure of Sensitive Information beyond the Acquired Party&#x2019;s and the Change of Control Group&#x2019;s personnel who need to know the Sensitive Information solely for the purpose of fulfilling the Acquired Party&#x2019;s obligations, and exercising the Acquired Party&#x2019;s licenses and other rights, under this Agreement. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In addition, in the event that (a) BPM is acquired through a Change of Control by a [&#x2026;***&#x2026;] (based on [&#x2026;***&#x2026;]) within [&#x2026;***&#x2026;] after the Effective Date and (b) within [&#x2026;***&#x2026;] after such Change of Control, BPM experiences a significant delay with respect to key deliverables included in the Research Plan for either [&#x2026;***&#x2026;] or [&#x2026;***&#x2026;] in effect as of the Change of Control and is unable to make up such delay to the anticipated Research Plan for [&#x2026;***&#x2026;] and/or [&#x2026;***&#x2026;] as applicable in the following [&#x2026;***&#x2026;], then, in lieu of exercising Roche&#x2019;s right to terminate this Agreement in accordance with Section 21.2.1, for any Collaboration Compounds that the JRC has determined have satisfied [&#x2026;***&#x2026;] for Collaboration Targets [&#x2026;***&#x2026;] or [&#x2026;***&#x2026;] (as applicable) prior to the closing of such Change of Control, Roche shall have the right, upon written notice to BPM, to step in and assume the medicinal chemistry efforts previously performed by BPM for such Collaboration Compounds that the JRC has determined have satisfied [&#x2026;***&#x2026;] as determined by the JRC.&nbsp;&nbsp;All other activities pursuant to the Research Plan shall be managed by the JRC in accordance with Section 8.4 and Section 4.1.3. For clarity, the foregoing rights (i) shall not apply to any Library Compounds or Other Compounds that have not satisfied Lead Series Identified Criteria for Collaboration Targets [&#x2026;***&#x2026;] or [&#x2026;***&#x2026;] (as applicable), or any other Collaboration Targets, and (ii) shall terminate in full [&#x2026;***&#x2026;] after the Effective Date.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">75</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.2.4&nbsp;&nbsp;Termination by Roche without Cause</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to exercise of its first Option Right, Roche shall have the right to terminate this Agreement as a whole or on a Collaboration Target-by-Collaboration Target basis, upon one hundred twenty (120) days prior written notice.&nbsp;&nbsp;Following the exercise of its first Option Right, Roche shall have the right to terminate this Agreement at any time as a whole, on a Collaboration Target-by-Collaboration Target basis, on a Program-by-Program basis, or, after First Commercial Sale, upon a country-by-country basis, upon (a) prior to First Commercial Sale of the first Licensed Product for such Collaboration Target or Program, one hundred twenty (120) days prior written notice or (b) after the First Commercial Sale of the first Licensed Product for such Collaboration Target or Program, one hundred eighty (180) days prior written notice. The effective date of termination under this Section&nbsp;21.2.4 shall be the date one hundred twenty (120) days (or one hundred eighty (180) days as the case may be) after Roche provides such written notice to BPM. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.2.5&nbsp;&nbsp;Termination by BPM for Roche Suspension of Development</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Program-by-Program basis, if (i) after the exercise of Roche&#x2019;s Option Right with respect to a Collaboration Target for such Program, [&#x2026;***&#x2026;], and (ii) such [&#x2026;***&#x2026;] was not due to events outside of the reasonable control of the Roche Group [&#x2026;***&#x2026;], then BPM will have the right, in its sole discretion, to terminate this Agreement with respect to such Program upon [&#x2026;***&#x2026;] written notice to Roche.&nbsp;&nbsp;In the event that the Roche Group does not proceed with development of the applicable Program as a result of events outside its reasonable control, the [&#x2026;***&#x2026;].&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3&nbsp;&nbsp;Consequences of Termination</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.1&nbsp;&nbsp;Termination by BPM for Breach by Roche, Roche Insolvency, by Roche Without Cause, or by BPM for Roche Suspension of Development or Commercialization </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Upon any termination by BPM for breach by Roche pursuant to Section&nbsp;21.2.1 or 21.2.5 or for an Insolvency Event of Roche pursuant to Section&nbsp;21.2.2 or by Roche without cause pursuant to Section&nbsp;21.2.4, on the effective date of termination (a) the rights and licenses granted by BPM to Roche under this Agreement shall terminate in their entirety or on a Collaboration Target-by-Collaboration Target basis or Program-by-Program basis or on a country-by-country basis, as applicable, (b) except as set forth in this Section 21.3.1, the rights and obligations of the Parties hereunder will terminate with respect to the Collaboration Target, Program, or country and any applicable Collaboration Target shall become a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Terminated Target</font><font style="display:inline;font-family:Times New Roman,Times,serif;">,&#x201D; and (c) Roche will execute all documents and take all such further actions as may be reasonably requested by BPM in order to give effect to the foregoing clauses. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If BPM desires to continue to Exploit Licensed Product(s) (or any derivatives, improvements, modifications or enhancements against the applicable Target, thereof) (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Reversion Products</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) in the Field after such termination, BPM shall give a Continuation Election Notice to Roche within ninety (90) days of the effective date of termination. If Roche receives such a timely Continuation Election Notice, and to the extent reasonably requested by BPM:</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As promptly as practicable after the effective date of termination, Roche shall, to the extent Roche has the right to do so under Applicable Law, assign and transfer to BPM or BPM&#x2019;s designee possession and ownership of all governmental or regulatory filings, regulatory materials, pricing approvals and Regulatory Approvals, all copies of material correspondence and conversation logs relating to the Exploitation of the Reversion Products, all final pre-clinical and clinical study reports and clinical study protocols, Global </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">76</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Trademarks, and all data, including non-clinical and clinical data and other material sales and marketing related information in Roche&#x2019;s possession and control related to Reversion Product(s) or the corresponding Collaboration Target(s) to the extent necessary or reasonably useful for BPM to continue to Exploit the Reversion Product(s) in the Field.&nbsp;&nbsp;All data and other information shall be transferred in the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if required by Applicable Law. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to BPM.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roche shall appoint BPM as Roche&#x2019;s or Roche&#x2019;s Affiliates&#x2019; (and to the extent permitted by the applicable sublicense, its Sublicensees&#x2019;) agent for all Reversion Product-related matters involving Regulatory Authorities in the Roche Territory until all Regulatory Approvals, regulatory materials, pricing approvals and other governmental or regulatory filings required to be assigned to BPM hereunder have, in fact, been assigned to BPM or its designee, but in no event longer than the one (1) year anniversary of the effective date of termination.&nbsp;&nbsp;In the event of failure to obtain assignment of any of the items required to be assigned under this Section&nbsp;21.3.1, Roche hereby consents and grants to BPM or its designee the right to access and reference (without any further action required on the part of Roche, whose authorization to file this consent with any Regulatory Authority is hereby granted) any such item with respect to all Reversion Products.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the effective date of termination is after First Commercial Sale of a Reversion Product, then, to the extent permitted by Applicable Law, Roche or its Affiliates (or to the extent permitted by the applicable sublicense, its Sublicensees) will appoint BPM or its designee as its exclusive distributor of such Reversion Products in the Roche Territory and grant BPM or its designee the right to appoint sub-distributors, until such time as all Regulatory Approvals in the Roche Territory have been transferred to BPM or its designee, but in no event longer than the one (1) year anniversary of the effective date of termination.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roche shall assign and transfer all Clinical Study agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any material consideration or commencing litigation in order to effect an assignment of any such agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BPM shall, upon transfer from Roche pursuant to this Section&nbsp;21.3.1, have the right to disclose such filings, approvals and data to (i)&nbsp;governmental agencies of the country to the extent required or desirable to secure government approval for the development, manufacturing or sale of Reversion Product(s) in the country, (ii)&nbsp;Third Parties acting on behalf of BPM, its Affiliates or licensees, to the extent reasonably necessary for the Exploitation of Reversion Product(s) in the country, and (iii)&nbsp;Third Parties to the extent reasonably necessary to Exploit Reversion Product(s) in the country.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roche shall grant (without any further action required on the part of BPM) to BPM (a) an exclusive (even as to Roche), perpetual, irrevocable (except as set forth below), license, with the right to grant sublicenses through multiple tiers, under the Roche Patent Rights and Roche Know-How, including Roche&#x2019;s interest in the Joint Patent Rights and Joint Know-How, solely to the extent necessary to allow BPM, its Affiliates or licensees to Exploit the Reversion Product(s) in the Field in the terminated country(ies), and (b) a non-exclusive, worldwide, perpetual, irrevocable (except as set forth below) license, with the right to grant sublicenses through multiple tiers, under the Roche Patent Rights and Roche Know-How, including Roche&#x2019;s interest in the Joint Patent Rights and Joint Know-How, </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">77</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">solely to the extent necessary to allow BPM, its Affiliates or licensees to research, have researched, develop, have developed, use, have used, make, have made, import, have imported, export and have exported (including all research, development and manufacturing activities) Reversion Product(s) in the Field anywhere in the world in order to market, have marketed, distribute, have distributed, sell, have sold and offer for sale and have offered for sale (including all commercialization activities) such Reversion Product(s) in the Field in the terminated country(ies) (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Reversion License</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;Royalties would be payable by BPM to Roche on worldwide BPM Net Sales depending upon the stage of development of the applicable Reversion Product at the time of termination as set forth in the following table:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:162.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Stage of Development of the applicable Reversion Product on the effective date of termination</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Royalty payable on portion of BPM Net Sales up to and including [&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Royalty payable on portion of BPM Net Sales greater than [&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:162.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:162.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:162.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:162.25pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td valign="top" style="width:141.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:13.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Payments would be made by BPM to Roche in a manner analogous to that set forth in Section 12.9.1 and 12.9.3 (provided that BPM shall have no obligation to pay royalties to Roche for Net Sales of Reversion Products for Program 2 or Program 4 in the BPM Territory), including adjustments in a manner analogous to those set forth in Sections 12.9.4 - 12.9.6 and 12.9.8.&nbsp;&nbsp;Notwithstanding anything to the contrary in this Section 21.3.1(f), Roche will have the right to terminate the licenses granted to BPM in this Section 21.3.1(f) with respect to a Reversion Product in full upon one hundred and twenty (120) days&#x2019; prior written notice to BPM in the event of any material breach by BPM of its payment obligations under this Section 21.3.1(f).&nbsp;&nbsp;Notwithstanding the foregoing, any such termination under this Section 21.3.1(f) will not be effective if such breach has been cured within one hundred and twenty (120) days after written notice thereof is given by Roche to BPM specifying the nature of the alleged breach.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For clarity, the Parties acknowledge and agree that with respect to any the Roche Patent Rights or Roche Know-How that is in-licensed by the Roche Group, BPM will be responsible for any payments due to a Third Party with respect thereto and BPM&#x2019;s rights will be subject to the terms of the applicable Third Party agreement.&nbsp;&nbsp;At BPM&#x2019;s written request, the Parties will enter into commercially reasonable prosecution and enforcement and defense terms for the Roche Patent Rights or Roche Know-How with respect to the Reversion Products, and BPM will bear the costs of such prosecution, enforcement and defense activities to the extent related to such Reversion Products.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roche will promptly transfer and assign to BPM all of Roche&#x2019;s and its Affiliates&#x2019; rights, title and interests in and to Roche&#x2019;s Global Trademark(s) solely used to identify the Reversion Products (but not any house marks, or logos or any trademark of Roche or its Affiliates, containing the word &#x201C;Roche&#x201D; or any such Affiliate) owned by Roche and used for the Reversion Products in the Field.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If BPM so requests, and to the extent permitted under Roche&#x2019;s obligations to Third Parties on the effective date of termination, Roche will transfer to BPM any Third Party agreements relating solely to the Exploitation of the Reversion Products to which Roche </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">78</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">is a party, subject to any required consents of such Third Party, which Roche will use Commercially Reasonable Efforts to obtain promptly.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roche will execute all documents and take all such further actions as may be reasonably requested by BPM in order to give effect to the foregoing clauses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.2&nbsp;&nbsp;Termination by Roche for Breach by BPM or BPM Insolvency</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Upon material breach by BPM or BPM&#x2019;s Insolvency, Roche shall have the right to terminate this Agreement in accordance with Section&nbsp;21.2.1 or Section&nbsp;21.2.2, as applicable. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If Roche exercises its aforementioned right to terminate, then, on the effective date of termination, (a) all rights and licenses granted to either Party under this Agreement with respect to such Collaboration Target(s) or Program(s) with terminate; (b) except as set forth in this Section&nbsp;21.3.2, the rights and obligations of the Parties hereunder shall terminate with respect to such Terminated Target(s) as of the effective date of such termination; and (c) BPM will execute all documents and take all such further actions as may be reasonably requested by Roche in order to give effect to the foregoing clauses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event of a material breach of this Agreement by BPM with respect to Program 2 or Program 4 (as applicable), then, following the expiration of all applicable notice and cure periods, and, if any dispute is initiated under Section 23.3.1 before the expiration of the applicable cure period with respect to the basis for the asserted basis of such termination, the confirmation by the arbitrators of the facts claimed by Roche to be the basis for termination under Section 21.2.1, Roche may elect, at its sole option, upon written notice to BPM that, in lieu of exercising its right to terminate this Agreement pursuant to Section 21.2.1 for Program 2 or Program 4 (as applicable), the licenses and other rights granted by BPM to Roche under this Agreement with respect to such Program remain in effect in accordance with their respective terms; provided, however, that (a) the Roche Territory for such Program shall mean all countries of the world, and Roche will be deemed granted all rights and obligations relating thereto, (b) Roche shall have the right to offset the full amount of any losses incurred by Roche as a result of such material breach by BPM with respect to such Program&nbsp;&nbsp;from any future payments relating to such Program due and payable to BPM under this Agreement, and (c) the Development Cost Share for such Program shall be 100% paid by Roche.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.3&nbsp;&nbsp;Sublicenses</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Irrespective of anything to the contrary in this Agreement, any existing, sublicense granted by Roche to Third Parties under Section 2.1.2 or Section 2.1.3 of this Agreement (and any further sublicenses thereunder) shall, upon the written request of Roche, remain in full force and effect, provided that (i) such Third Party Sublicensee is not then in breach of its sublicense agreement (and, in the case of termination by BPM for breach by Roche, that such Third Party Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by BPM); and (ii) and such Third Party Sublicensee agrees to be bound to BPM under the terms and conditions of such sublicense agreement.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.4&nbsp;&nbsp;Other Obligations</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.4.1&nbsp;&nbsp;Obligations Related to Ongoing Activities</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If BPM does not provide a timely Continuation Election Notice, then each Party (a)&nbsp;shall have the right to cancel all ongoing obligations and (b)&nbsp;shall complete all non-cancellable obligations. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">79</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">If BPM provides such timely Continuation Election Notice, then from the date of notice of termination until the effective date of termination, Roche shall continue all activities contemplated by this Agreement, including preparatory activities, ongoing as of the date of notice of termination. However, Roche shall not be obliged to initiate any new activities not ongoing at the date of notice of termination.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">After the effective date of termination, neither Roche nor BPM shall have an obligation to perform and/or complete any activities except as expressly stated herein.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the foregoing, in case of termination by BPM under Section&nbsp;21.2.1, Section 21.2.2 or Section 21.2.5 or by Roche under Section&nbsp;21.2.4, upon the request of BPM, Roche shall complete any Clinical Studies related to the Licensed Product(s) that are being conducted under its IND(s) for the Licensed Product(s) and are ongoing as of the effective date of termination; provided, however, that</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;both BPM and Roche in their reasonable judgment have concluded that completing any such Clinical Studies does not present an unreasonable risk to patient safety; and </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Roche shall have no obligation to recruit or enroll any additional patients after the date of termination; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iii)&nbsp;&nbsp;&nbsp;Roche shall transfer all Clinical Studies to BPM as soon as practicable, and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iv)&nbsp;&nbsp;&nbsp;BPM agrees to reimburse Roche for all of its Development Costs that arise after the effective date of termination in completing such Clinical Studies.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event that BPM does not elect to have Roche complete any Clinical Studies related to the Licensed Product(s) that are being conducted under Roche&#x2019;s IND(s) for the Licensed Product(s) and are ongoing as of the effective date of termination, then Roche will wind down such ongoing Clinical Studies, subject to the Parties&#x2019; sharing any remaining Phase I Development Costs or Development Costs for such Clinical Studies.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.4.2&nbsp;&nbsp;Obligations Related to Manufacturing</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">a)&nbsp;&nbsp;Clinical Supplies</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the case of termination by BPM according to Section&nbsp;21.2.1, Section 21.2.2 or Section 21.2.5 or by Roche under Section&nbsp;21.2.4, if BPM elects to develop the Reversion Products, Roche shall transfer all existing and available clinical material to BPM at [&#x2026;***&#x2026;] and upon the request of BPM. After such transfer is effectuated, (i) Roche shall have no obligation to perform any additional activities concerning the clinical supplies (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, retesting, analyses) and (ii) BPM shall assume all liability for the use of such material.&nbsp;&nbsp;At BPM&#x2019;s request, immediately after notice of termination, Roche will cooperate to accelerate the transfer of the technology necessary to manufacture the clinical material to BPM or its designee as soon as practicable, and Roche will leverage its relationships with CROs to enable BPM to assume responsibility for manufacturing.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">b)&nbsp;&nbsp;Commercial Supplies</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the case of termination by BPM according to Section&nbsp;21.2.1 or Section 21.2.2 or by Roche under Section&nbsp;21.2.4, if a Reversion Product is marketed in any country of Territory on the date of the notice of termination of this Agreement, upon the request of BPM, Roche shall manufacture and supply such Reversion Product to BPM for a period that shall not exceed [&#x2026;***&#x2026;] from the effective date of the termination of this Agreement at [&#x2026;***&#x2026;]. BPM shall use Commercially Reasonable Efforts to take over the manufacturing as soon as reasonably possible after the effective date of termination.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">80</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.4.3&nbsp;&nbsp;Ancillary Agreements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Unless otherwise agreed by the Parties, the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto, including but not limited to the Manufacturing and Supply Agreement(s), if any, and the Pharmacovigilance Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.4.4&nbsp;&nbsp;Limitations on Grant-Backs; Transfer Expenses</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For purposes of clarity, irrespective of anything to the contrary in this Agreement:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;All assignments, transfers and licenses from Roche to BPM or other obligations of Roche under Section&nbsp;21.3 are solely with respect to Reversion Product(s) that are not Combination Product(s) or Companion Diagnostic(s). Such transfers, licenses and obligations do not extend to other therapeutically active ingredients or products, even if physically mixed, combined or packaged together with a Reversion Product, and even if a Reversion Product is intended (according to the investigation plan, proposed labeling or actual labeling, as applicable) for use with such other therapeutically active ingredients or products.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;In connection with research studies or Clinical Studies, Roche may have collected human samples and related clinical information for additional limited research and development programs (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Samples</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). Legal and contractual restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. BPM acknowledges and accepts that notwithstanding anything herein, at the request of BPM and subject to BPM compensating Roche for all costs incurred by Roche in transferring such Samples, Roche shall use Commercially Reasonable Efforts to transfer any such Samples to BPM to the extent permitted under Applicable Law and consistent with Roche&#x2019;s business practices. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;Nothing in this Agreement shall be construed as granting BPM any license under the Excluded Patent Rights.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;Within thirty (30) days after the date of a Continuation Election Notice, BPM shall make a payment to Roche of [&#x2026;***&#x2026;] as consideration for the transfer activities performed by Roche under Sections&nbsp;21.3.1 and 21.3.4 (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche Transfer Activities</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), which amount shall be creditable against any royalties payable by BPM to Roche pursuant to Section 21.3.1(f).&nbsp;&nbsp;Roche shall be under no obligation to provide Roche Transfer Activities prior to receipt of the Minimum Transfer Payment.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.3.4.5&nbsp;&nbsp;Royalty and Payment Obligations</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Termination of this Agreement by a Party, for any reason, shall not release the other Party from any obligation to pay royalties or make any other payments that are payable prior to the effective date of termination. However, termination of this Agreement by a Party, for any reason, will release a Selling Party from any obligation to pay royalties or make any payments to the Non-Selling Party that would otherwise become payable on or after the effective date of termination.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.4&nbsp;&nbsp;Survival</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Last sentence of Section 2.1.4 (Licenses), last paragraph of Section 3.1.3 (Option Right), Section&nbsp;16.1 (Ownership of Inventions), Section 16.2 (Patent Rights Owned Jointly), Section 16.3 (German Statute on Employee&#x2019;s Inventions), Section 16.9 (CREATE Act), Section 16.12 (Common Interest Disclosures), Section 17.10 (No Other Representations), Section 21.3 (Consequences of Termination), and Section 21.4 (Survival); Article 1 (Definitions, but only to the extent necessary to interpret the Agreement), Article 12 (Payment, but only with respect to any payments accrued thereunder prior to expiration or termination), Article 13 (Accounting and </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">81</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Reporting, but only with respect to any payments accrued thereunder prior to expiration or termination), Article 14 (Taxes), Article 15 (Auditing), Article&nbsp;18 (Indemnification), Article 19 (Liability), Article&nbsp;20 (Obligation Not to Disclose Confidential Information), Article 22 (Bankruptcy), and Article 23 (Miscellaneous) shall survive any expiration or termination of this Agreement for any reason.&nbsp;&nbsp;Expiration or termination of this Agreement for any reason will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity, with respect to any breach of this Agreement.&nbsp;&nbsp;For the avoidance of doubt, termination of this Agreement will not affect any Pharmacovigilance Agreement, which will continue to survive so long as any Licensed Products thereunder are being commercialized.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">22.&nbsp;&nbsp;Bankruptcy</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by a Party to the other are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of Title&nbsp;11, US Code (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Bankruptcy Code</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) licenses of rights to &#x201C;intellectual property&#x201D; as defined under Section&nbsp;101(35A) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that the Parties and their respective Sublicensees, as a licensees or sublicensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the Bankruptcy Code (or any foreign counterpart thereto), subject to the continued performance of its obligations under this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.&nbsp;&nbsp;Miscellaneous</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.1&nbsp;&nbsp;Governing Law</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.2&nbsp;&nbsp;Disputes</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:76.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">For BPM:</font></p>
				</td>
				<td valign="top" style="width:369.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">For Roche:</font></p>
				</td>
				<td valign="top" style="width:369.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Head of Roche Partnering</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.3&nbsp;&nbsp;Arbitration</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Except as otherwise expressly set forth in this Agreement (including with respect to any matters that are determined by Expedited Arbitration, Expert or Expert Committee), should the Parties fail to agree within two (2) months after such dispute has first arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">AAA</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) as in force at the time when initiating the arbitration. The tribunal shall consist of three (3) arbitrators. The place of arbitration shall be New York City, New York, US and the arbitration will be governed by the Laws of the State of New York. The language to be used shall be English.&nbsp;&nbsp;Documents submitted in the arbitration (the originals of which are not in English) shall be submitted together with an English translation.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">82</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.3.1&nbsp;&nbsp;Arbitrators</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party shall nominate one arbitrator who are retired judges or attorneys with at least ten (10) years of relevant experience in the pharmaceutical or biotechnology industry, each of whom will be impartial and independent. Should the claimant fail to appoint an arbitrator in the request for arbitration within thirty (30) days of being requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within thirty (30) days of being requested to do so, the other Party shall request the AAA to make such appointment.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The arbitrators nominated by the Parties shall, within thirty (30) days from the appointment of the arbitrator nominated in the answer to the request for arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the three arbitrator committee (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Arbitral Tribunal</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). Should such procedure not result in an appointment within the thirty (30) day time limit, either Party shall be free to request the AAA to appoint the third arbitrator.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Where there is more than one (1) claimant and/or more than one (1) respondent, the multiple claimants or respondents shall jointly appoint one (1) arbitrator.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If any Party-appointed arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.3.2&nbsp;&nbsp;Decisions; Timing of Decisions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than six (6) months from the date on which the arbitrators were appointed to the dispute.&nbsp;&nbsp;A transcript of the evidence adduced at the arbitration hearing shall be made and, upon request, shall be made available to each Party.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The time periods set forth in the AAA Arbitration Rules shall be followed; provided however that the arbitrators may modify such time periods as reasonably necessary to render a written opinion in accordance with this Section&nbsp;23.3.2.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Arbitrator is empowered to award any remedy allowed by law, including money damages, prejudgment interest and attorneys&#x2019; fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court of competent jurisdiction including, without limitation, the courts having jurisdiction by reason of either Party's domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim measures. Conservatory or interim measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In the event that any issue shall arise which is not clearly provided for in this Section&nbsp;23.3, the matter shall be resolved in accordance with the AAA Arbitration Rules.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard each Party&#x2019;s Confidential Information.&nbsp;&nbsp;Except as required by Applicable Law or in a proceeding to enforce the results of the arbitration, neither </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">83</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written consent of the other Party.&nbsp;&nbsp;The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise required by Applicable Law.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction, validity and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party&#x2019;s obligations under Article&nbsp;20 (Obligation Not to Disclose Confidential Information) shall be determined in a court of competent jurisdiction under the laws of the State of New York, with express exclusion of its conflict of laws principles.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Fees, costs and expenses of arbitration are to be divided by the Parties in the following manner: BPM will pay for the arbitrator it chooses, Roche will pay for the arbitrator it chooses, and the Parties will share payment for the third arbitrator.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.3.3&nbsp;&nbsp;Expedited Arbitration</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If a Party exercises its rights under this Agreement to refer a dispute to expedited arbitration (an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Expedited Dispute</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), then the Parties will follow the expedited dispute resolution process in this Section 23.3.3 (and not the dispute resolution process at the beginning of this Section 23.3 of this Agreement) (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Expedited Arbitration</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;The Parties agree and acknowledge that any good faith dispute under Expedited Arbitration will not be deemed to be a material breach of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Expedited Dispute will be submitted to fast-track, binding arbitration in accordance with the following:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arbitration will be conducted in New York, New York under the rules of the AAA for the resolution of commercial disputes in the most expedited manner permitted by such rules.&nbsp;&nbsp;The arbitration will be heard and determined by three (3) arbitrators, each of whom will be impartial and independent.&nbsp;&nbsp;Each Party will appoint one (1) arbitrator and the third (3rd) arbitrator will be selected by the two (2) Party-appointed arbitrators, or, failing agreement regard the selection of such third (3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">rd</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) arbitrator within thirty (30) days following appointment of the second arbitrator, the third (3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">rd</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) arbitrator will be selected by the AAA.&nbsp;&nbsp;Each arbitrator will be a professional in business or licensing experienced in the valuation of biopharmaceutical products with at least ten (10) years of experience in the pharmaceutical and life sciences industries, including the conduct of research, development and commercialization collaborations.&nbsp;&nbsp;The cost of the arbitration will be borne equally by the Parties.&nbsp;&nbsp;Except in a proceeding to enforce the results of the arbitration or as otherwise required by Applicable Laws, neither Roche nor BPM nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written agreement of Roche and BPM.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30) days after such matter is referred to arbitration, each Party will provide the arbitrators with a proposal and written memorandum in support of its position regarding the Expedited Dispute, as well as any documentary evidence it wishes to provide in support thereof </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">84</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">(each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Brief</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) and the arbitrators will provide each Party&#x2019;s Brief to the other Party after it receives it from both Parties.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30) days after a Party submits its Brief, the other Party will have the right to respond thereto.&nbsp;&nbsp;The response and any material in support thereof will be provided to the arbitrators and the other Party.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The arbitrators will have the right to meet with the Parties as necessary to inform the arbitrators&#x2019; determination and to perform independent research and analysis.&nbsp;&nbsp;Within thirty (30) days of the receipt by the arbitrators of both Parties&#x2019; responses (or expiration of the thirty (30) day period if any Party fails to submit a response), the arbitrators will deliver their decision regarding the Expedited Dispute in writing; provided that the arbitrators will select one of the resolutions proposed by the Parties.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Parties shall have the right to terminate such Expedited Arbitration in accordance with Section 2.2 or upon mutual agreement prior to delivery of the arbitrators&#x2019; decision. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.4&nbsp;&nbsp;Assignment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Except as provided in this Section&nbsp;23.4, neither Party shall have the right to assign or otherwise transfer this Agreement or any part thereof, or its rights or obligations under this Agreement absent the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party&#x2019;s written consent, assign this Agreement and its rights and obligations hereunder in whole or in part to any of its Affiliates in whole or to a party that acquires, by or otherwise in the context of a merger, acquisition, sale, reorganization, consolidation, Change of Control or other transaction involving all or substantially all of the assets of the business of the assigning Party to which the subject matter of this Agreement relates. Any permitted assignment shall be binding on the successors of the assigning Party. Any purported assignment in violation of this Section&nbsp;23.4 will be void and of no force and effect.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.5&nbsp;&nbsp;Debarment</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party represents and warrants that it has never been debarred under 21 U.S.C. &#xA7;335a, disqualified under 21 C.F.R. &#xA7;312.70 or &#xA7;812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C &#xA7;1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes, such Party shall immediately notify the other Party in writing and such other Party shall have the right, but not the obligation, to terminate this Agreement, effective, at such other Party&#x2019;s option, immediately or at a specified future date.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.6&nbsp;&nbsp;Independent Contractor</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party's prior written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, each Party&#x2019;s legal relationship to the other Party under this Agreement shall be that of independent contractor, and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.7&nbsp;&nbsp;Unenforceable Provisions and Severability</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">85</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">as far as possible the economic business intentions of the Parties. However the remaining provisions of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.8&nbsp;&nbsp;Waiver</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.9&nbsp;&nbsp;Appendices</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All Appendices to this Agreement shall form an integral part to this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.10&nbsp;&nbsp;Entire Understanding</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Agreement, together with the Pharmacovigilance Agreement and any supply agreement entered into the Parties in connection with this Agreement, contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral, including, effective as of the Effective Date, that Non-Disclosure Agreement between BPM and Roche, effective as of February 9, 2015, as amended by First Amendment, dated May 1, 2015 (provided that all information disclosed or exchanged under such agreement will be treated as Confidential Information hereunder).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.11&nbsp;&nbsp;Amendments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">No amendments of the terms and conditions of this Agreement, including the Appendices attached hereto, shall be binding upon either Party hereto unless in writing and signed by both Parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.12&nbsp;&nbsp;Invoices</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All invoices that are required or permitted hereunder shall be in writing and sent by BPM to Roche at the following address or such other address as Roche may later provide:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">F. Hoffmann-La Roche Ltd</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Kreditorenbuchhaltung</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Grenzacherstrasse 124</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">4070 Basel</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Switzerland</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.13&nbsp;&nbsp;Notice</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">86</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:220.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:336.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:220.50pt;height:63.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">if to BPM, to:</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:336.80pt;height:63.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Blueprint Medicines Corporation</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">38 Sidney Street, Suite 200</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Cambridge, Massachusetts 02139</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S.A. </font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn:&nbsp;&nbsp;Chief Executive Officer</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Facsimile No.: + 1 617 374-7588</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:220.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:336.80pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:220.50pt;height:26.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">and:</font></p>
				</td>
				<td valign="top" style="width:336.80pt;height:26.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn: Legal Department</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Facsimile No.:&nbsp;&nbsp;+ 1 617 374-7588</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:220.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">if to Roche, to:</font></p>
				</td>
				<td valign="top" style="width:336.80pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">F. Hoffmann-La Roche Ltd</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Grenzacherstrasse 124</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">4070 Basel</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Switzerland</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn:&nbsp;&nbsp;Legal Department</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Facsimile No.:&nbsp;&nbsp;+41 61 688 13 96</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:220.50pt;height:79.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">and:</font></p>
				</td>
				<td valign="top" style="width:336.80pt;height:79.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Hoffmann-La Roche Inc.</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">150 Clove Road</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Suite 8</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Little Falls, New Jersey 07424</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S.A.</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn.&nbsp;&nbsp;Corporate Secretary</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Facsimile No.: +1 973 890-8433</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice will be deemed to have been given: (a) when delivered if personally delivered on a Business Day (or if delivered or sent on a non-Business Day, then on the next Business Day); (b) on the Business Day of receipt if sent by overnight courier or facsimile; or (c) on the Business Day of receipt if sent by mail.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.14&nbsp;&nbsp;Counterparts</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.&nbsp;&nbsp;Counterparts may be delivered via facsimile, electronic mail (including pdf or other electronic signature) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.15&nbsp;&nbsp;Performance by Affiliates</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party acknowledges and accepts that the other Party may exercise its rights and perform its obligations (including granting or continuing licenses and other rights) under this Agreement either directly or through one or more of its Affiliates.&nbsp;&nbsp;A Party&#x2019;s Affiliates will have the benefit of all rights (including all licenses and other rights) of such Party under this Agreement, but not be subject to such Party&#x2019;s obligation, unless expressly provided herein, or in the case of a permitted assignment, in accordance with Section&nbsp;23.4.&nbsp;&nbsp;Accordingly, in this Agreement &#x201C;Roche&#x201D; will be interpreted to mean &#x201C;Roche or its Affiliates&#x201D; and &#x201C;BPM&#x201D; will be interpreted to mean &#x201C;BPM or its Affiliates&#x201D; where necessary to give each Party&#x2019;s Affiliates the benefit of the rights provided to such Party in this Agreement and the ability to perform its obligations (including granting or continuing </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">87</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">licenses and other rights) under this Agreement; provided, however, that in any event each Party will remain responsible for the acts and omissions, including financial liabilities, of its Affiliates.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.16&nbsp;&nbsp;Force Majeure</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Neither Party will be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, earthquakes, floods, or other acts of God. The affected Party will notify the other Party of such force majeure circumstances as soon as reasonably practical, and will promptly undertake all reasonable efforts necessary to cure such force majeure circumstances and resume performance of its obligations hereunder.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.17&nbsp;&nbsp;Compliance with Export Regulations</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Neither Party will export any technology licensed to it by the other Party under this Agreement except in compliance with U.S. export Laws and regulations.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.18&nbsp;&nbsp;Interpretation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa); (b) the words &#x201C;include&#x201D;, &#x201C;includes&#x201D; and &#x201C;including&#x201D; will be deemed to be followed by the phrase &#x201C;without limitation&#x201D; and will not be interpreted to limit the provision to which it relates; (c) the word &#x201C;shall&#x201D; will be construed to have the same meaning and effect as the word &#x201C;will&#x201D;; (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (e) any reference herein to any Person will be construed to include the Person&#x2019;s successors and assigns; (f) the words &#x201C;herein&#x201D;, &#x201C;hereof&#x201D; and &#x201C;hereunder&#x201D;, and words of similar import, will be construed to refer to this Agreement in each of their entirety, as the context requires, and not to any particular provision hereof; (g) all references herein to Articles, Sections, Exhibits or Schedules will be construed to refer to Articles, Sections, Exhibits or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto; (h) the word &#x201C;notice&#x201D; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement; (i) provisions that require that a Party, the Parties or any committee hereunder &#x201C;agree,&#x201D; &#x201C;consent&#x201D; or &#x201C;approve&#x201D; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging); (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof; and (k) the term &#x201C;or&#x201D; will be interpreted in the inclusive sense commonly associated with the term &#x201C;and/or&#x201D;.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.19&nbsp;&nbsp;Waiver of Rule of Construction </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">88</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">23.20&nbsp;&nbsp;Headings</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The captions to the Sections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Sections hereof.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">[Signature Page Follows]</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">89</font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Blueprint Medicines Corporation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0.5pt;">
			<tr>
				<td colspan="2" valign="bottom" style="width:36.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:237.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:36.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:227.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Jeffrey Albers</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:36.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:237.40pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jeffrey Albers</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:36.15pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: </font></p>
				</td>
				<td valign="bottom" style="width:237.40pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Chief Executive Officer</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">F. Hoffmann-La Roche Ltd</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Vikas Kabra</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Stefan Arnold</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:36.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:237.40pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Vikas Kabra</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:36.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:227.05pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Stefan Arnold</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:36.15pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: </font></p>
				</td>
				<td valign="bottom" style="width:237.40pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Head of Transaction Excellence</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:36.10pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: </font></p>
				</td>
				<td valign="bottom" style="width:227.05pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Head Legal Pharma</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Hoffmann-La Roche Inc.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ John P. Parise</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:36.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:237.40pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">John P. Parise</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:36.15pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: </font></p>
				</td>
				<td valign="bottom" style="width:237.40pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Authorized Signatory</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.9</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">BPM Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.18</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">CCS Criteria</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0.5pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #BFBFBF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Property</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #BFBFBF;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Minimum Acceptable</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:556.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:556.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.23</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">CLS Criteria</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0.5pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:278.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:278.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #BFBFBF;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Property</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #BFBFBF;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Criteria/Purpose</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:557.80pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:13.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:13.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:13.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:13.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:557.80pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:43.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:43.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:18.64pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:18.64pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:557.80pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:9.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:18.64pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:18.64pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:30.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:30.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:23.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:23.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:557.80pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:22.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:557.80pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.90pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #auto;height:12.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.38</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Approved CROs</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.44</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Excluded Targets </font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.72</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Lead Series Identified Criteria</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0.5pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #BFBFBF;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Properties</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #BFBFBF;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Criteria/Purpose</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:556.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:556.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:25.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:25.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:25.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:25.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:556.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:28.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:28.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:29.65pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:29.65pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:556.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:6.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:18.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:18.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:25.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:25.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:12.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:18.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:18.85pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="4" valign="top" style="width:556.30pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #F2F2F2;height:14.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:14.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:14.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:14.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:14.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
				<td colspan="2" valign="top" style="width:278.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.81</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Option Data Package</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Categories of information:</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 1.114</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Excluded Patent Rights</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;], which means (a) U.S. Patent No. [&#x2026;***&#x2026;], issued [&#x2026;***&#x2026;], and any and all patents issuing from divisionals, continuations, or continuations-in part of any application from which U.S. Patent No. [&#x2026;***&#x2026;] claims priority, as well as reissues, reexaminations, extensions, and foreign patent counterparts, including inventors certificates, of any of the foregoing, and including any related supplemental protection certificates; and (b) U.S. Patent No. [&#x2026;***&#x2026;], issued [&#x2026;***&#x2026;], and any and all patents issuing from divisionals, continuations, or continuations-in-part of any application from which U.S. Patent No. [&#x2026;***&#x2026;] claims priority, as well as reissues, reexaminations, extensions, and foreign patent counterparts, including inventors certificates, of any of the foregoing, and including any related supplemental protection certificates.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;], which means any of the U.S. patents listed below and any and all patents issuing from divisionals, continuations or continuations-in-part, and any reissues, reexaminations or extensions, of these patents or of any application from which these U.S. patents claim priority, as well as foreign counterparts, including inventors certificates, of the foregoing, and including any related supplemental protection certificates:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;], which means any of the U.S. patents/patent application listed below and any and all patents issuing from divisionals, continuations or continuations-in-part, and any reissues, reexaminations or extensions, of these patents or of any application from which these U.S. patents claim priority, as well as foreign counterparts, including inventors certificates, of the foregoing, and including any related supplemental protection certificates:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[&#x2026;***&#x2026;], which means the following U.S. patent and any and all divisionals, continuations, continuations-in-part of any application from which these U.S patents claim priority, including reissues, reexaminations or extensions of these patents and foreign counterparts and supplementary protection certificates of the foregoing:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">U.S. Patent No. [&#x2026;***&#x2026;]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 4.1.5</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche Senior Management</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Global Head of Therapeutic Modalities</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Global Head of Medicinal Chemistry</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Global Head of Molecular Targeted Therapies in Oncology Discovery</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Global Head of Oncology Discovery (Oncology DTA)</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Appendix 20.3 </font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Form of Press Release</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[Attached]</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">&#x2014; Collaboration Combines Blueprint Medicines&#x2019; Proprietary Drug Discovery Platform and Immunokinase Expertise with Roche&#x2019;s Cancer Immunotherapy Expertise &#x2014;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">&#x2014; Blueprint Medicines to Receive $45 Million Upfront Payment and is Eligible to Receive Additional Contingent Fees and Milestone Payments&#x2014; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">&#x2014; Blueprint Medicines to Host Conference Call Today at 8:00 A.M. ET &#x2014;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">CAMBRIDGE, Mass., March 15, 2016 </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&#x2013;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Blueprint Medicines Corporation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">(NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it has entered into a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) for the discovery, development and commercialization of up to five small molecule therapeutics targeting kinases believed to be important in cancer immunotherapy. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $45 million and will be eligible to receive up to an additional approximately $965 million in contingent option fees and milestone payments related to specified research, preclinical, clinical, regulatory and sales-based milestones across all five potential programs. Of the total contingent payments, up to approximately $215 million are for option fees and milestone payments for research, preclinical and clinical development events prior to licensing across all five potential programs.&nbsp;&nbsp;In addition, the agreement provides for specified royalties and cost sharing, which are described in more detail below.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Immunokinases are intracellular targets known to regulate numerous aspects of immune response and represent an important opportunity for potentially innovative approaches to enhance the immune system&#x2019;s ability to recognize and eradicate tumor cells. To date, cancer immunotherapies have demonstrated important clinical benefits. However, most cancer immunotherapies have focused on antibodies or combinations with existing approved therapies and have not yet targeted immunokinases with small molecules.&nbsp;&nbsp;This collaboration seeks to develop new mechanisms of modulating the tumor immune response by targeting immunokinases with the goal of enhancing response rates and broadening the utility of using cancer immunotherapies to treat additional cancer types. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201C;We believe Blueprint Medicines&#x2019; proprietary drug discovery platform and expertise in immunokinases, combined with our proven ability to move quickly through drug discovery, is a perfect complement to Roche&#x2019;s expertise with cancer immunotherapy biology and in developing and commercializing innovative therapies,&#x201D; said Jeff Albers, Chief Executive Officer of Blueprint Medicines. &#x201C;Under this collaboration, Blueprint Medicines will lead preclinical research and development through Phase 1 proof of concept for all five programs and retain U.S. commercial rights for two programs. We believe this highly collaborative relationship will enable us to accelerate our efforts in the emerging field of cancer immunotherapy and to continue building a leading biotechnology company.&#x201D;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The collaboration provides for the worldwide development and commercialization of immunokinases in the field of cancer immunotherapy for up to five small molecule drug candidates as single products or possibly in combination with Roche&#x2019;s portfolio of therapeutics. Roche&#x2019;s rights are structured as an option, triggered upon achievement of Phase I proof-of-concept, for an exclusive license to each drug candidate developed under the collaboration. Blueprint Medicines will be primarily responsible for preclinical research and conduct of clinical development for each</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">program prior to any exercise of Roche&#x2019;s option for such program. If Roche exercises an option for a program, Roche will be responsible for subsequent global development for that program through registrational clinical trials. For up to three of the five programs, if Roche exercises its option, Roche will receive worldwide commercialization rights for the licensed product. For up to two of the five programs, if Roche exercises its option, Blueprint Medicines will retain commercialization rights in the United States for the licensed product, and Roche will receive commercialization rights outside of the United States for such licensed product. Blueprint Medicines will also retain worldwide rights to any drug candidates for which Roche elects not to exercise the applicable option. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For any licensed product for which Roche retains worldwide commercialization rights, Blueprint Medicines will be eligible to receive tiered royalties ranging from low double-digits to high-teens on future net sales of the licensed product. For any licensed product for which Blueprint Medicines retains commercialization rights in the United States, Blueprint Medicines and Roche will be eligible to receive tiered royalties ranging from mid-single-digits to low double-digits on future net sales in the other party&#x2019;s respective territories in which it commercializes the licensed product. Blueprint Medicines and Roche will share the costs of Phase 1 development for each collaboration target. In addition, Roche will be responsible for post-Phase 1 development costs for each licensed product for which it retains global commercialization rights, and Blueprint Medicines and Roche will share post-Phase 1 development costs for each licensed product for which Blueprint Medicines retains commercialization rights in the United States. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Conference Call Information</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Blueprint Medicines will host a conference call and live audio webcast for investors at 8:00 A.M. ET today. To participate in the conference call, please dial 877-516-3348 (domestic) or 281-973-6089 (international) and refer to conference ID 63223687. A live webcast of the conference call will be available by visiting the Investors section of Blueprint Medicines' website at </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">http://ir.blueprintmedicines.com</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. The archived webcast will be available on Blueprint Medicines' website approximately 2 hours after the call and will be available for 30 days following the call.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">About Blueprint Medicines</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">www.blueprintmedicines.com</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the collaboration and license agreement among Blueprint Medicines and Roche, including anticipated payments, as well as the future development, manufacture and commercialization of cancer immunotherapies under the agreement; Blueprint Medicines&#x2019; and Roche&#x2019;s ability to successfully develop and commercialize cancer immunotherapies; and Blueprint Medicines' strategy and business plans. The words &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;should,&#x201D; &#x201C;expect,&#x201D; &#x201C;plan,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;intend,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;predict,&#x201D; &#x201C;project,&#x201D; &#x201C;potential,&#x201D; </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201C;continue,&#x201D; &#x201C;target&#x201D; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials. These and other risks and uncertainties are described in greater detail in the section entitled &#x201C;Risk Factors&#x201D; in Blueprint Medicines' Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (SEC) on March 11, 2016, and other filings that Blueprint Medicines may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Contact:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Investor Relations:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Kristin Williams</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Blueprint Medicines Corporation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">617-714-6674 </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">KWilliams@blueprintmedicines.com</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Media Relations: </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Dan Quinn</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Ten Bridge Communications, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">781-475-7974</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">dan@tenbridgecommunications.com</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Amendment, effective April 15, 2016 (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Effective Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), is by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together referred to as &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Roche</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) and Blueprint Medicines, located at 38 Sidney Street, Cambridge, Massachusetts 02139 (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Blueprint</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, Blueprint and Roche entered into a Collaboration and License Agreement dated March&nbsp;14, 2016 (&#x201C;Agreement&#x201D;); </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 36pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NOW THEREFORE, Roche and Blueprint hereby agree as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The 5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> paragraph of Section 4.1.5 of the Agreement shall be deleted in its entirety and replaced by the following:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Two chemistry experts at Roche (&#x201C;Insulated Chemistry Experts&#x201D;) shall be designated in writing by Roche to review structures of Other Compounds and Collaboration Compounds at the start of the collaboration and throughout the Lead Nomination phase. The Insulated Chemistry Experts shall independently handle the structural information and no structures provided by BPM to the Insulated Chemistry Experts can be shared with any other individuals within Roche other than members of senior management specified on Appendix 4.1.5 acting in their decision making capacity. For clarity, these structures cannot be used for any other purpose, including any research purpose.&nbsp;&nbsp;Appropriate safeguards will be established by Roche that are intended to prevent any inadvertent disclosure or improper use of these structures and any structural information related to such structures. From Lead Nomination onwards and throughout Lead Optimization, the structures of Other Compounds and Collaboration Compounds in the Lead Optimization phase shall be shared with the Roche project team members (including Collaboration Compounds meeting Lead Series Identified Criteria, CLS Criteria and CCS Criteria).</font>
		</p>
		<p style="margin:0pt 36pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">All other terms defined in the Agreement are to be interpreted as defined therein, and all other terms of the Agreement are to remain in full force and effect.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Amendment may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Blueprint Medicines Corporation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0.5pt;">
			<tr>
				<td colspan="2" valign="bottom" style="width:37.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:236.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:35.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:228.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Jeffrey Albers</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:37.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:236.40pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Jeffrey Albers</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:37.15pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: </font></p>
				</td>
				<td valign="bottom" style="width:236.40pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Chief Executive Officer</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">and President</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">F. Hoffmann-La Roche Ltd</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Stefan Arnold</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Barbara Lueckel</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:37.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:236.40pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Stefan Arnold</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:35.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:228.05pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Dr. Barbara Lueckel</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:37.15pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="bottom" style="width:236.40pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Head Legal Pharma</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:35.10pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: </font></p>
				</td>
				<td valign="bottom" style="width:228.05pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Head of Research &amp; Technologies Partnering</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Hoffmann-La Roche Inc.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ John P. Parise</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:37.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: </font></p>
				</td>
				<td valign="bottom" style="width:236.40pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">John P. Parise</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:37.15pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: </font></p>
				</td>
				<td valign="bottom" style="width:236.40pt;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Authorized Signatory</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:273.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:263.15pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
